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 Abstract of Thesis 
GABA (gamma-amino butanoic acid) is the main inhibitory neurotransmitter in 
the mammalian central nervous system. GABA has been found to play an 
inhibitory role in some cancers, including colon carcinoma, cholangiocarcinoma, 
and lung adenocarcinoma. 
Growing evidence shows that GABAB receptors are involved in tumour 
development. The expression level of GABAB receptors was found to be 
upregulated in some human tumours, including the pancreas, and cancer cell 
lines, suggesting that GABAB receptors may be potential targets for cancer 
therapy and diagnosis.  
In this research programme, several diverse series of potential anticancer 
prodrugs of GABA and GABA receptor-targeting agents have been rationally 
designed and synthesised for selective activation in the tumour 
microenvironment.  
In one approach, a series of oligopeptide conjugate prodrugs have been 
synthesised as protease-activatable substrates for either the extracellular matrix 
metalloproteinase MMP-9 or the lysosomal endoprotease legumain; each of 
which are overexpressed in the tumour environment and are effectors of tumour 
growth and metastasis. Specifically, a novel fluorogenic, oligopeptide FRET 
substrate prodrug of legumain HZ101 (Rho-Pro-Ala-Asn~GABA-spacer-AQ) has 
been characterised and shown to have theranostic potential. Proof of principle 
has been demonstrated using recombinant human legumain for which HZ101 is 
an efficient substrate and is latently quenched until cleaved. HPLC methods 
have been developed to monitor prodrug activation.  
In another approach, cyclic prodrugs of the GABA-B receptor agonist baclofen 
have been designed to be activated in the acidic environment of solid tumours to 
exert antitumour effects through modulation of the receptor response.  
During the oligopeptide synthetic work, novel, coloured, anthraquinone-based 
reagents have been designed and evaluated as new chemical tools for amine 
detection and monitoring in solid phase peptide synthesis (SPPS); 
characterisation by spectroscopic and HPLC methods have demonstrated their 
advantages over existing methods and their potential applications for use on 
solid supported resins.
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Graphical Abstract Concept Diagrams 
Chapter 1: MMP-9 Activated Prodrugs  
Chapter 1 presents the results and discussion of a series of novel oligopeptide 
Matrix Metalloproteinase (MMP)-9 substrates for prodrug therapy, designed to 
be activated by overexpressed MMP-9 in the tumour microenvironment. 
 
             
Figure 1. Design strategy and concept for MMP-9 activated prodrugs 
 
Figure 1 illustrates the general concept for the design of the MMP-9 targeted 
prodrugs, where an MMP-9 cleavable peptide is amide linked at its carboxy 
2 
 terminus to either a GABAB receptor agonist or antagonist or cytotoxic agent; the 
amino terminus is protected by either a capping group, fluorophore (for 
diagnostic purpose) or antiangiogenic agent. Activation of the prodrug at the 
MMP-9 specific cleavage site (‘hotspot’), followed by further degradation by 
ubiquitous aminopeptidase should result in release of the active agents in the 
tumour microenvironment, which may then enter into tumour cells and lead to cell 
death.  
 
Chapter 2: Baclofen Based Prodrugs 
Chapter 2 describes the synthesis and preliminary evaluation of new cancer 
chemotherapeutic prodrugs targeted to the GABAB receptor with the potential to 
increase therapeutic index. 
 
Figure 2. Design strategy and concept for cyclic baclofen based prodrugs  
 
Figure 2 outlines the rationale for the synthesis of a series of compounds where 
the GABAB receptor agonist baclofen was converted into a lipophilic cyclic 
3 
 prodrug form in order to enhance cell membrane and blood brain barrier 
permeability for potential brain tumour therapy.  
 
Chapter 3: Design of legumain activated GABA prodrugs  
This chapter focuses on the synthesis of a legumain targeted prodrug and 
presents the results of in vitro metabolism studies by HPLC and fluorescence 
spectroscopic methods. 
 
Figure 3 Design strategy for legumain activated prodrugs 
 
Figure 3 illustrates the general design strategy and activation concept for 
legumain targeted fluorogenic prodrugs/probes. The prodrug has been 
designed to exploit the proteolytic activity of overexpressed legumain, a 
lysosomal endoprotease with strict specificity for Asn at the P1 position of 
peptide substrates. On activation by legumain, the latently fluorogenic prodrug 
releases a fluorogenic tripeptide and a GABA-containing aminoanthraquinone 
fragment, designed to be further cleaved by aminopeptidases to release the 
ligand GABA which may then enter into tumour cells and lead to cell death or 
4 
 modulate GABA receptors to induce an antitumour effect.  
 
Chapter 4: New colour reagents for SPPS  
In the course of this research programme, synthetic peptide chemistry methods 
were used considerably (as reported in chapter 1 to 3). Due to inherent 
difficulties in monitoring peptide coupling reactions by published available 
methods, novel methods were explored. Chapter 4 describes how new colour 
test reagents were developed for the amine detection and monitoring of reaction 
steps in solid phase peptide synthesis (SPPS). Three new colour reagents (blue, 
red, and purple) were synthesized that gave a rapid colour change to resin 
beads at room temperature with both sterically hindered primary and secondary 
amines. Examples of their application are described. 
 
AQ-Ahx-OPFP (HZ22) 
 
 
 
 
Figure 4. An example reagent for amine detection and resin bead colouration 
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Graphical Summary of Research Undertaken 
 
Venn diagram representation of the Areas of Research presented in this thesis 
showing the fundamental relationships between them. The common theme 
running through all chapters is GABA (gamma aminobutanoic acid). This natural 
ligand may be a pro- or anti-tumour effector. Protease activated prodrugs of 
GABA are targeted either to MMP-9 or legumain endoproteases that are 
overexpressed in the tumour microenvironment. Prodrugs of the GABAB 
receptor agonist baclofen (which has antitumor properties) are designed to be 
either oligopeptide prodrugs activated by MMPs or cyclic, hydrophobic prodrugs 
activated by a pH-dependent mechanism in tumours. Peptide labelling with 
novel reagents developed for N-terminus capping in SPPS methodology spans 
the areas of endoprotease mediated GABA prodrug activation. 
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 Abbreviations 
 
Ala Alanine 
AQ Anthraquinone 
BBB Blood brain barrier 
cAMP Cyclic adenosine monophosphate  
DCC N,N-Dicyclohexylcarbodiimide 
DCU Dicyclohexylurea 
DIPEA N,N-Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DMSO Dimethysulphoxide 
DMF N,N-Dimethylformamide 
EDTA Ethylene diamine tetraacetic acid 
GABA Gamma-amino butyric acid 
GAD Glutamate decarboxylase 
MeOH Methanol 
MMPs Matrix metalloproteinases 
NU:UB Napier University: University of Bradford 
PBS Phosphate buffered saline 
PFP Pentafluorophenol 
Pro Proline 
RT Room temperature 
SPPS Solid phase peptide synthesis 
TLC Thin layer chromatography 
UV Ultraviolet 
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 Nomenclature 
 
The compounds synthesised here are relatively large molecules. To facilitate 
communication through the thesis, the compounds were described in their 
simplest format. The chemical structure (Example A) below represents one of 
the synthesised MMP-9 activated prodrugs (HZ16).  
 
Example A: 
 
 
The hexapeptide chain in the middle is described conventionally using 3-letter 
codes as Pro-Ala-Gly-Leu-Ala-Ala to allow easy recognition of the amino acids 
present in the prodrug. The spacer groups have been abbreviated to succinyl 
and piperazinyl. The short term ‘AQ’ is used in this thesis to represent the most 
commonly used anthraquinone group. Podophyllotoxin is the active agent of the 
prodrug. Eventually, the synthesised prodrug has the short name in the context 
described as: Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ 
8 
 (HZ16). HZ16 is the descriptor and number wherein HZ is the code name for 
newly synthesised compounds. 
 
Example B: 
 
Numbering of anthraquinone conjugate 
 
A numbering system of anthraquinone conjugates were used here. This will 
particularly support the NMR spectral analysis. The Example B (AQ-Ahx-OPFP 
HZ22) is one of the synthesised compounds from Chapter 4. The numbers in red 
indicate the positions of atoms or groups of atoms allocated to the reported nmr 
signals of the HZ22 chemical structure.  
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 Chapter 1. MMP-9 Activated Prodrugs 
1.1 Abstract 
One aspect of this project aims to design, synthesize and evaluate MMP-9 
activated prodrugs that target GABA receptors (with GABA modulators) and 
further incorporating either an antiangiogenic and/or cytotoxic agent. The 
objective will be to find out whether tumour-selective targeting the MMP-9 
increases the anticancer activity (a synergistic effect) and reduces the general 
toxicity compared to using the cytotoxic/antiangiogenic agent alone.  
 
1.2 Hypothesis 
The specificity of the human matrix metalloproteinase, MMP-9 (overexpressed in 
ovarian and colon cancer) for key amino acid residues in the P1- P1´ positions 
can be exploited to activate synthetic oligopeptide prodrug substrates in the 
tumour microenvironment selectively, with concomitant improvement in 
therapeutic index.  
It is proposed that MMP-mediated prodrug activation can be exploited to deliver 
GABA (free ligand) and/or GABA receptor-targeting agents to modulate tumour 
response to cytotoxic and/or vascular disrupting agents. 
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 1.3  Introduction 
1.3.1 MMPs in Tumour and Neurodegenerative Disease 
Matrix metalloproteinases (MMPs) are detected to be over expressed in a variety 
of tumour types. For instance, small cell lung cancer was detected with high 
levels of MMP-3, MMP-11 and MMP-14. High expression of MMP-11 has been 
demonstrated in breast cancer. Patients with prostate cancer have high MMP-2 
level. It was also found that MMP-2 and MMP-9 levels were increased in gastric 
cancer. These findings suggest that MMPs have potential to be used as the 
markers for cancer diagnosis (Zucker et al. 1999). The role of MMPs in tumour 
growth, invasion and metastasis was proposed mainly by preclinical animal 
studies (Vihinen and Kähäri, 2002). It is now widely believed that the activity of 
MMPs facilitates the tumour progression through the extracellular matrix (ECM) 
in two aspects: First, MMPs are responsible for degrading the ECM and 
basement membrane, consequently malignant cells can move through blood 
vessel walls and connective tissues and resulting in cancer metastases (Ray 
and Stetler-Stevenson 1994). Second, MMPs stimulate the secretion or 
activation of ECM growth factors, such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and insulin-like growth factor. The 
multiple roles of MMPs in cancer progression are illustrated in Figure 1.  
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Figure 1. The role of MMPs in cancer progression 
(Adapted from Klein et al. 2004) 
 
Based on extensive literature, MMP-2 and MMP-9 are the most discussed 
MMPs in relation to cancer (for reviews, see Gialeli, Theocharis and Karamanos, 
2011; Hidalgo and Eckhardt, 2001). 
Moreover, MMP activities are linked to the pathogenesis of acute and chronic 
neurodegenerative disorders (Rosenberg, 2009). The level of MMPs, especially 
MMP-9 was detected to be elevated in patients with Alzheimer’s disease, 
epilepsy, dementia, and Parkinson’s disease (Ethell and Ethell, 2007; Mizoguchi, 
Yamada and Nabeshima, 2011; Yong et al., 1998). It is believed that MMPs can 
increase the permeability of the blood-brain barrier and eventually cause white 
matter damage, brain edema, haemorrhage, ischemia and stroke 
(Candelario-Jalil et al., 2011). Recent studies revealed that MMPs are also 
involved in the degradation of amyloid β-proteins in Alzheimer’s disease and 
dopaminergic neurons in Parkinson’s disease (Yong et al., 2001; Mizoguchi, 
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 Yamada and Nabeshima, 2011). To sum up, MMPs are promising targets for the 
treatment of cancer and neurodegenerative disease because of their 
involvement in disease initiation and progression. 
 
1.3.1.1 MMPs activation and regulation 
MMPs are a family of zinc-dependent endopeptidases that are capable of 
degrading a variety of Extracellular Matrix (ECM) components and involved in 
remodeling of many tissues and organs. The MMPs were first described in 1962 
as the enzymes with proteolytic action for dissolution of the tadpole tail (Tallant 
et al., 2010). Now there are more than 20 enzymes classified as MMPs. MMPs 
were found to be over-expressed in a variety of tumours and play a pivotal role in 
tumor growth, invasion, metastasis and angiogenesis (Curran and Murray, 2000). 
The general structure of MMPs consists of five domains: a signal peptide domain, 
a propeptide domain containing a cysteine switch, a catalytic domain, a hinge 
region, and a hemopexin-like domain at the C terminus (showed in figure 2) 
(Nagase and Woessner, 1999). Most MMPs are produced as inactive enzymes 
(zymogens) with a propeptide domain that must be removed for the enzyme 
activation. The propeptide domain contains a cysteine residue which interacts 
with the catalytic zinc atom and prevents the binding and cleavage of the 
substrate. The proteolytic cleavage of propeptide domain triggers a 
conformational change and exposes the catalytic site to the substrate (Murphy 
and Knäuper, 1997).  
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Figure 2. The general domain structure of matrix metalloproteinases (MMPs), 
MMP2 and MMP-9 are gelatinases which contain a fibronectin type II domain 
inserted into the catalytic domain 
(Adapted from Murphy and Nagase, 2008) 
 
The MMPs activity is closely regulated by gene expression and proenzyme 
activators. Most of the time, the level of MMPs produced is very low. The 
expression of MMPs can be induced by a variety of growth factor, cytokines, 
hormones and oncogenes in respond to normal tissue remodelling, wound 
healing, inflammation and cancer (Clark et al., 2009). 
 
1.3.1.2 MMPs inhibitors 
The MMPs activity can be inhibited by non-specific endogenous inhibitors which 
include α1-antiprotease and α2-macroglobulin, and by specific tissue inhibitors 
of the metalloproteinases (TIMPs) (Woessner, 1991; Cao, 2001). The family of 
TIMPs is composed of TIMP-1, TIMP-2, TIMP-3, and TIMP-4. A variety of cell 
types produce the TIMPs (Bonomi, 2002). The TIMPs contain a chelating group 
which binds to the active zinc atom of MMPs resulting in the formation of a 
non-covalent complex. TIMPs are able to inhibit the proteolytic activity of all 
MMPs and many pro-MMPs (Clark et al., 2009; Brew and Nagase, 2010). The 
design of MMPs inhibitors represents an important approach of MMPs targeting 
anticancer drugs (Hinnen et al., 2001). 
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 A number of synthesised MMPs inhibitors have been shown to be effective in the 
treatment of cancer. The peptidomimetic and nonpeptidic MMP inhibitors are 
most studied in clinical trials (Hidalgo and Eckhardt, 2001). The peptidomimetic 
inhibitors were synthesised to mimic the structure of collagen and irreversibly 
bind at the active site of MMPs. The most common clinical used zinc-binding 
group of inhibitors is hydroxamate (Konstantinopoulos et al., 2008). Batimastat is 
the first peptidomimetic inhibitor used in cancer patients. The beneficial aspects 
of Batimastat include mild toxic side effects, prolonged half-life up to 3-4 weeks 
and well tolerated in patients. However, this drug has poor orally bioavailability 
and needed to be intraperitoneally or intrapleurally administered. Marimastat is a 
low molecular weight analogue of Batimastat that has improved solubility. 
Marimastat has now been withdrawn due to the poor performance in clinical 
trials (Sparano et al., 2004). Furthermore, both Batimastat and Marimastat have 
nonselective binding to MMPs (Rasmussen and McCann, 1997). 
One major problem of peptidomimetic inhibitors is the lack of specificity for 
MMPs. In order to overcome this problem, a series of nonpeptidic inhibitors have 
been developed based on the differential three-dimensional conformations of the 
MMPs active zinc sites. Prinomastat (AG3340), BAY 12-9566 and BMS-275291 
were synthesised as specific inhibitors of MMP-2, 3 and 9. The antitumour 
activity of these drugs has been demonstrated in preclinical models (Gatto et al., 
1999; Giavazzi and Taraboletti, 2001). These agents then underwent clinical 
trials for cancer therapy. However, the trials of prinomastat, BAY 12-9566 and 
BMS-275291 had been stopped at phase III because of negative findings and 
did not improve the outcome of chemotherapy (Bissett et al., 2005; Giavazzi and 
Taraboletti, 2001; Leigh et al., 2004) 
 
The tetracycline derivatives have also been found to inhibit both the activity and 
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 production of MMPs. The tetracycline analogues, Doxycycline and Col-3 both 
inhibit the secretion of activity of MMP-2 and MMP-9. Bisphosphonates are 
prevalently used in patients with breast cancer and multiple myeloma. The drug 
also has inhibitory effects on MMPs activity (Hidalgo and Eckhardt, 2001).  
 
1.3.1.3 The substrate preference of MMP-9 
The proteolysis domain structure of MMP-9 gives it well-defined substrate 
preference. The catalytic sites of MMPs are determined by X-ray crystallography 
and NMR spectroscopy, and are assigned to mainly six subunits (subsites or 
pockets): S1, S2, S3 and S1’, S2’, S3’. Correspondingly, the functional residues 
(individual amino acid side-chains) of an MMP substrate interacting with these 
pockets are designated as P1, P2, P3 and P1’, P2’, P3’ positions (Gupta and 
Patil, 2012). The structure relationship between MMPs and their substrates is 
shown in Figure 3. The amide (peptide) bond between the P1 and P1’ position of 
the MMP peptide substrate is called the scissile bond or cleavage ‘hot spot’.  
The substrate selectivity of MMP-9 has been investigated. It becomes clear that 
the deep S1’ pocket prefers a large hydrophobic residue, such as leucine (Leu), 
in the P1’ position of MMP-9 substrates (Gupta and Patil, 2012). Proline (Pro) is 
the most optimizing binding residue in the P3 position. This is because proline 
has a cambered structure which fits well in the S3 pocket of MMP-9. However, 
other MMPs with the same substrate preference in P3 positions are very 
common, such as MMP-7 and MMP-13. For the P2 position, an amino acid with 
long side chain is favoured for MMP-9, such as arginine (Arg). Although Arg was 
also found at P2 in substrates for MMP-13, the frequency was much lower than 
MMP-9 (Kridel et al. 2001). Besides, aspartic acid (Asp) was also reported to be 
prevalent in the P2’ position of natural MMP-9 substrates, whereas MMP-2 
prefers glutamic acid (Glu) (Chen et al. 2003). It has been revealed that glycine 
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 (Gly) most often occupies the P1 position of MMP-2 and MMP-9 substrates 
(Lauer-Fields et al. 2003). The binding of serine (Ser) and threonine (Thr) to the 
S2’ pocket of MMP-9 also showed high frequency (Kridel et al., 2001). 
 
The MEROPS data base was searched for information on preferred peptide 
sequence of MMP-9. Based on 367 cleavages, for example, Gly was in the P1 
position most times (120). Previous work from this laboratory had indicated that 
long, straight chain hydrocarbon residues of the non-proteinogenic amino acids 
norvaline and norleucine were favoured in the P1´ position (Mincher et al., 2006; 
Mincher et al., 2008). The rest of the amino acids of peptide substrate for design 
and synthesis of MMP-9 activated prodrugs in this study were chosen here by 
most common occurrences in reported cleavages (Rawlings, Barrett and 
Bateman, 2012) and illustrated in Figure 3.  
 
Figure 3. MMPs proteolysis pockets and MMP-9 substrate specificity 
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 1.3.2 GABA and its receptors  
GABA (gamma-amino butyric acid) is the main inhibitory neurotransmitter in the 
mammalian central nervous system (CNS). The catalytic enzyme, glutamate 
decarboxylase (GAD), is involved as the major effector in the biosynthesis of 
GABA from glutamate (Barker et al., 1998). 
GABA acts on two distinct types of receptors, GABAA and GABAB. GABAA 
receptor is a ligand-gated chloride ion channel with a fast synaptic inhibition 
effect (Jacob et al., 2008), while GABAB receptor is a G-protein coupled receptor 
with slower synaptic inhibitory transmission. They are both important therapeutic 
targets for the clinical treatment of psychiatric and neurological disease 
(Watanabe et al., 2002). 
It is also found that GABA and its receptors exist in many peripheral organs, for 
instance, liver, pancreas, intestine, kidney, prostate and ovary (Watanabe et al., 
2006). This fact indicates that GABA has more functions than being a 
neurotransmitter. Many studies suggested that GABA plays a regulatory role in 
cell proliferation and migration, which leads to the consideration of the 
involvement of GABA in tumour cell proliferation (Szczaurska et al., 2003). 
 
1.3.2.1 Regulatory role of GABA in Tumour  
The GABA content and its synthesizing enzyme (GAD) activity were reported to 
be increased in certain cancer types such as prostate, gastric, colon, ovarian, 
glioma, and breast cancers (Young and Bordey, 2009).  
In 2003, Azuma et al. reported that GABA promotes prostate cancer metastasis 
by increasing MMP production in cancer cells via the GABAB receptor pathway. 
Also, GABA showed a stimulatory effect on pancreatic cancer with upregulated 
the π subunit of the GABAA receptor (Takehara et al., 2007). 
In contrast, GABA was found to play an inhibitory role in colon carcinoma 
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 (Joseph et al., 2002; Ortega, 2003), cholangiocarcinoma (Fava et al., 2005), and 
lung adenocarcinoma (Schuller et al., 2008b). At this point, it is evident that the 
connections between GABA and cancer are not well understood and this adds to 
the motivation behind this research project. 
 
1.3.2.2 GABAA receptors in Tumour 
The GABAA receptor is a ligand-gated ion channel which selectively conducts 
chloride anions (Cl―) through its pore. GABAA receptors can be found in all 
organisms that have a nervous system (Campagna-Slater and Weaver, 2007). 
In humans, the structure of GABAA receptor consists of varying combinations of 
α, β, γ, π, θ, ε, δ, and ρ protein subunits (Figure 4). Five subunits can combine 
in different ways to form GABAA receptors. Different combinations of these 
subunits may result in distinct pharmacological properties (Olsen and Sieghart, 
2009). The minimal requirement to build a GABAA receptor pentamer is the 
inclusion of both α and β subunits (Connolly et al., 1996). When endogenous 
ligand GABA binds to the GABAA receptor complex, the protein receptor 
changes conformation that cause opening the pore to allow Cl― pass through 
the membrane. Consequently, agonists activate the GABAA receptor resulting in 
increased Cl− conductance. Muscimol is one of selective agonists for the GABAA 
receptor that binds to the same site as GABA, as opposed to drug 
benzodiazepine which binds to a separate regulatory site. For antagonists, 
though they have no effect on their own, compete with GABA for binding and 
thereby inhibit its action, resulting in decreased Cl− conductance (Frølund et al., 
2002) 
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Figure 4. Structure of GABAA receptor 
(Adapted from Jacob at al. 2008) 
 
A number of reports suggested a relationship between GABAA receptors and 
oncogenesis. Considering brain tumours, the expression of GABAA receptors 
was upregulated in human glioma cells (Synowitz et al., 2001), but glioblastoma 
had downregulated GABAA receptor expression (Aronica et al., 2007). The 
decreased level of GABAA α3 subunit and increased level of GABAA β3 subunit 
were detected in human hepatocelluar carcinoma (Liu et al., 2008; Minuk et al., 
2007). The π subunit of GABAA receptor was upregulated in pancreatic and 
breast cancers (Johnson and Haun, 2005). In addition, patients with prostate 
cancer have upregulated expression of GABA and GABAA receptor (Abdul, et al., 
2008). 
The stimulatory action of propofol, a well-known anaesthetic agent and a GABAA 
receptor agonist, on colon tumours inhibited the cancer cell invasion and 
expression of MMP-2 and MMP-9 (Miao et al., 2010). Additionally, the GABAA 
receptor antagonist picrotoxin inhibited prostate cancer cell proliferation (Ippolito 
et al., 2006). 
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 1.3.2.3 GABAB receptors in Tumour 
The heterodimer structure (Figure 5) of the GABAB receptor is composed of two 
subunits GABAB1 and GABAB2. The extracellular domain (ECD) of GABAB1 is 
capable of binding GABA, agonist and antagonist, whereas the ECD of GABAB2 
does not bind any ligands (Kaupmann et al., 1998). The transmembrane domain 
of GABAB2 can bind to certain modulators. The Intracellular domain of GABAB2 
coupled to G-protein and regulates the activities of the Ca2+ channel, K+ channel 
and Adenylyl Cyclase (AC). Both subunits are required for normal GABAB 
receptor function in vivo (Filip and Frankowska, 2008). 
 
Figure 5. The schematic structure of GABAB receptors 
(Adapted from Jiang et al. 2012) 
 
Growing evidence showed that GABAB receptors are involved in tumour 
development. The expression level of GABAB receptors was found to be 
upregulated in human colon cancer cell lines (Thaker et al., 2005), thyroid 
tumours (Roberts et al., 2009), breast cancer (Jiang et al., 2012) and 
hepatocellular carcinoma cell lines (Wang et al., 2008). Furthermore, Zhu et al. 
(2004) revealed that in human gastric cancers, not only GABAB receptors were 
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 overexpressed, but also the localization of GABAB receptors in gastric cancer 
cells is different from normal cells. They found that the majority of GABAB 
receptors were localized on the gastric cancer cell surface other than in the 
cytoplasm which is the main location site of GABAB receptors in normal cells. 
These facts suggest that GABAB receptors may be potential targets for cancer 
therapy and diagnosis. 
The GABAB receptor agonist baclofen significantly attenuated the malignancy of 
human pancreatic (Schuller et al., 2008a), lung (Schuller et al., 2008b), liver 
(Wang et al., 2008), breast, colon, and gastric tumours (Jiang et al., 2012). The 
activation of GABAB receptors has an inhibitory effect on most of human tumour 
types except prostate cancer (Abdul et al., 2008). 
 
1.3.3 Tumour activated prodrugs 
The majority of anticancer drugs are anti-proliferative agents that are able to kill 
rapidly dividing tumours cells. However, these drugs affect normal proliferating 
cells such as hair follicles, bone marrow, lymphatic cells and red blood cells 
(Denny, 2001).The poor selectivity of these chemotherapy drugs could cause 
lethal damage of normal cells and making them not suitable for long term use. 
Hence, improving the target ability and selectivity of anticancer drugs is a major 
challenge. The tumour activated prodrugs (TAPs) strategy in anticancer 
chemotherapy represents a promising approach. TAPs are relatively non-toxic 
and the active pharmacologic agents can be selectively released in tumour cells 
(Rautio et al., 2008). The general design of TAPs is depicted in Figure 6. TAPs 
may consist of four components: 1) an active drug that exhibits the 
pharmacologic effect. 2) a chemical linker which links the active drug to the rest 
part of TAPs. 3) a peptide spacer that can be cleaved by tumour specific 
enzymes, or a polymer spacer 4) a targeting moiety that is responsible for 
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 specific delivery to tumour cells. Many antigens and enzymes have been proven 
to be over expressed in tumour cells and are commonly used targets for TAPs 
(Mahato et al., 2011). 
 
Figure 6. General design of a tumour activated prodrug 
(Adapted from Mahato et al., 2011). 
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 1.4  Results and discussion 
1.4.1 The design strategy of MMP-9 activated prodrugs 
In this study, the general proposed design of MMP-9 activated prodrugs is 
composed of three main parts (Figure 7): an MMP-9 cleavable peptide linker in 
the middle of the prodrug, one side of the peptide linker is attached with a ligand 
of GABA, either a GABA agonist or antagonist that targets GABA receptors, the 
other side of the cleavable oligopeptide linker can be an antiangiogenic/cytotoxic 
agent (for therapeutic purpose) or a fluorescent label such as a 
fluorescein-derived agent (for diagnostic purpose). 
 
 
Figure 7. General concept of MMP-9 activated prodrug design 
 
Once the prodrug has been administered and reached the tumour, because 
tumour cells have over expressed MMP-9, the prodrug will be cleaved 
extracellularly at the MMP-9 specific peptide cleavage site or ‘hotspot’. After that, 
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 the remaining amino acids that are still attached to the active agent will be 
degraded by aminopeptidases, which are ubiquitous in almost all cell types. This 
will cause the release of the active drugs to the tumour cells. 
The MMP-9 activated prodrug will remain inactive until the peptide linker is 
cleaved by MMP-9. The presence of high levels of MMP-9 in tumours but not in 
normal tissues increases the prodrug selectivity (Lim et al. 2010) 
Based on the previous work of this lab, a prototype, latently fluorescent 
oligopeptide conjugate of a cytotoxic topoisomerase inhibitor, EV1-FITC was a 
good proof-of-principle example of MMP-9 activated prodrugs. The prodrug was 
able to target multiple myeloma and release fluorescence by MMP-9 activation 
(Van Valckenborgh et al. 2005). 
 
1.4.2 Synthesis of Model compounds 
The active drug propranolol was first considered in this study. Propranolol is a 
well-known non-selective beta-blocker (or GABAB receptor antagonist) and has 
been introduced as a novel drug for the treatment of haemangiomas, which are 
the most common tumours of infants (Zimmermann et al. 2010). Several recent 
papers reported the Inhibitory efficacy of propranolol on MMP-9 secretion 
(Annabi et al. 2001) and the anti-angiogenic property in tumours (Lamy et al. 
2010; Pasquier et al. 2011). 
Before using the active drug propranolol for the synthesis of designed MMP9 
activated prodrugs, a model compound (NU: UB 491), which serves as a mimic 
of the structure of propranolol was used first. The compound NU:UB 491 used in 
this study had been previously synthesised, in two steps, from the reaction of 
1-chloroanthraquinone with 1,3-diamino-2-propanol in DMSO, following methods 
described by Katzhendler et al. (1989), to give the 
(aminoalkyl)aminoanthraquinone intermediate. This was further reacted with 
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 di-tert-butyl dicarbonate (Boc2)O, in order to protect the primary amino group, 
ensuring that only the secondary alcohol was available for reaction.  
The model compound NU: UB 491 and propranolol both have hydroxyl (-OH) 
and amine (-NH) functional group which are important sites for chemical 
reactions, including acting as potential positions for attachment of peptide linkers 
in the intended prodrug substrates here (Figure 8). 
 
 
Figure 8. Chemical structures of NU:UB 491 and propranolol 
 
In order to find conditions for selective reactions on the NH or OH functional 
group of propranolol, the model compound was used as a starting material for 
the synthesis of HZ26, HZ27 and HZ28. Moreover, the model compound is red 
which makes it easier for monitoring the synthesis of derivatives and easier to 
establish good chromatographic purification methods ahead of using the 
colourless and more expensive propranolol. 
 
1.4.2.1 Synthesis of Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) 
The N-Fmoc protected β-Alanine amino acid (Fmoc-β-Ala-OH) (intended linker) 
was reacted with the model compound, NU: UB 491 using DCC and DMAP as 
ester coupling reagents (El-Faham and Albericio, 2011) in dichloromethane 
(solvent) (Scheme 1). The mixture was stirred and monitored by thin-layer 
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 chromatography on silica plates (TLC test). The reaction was completed in 1 
hour. The precipitated byproduct DCU was filtered off. The crude product was 
purified by solvent extraction and silica gel column chromatography using the 
eluting solvent dichloromethane-ethyl acetate (7:1). The pure product (HZ26) 
was triturated by the addition of diethyl ether and the resulting red solid was 
collected. Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) was characterized by NMR 
spectroscopy. The 1H spectrum showed a signal for a 9-proton singlet at 1.45 
ppm confirming the Boc group. All of the anthraquinone protons were 
successfully assigned; a doublet at 7.15 was assigned to H-2, H-3 and H-4 gave 
a triplet at 7.4ppm, H-6 and H-7 were found between 7.5 and 7.63 ppm, H-5 and 
H-8 appeared as a triplet at 8.22 ppm and 8.3 ppm respectively. 
 
Reagents and Conditions: (a) DCC & DMAP In dichloromethane 
                 Scheme 1. Outline of HZ26 chemical synthesis  
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 1.4.2.2 Synthesis of H-Ala-Spacer-AQ TFA salt (HZ27) 
The Boc protecting group of Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) was removed 
by TFA (Montalbetti and Falque, 2005) in solution after 10 minutes of reaction 
(Scheme 2). According to TLC test, the product was pure and ready to collect. 
The solution was then evaporated to a small volume and diethyl ether was 
added to precipitate the solid product. H-Ala-Spacer-AQ TFA salt (HZ27) was 
characterized by NMR spectroscopy. 
 
 
Reagents and Conditions: (a) TFA 
Scheme 2. Outline of HZ27 synthesis 
 
1.4.2.3 Synthesis of H-Ala-[Boc-Spacer]-AQ (HZ28) 
Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) was Fmoc deprotected by 2% piperidine in 
DMF (Scheme 3). The reaction was completed in 30 min by checking the TLC. 
The amount of piperidine used in this reaction was much less than usual 
literature precedent which is 20% in DMF (Montalbetti and Falque, 2005). The 
crude compound was purified by extraction and column chromatography using 
chloroform-methanol (8:1) solvent system. The pure product was collected by 
precipitation in diethyl ether. The chemical structure of H-Ala-[Boc-Spacer]-AQ 
(HZ28) was confirmed by NMR spectroscopy. 
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Reagents and Conditions: (a) 2% piperidine in DMF 
Scheme 3. Outline of HZ28 synthesis 
 
1.4.2.4 Synthesis of Fmoc-Ala-Propranolol (HZ29) 
Using some of the knowledge gained from selective reaction on functional 
groups in the model compound (above), derivatisation of the antiangiogenic 
GABAB antagonist propranolol was attempted. The design strategy was to 
introduce an amino acid (β-alanine) as the first residue for peptide synthesis, by 
selective reaction on the amino group (NH) of the drug. The success of this 
reaction would depend on the intrinsic greater reactivity of the amino group over 
hydroxyl. If reaction occurs at the hydroxyl group then an ester would be formed. 
Propranolol hydrochloride (its OH and NH functions unprotected) was reacted 
with Fmoc-β-Ala-OH, using standard coupling reagents TBTU, HOBt, and 
DIPEA (Montalbetti and Falque, 2005). The mixture was suspended in DMF at 
RT overnight (Scheme 4). All reagents and product are colourless in solution 
and on TLC plates. In order to confirm which spot on the TLC plate is the product, 
a de-Fmoc mini test using piperidine (20%) in dichloromethane was performed. 
After 2 hours reaction, a TLC was checked under the UV light and found that one 
of the spots on product lane moved down to the bottom line, which indicates that 
spot is the product HZ29. The crude product was extracted with 
dichloromethane/water, dichloromethane/aqueous citric acid (to remove 
propranolol free base) and dichloromethane/aqueous sodium bicarbonate (to 
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 remove excess Fmoc-β-Ala-OH). Further purification was done by column 
chromatography using eluting system dichloromethane-ethyl acetate (1:1). The 
pure product fractions were combined, filtered and evaporated to dryness. The 
white solid Fmoc-Ala-Propranolol (HZ29) was collected under vacuum. 
 
Reagents and Conditions: (a) TBTU, HOBt, DIPEA in DMF 
Scheme 4. Outline of HZ29 synthesis 
 
The structure of Fmoc-Ala-Propranolol (HZ29) was confirmed by is 1H NMR 
spectrum. The signals between 7.28 and 7.58 were assigned to the aromatic 
protons of the Fmoc protecting group. The propranolol protons were fully 
assigned; H-2 at 6.9 ppm, H-3 and H-4 gave a multiplet at 7.6-7.7 ppm, H-5, H-6, 
H-7 and H-8 gave a multiplet between 7.7 and 7.9 ppm. The signals at 1.2-1.45 
ppm reflected the protons of the two methyl group.  
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 1.4.3 Synthesis of Prodrug 1: Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol 
(HZ32) 
After the work on model compound derivatives, a series of MMP-9 activated 
prodrugs targeting GABA receptors were synthesised. The design strategy of 
prodrug 1 was to use a MMP-9 cleavable peptide substrate 
(Pro-Ala-Gly-Leu-Ala-Ala) as a linker. One side of the peptide linker is attached 
to propranolol which is both an antiangiogenic agent and a GABAB receptor 
antagonist. The other side of the linker is an Fmoc protecting or so called 
‘capping’ group. 
The synthetic process for prodrug 1 was started with the N-terminal 
Fmoc-protected hexapeptide linker, Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31) 
which was synthesised by a solid phase peptide synthesis (SPPS) method. 
SPPS is the process by which peptide synthesis can be carried out on solid 
support, was first developed by Bruce Merrifield and earned him the Nobel Prize 
in 1984. SPPS has many advantages over traditional synthesis such as all 
reagents can be simply washed away each step, overall quicker time for 
synthesis, convenient work-up and the synthetic intermediates do not have to be 
isolated (Montalbetti & Virginie 2005). By contrast, in solution phase peptide 
synthesis, all peptide intermediates requires isolation and the synthesis cycles 
are very labour intensive. In this study, five steps were involved in the SPPS: (1) 
Resin swelling (2) Amino acid deprotection (3) Colour test to detect the presence 
or absence of free amino groups during the synthesis process (4) Peptide 
coupling (5) Hexapeptide-resin cleavage. 
 
1.4.3.1 Resin swelling 
Fmoc-Ala-Wang resin (Figure 9) was shaken at RT, 750 rpm for 1.5 hour in 10ml 
dichloromethane using an orbital shaker to maximize its surface area for peptide 
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 coupling. Dichloromethane was drained off and resin was washed by DMF 3 
times (2 mins each time) for the next step. 
 
Figure 9. Fmoc-Ala-Wang Resin 
 
1.4.3.2 Deprotection of Fmoc protecting group 
The Fmoc protected group of the amino acid must be removed before growing 
the peptide. This was achieved by the addition of 20% (v/v) piperidine in DMF to 
the SPPS vessel and shaken for 15 mins. The deprotection step was repeated 
for 3 times. The reagents were drained off and the resin was washed by DMF 3 
times (2 mins each time). The chemical mechanism of Fmoc deprotection by 
piperizine is showed in Scheme 5. 
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Scheme 5. Proposed mechanism of Fmoc deprotection by piperidine 
(Adapted from Okada 2001) 
1.4.3.3 Colour Test 
In this study, an in-house Colour test (Figure 10) was performed to replace the 
Kaiser test (which often gives poor results with Wang resin and requires toxic 
reagents). [Refer also to the topic of Chapter 4]. 
 
Figure 10. The reaction mechanism of HZ22 colour test. 
 
About 1 mg of the colour test reagent AQ-Ahx-OPFP (HZ22) compound, 2 drops 
of DMF and 1 drop of DIPEA were added to a sample bottle to give a red solution. 
A small number of resin beads were then transferred to the vial. After 5 minutes, 
a large amount of DMF was added to dilute the solution. This facilitated the 
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 colour observation of the beads. All beads had turned into red from their original 
light yellow colour, which indicated that the deprotection has completed. For 
each stage of amino acid coupling or Fmoc deprotection, the colour test was 
performed. The synthesis of AQ-Ahx-OPFP (HZ22) compound is discussed in 
Chapter 4. 
Compared to the Kaiser Test, this colour test is more sensitive and less toxic. For 
instance, one of the reagents for the Kaiser test is potassium cyanide which is 
highly toxic (Friedman 2004). Based on the experiments in our laboratory, the 
Kaiser test is not very effective for some amino acids, eg. Proline. Needless to 
say, the Kaiser test requires 80°C for the reaction while the colour test used in 
this study was done at RT. Hence, the colour test can be a promising technique 
for future SPPS. 
 
1.4.3.4 Peptide coupling 
At the peptide coupling stage, an Fmoc-protected amino acid containing its free 
carboxylic acid was reacted with the free amino group of the growing 
peptide-resin. Based on the formation of amide bond, the basic conditions and 
coupling agents included Fmoc-protected amino acid, TBTU, HOBt and DIPEA 
dissolved in DMF. The coupling solution was added to the SPPS vessel by two 
times, each time shaken for 40 min at RT. The colour test was performed to 
confirm the completion of peptide coupling.  
The Fmoc-protected amino acid was deprotonated by DIPEA and nucleophilic 
substituted by TBTU which had two forms, uranium salt and guanidium in 
solution. The generated uranium ester intermediate was rapidly reacted with 
HOBt and leading to the production of the coupled peptide (Scheme 6). 
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Scheme 6. Chemical mechanism of peptide coupling using reagents TBTU, 
HOBt and DIPEA 
(Adapted from Carpino et al. 2001; Montalbetti & Virginie 2005) 
 
1.4.3.5 Hexapeptide-resin cleavage 
After the hexapeptide coupling, the Fmoc-protected hexapeptide needed to be 
removed from the resin. The Wang resin is known to be sensitive to acid and 
hence the attached hexapeptide was cleaved by the addition of 95% TFA and 5% 
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 dichloromethane to the vessel for 2-3 min with shaking. The solution was 
drained into the flask and checked by TLC The procedure was repeated up to 10 
times until there was no new spot on the TLC The resin was then washed with 
dichloromethane (2 times), methanol (2 times), and dichloromethane once. All 
filtrates were combined, evaporated to dryness and triturated in diethyl ether at 
5 °C for 1 hour. The product was collected by filtration and dryness in a 
desiccator. Figure 11 shows the overview of Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH 
(HZ31) on solid phase peptide synthesis. 
 
 
 
Figure 11. Solid phase peptide synthesis of Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH 
(HZ31) 
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 The prodrug 1 Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ32) was prepared 
from the reaction of propranolol hydrochloride and 
Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31) in DMF using TBTU, HOBt and 
DIPEA as the coupling agent. DIPEA was added to make the free base of 
propranolol hydrochloride (Scheme 7). Because the reaction between NH group 
and COOH group is faster than OH group and COOH group, a large amount of 
DMF was used to facilitate the NH group of propranolol to react with the COOH 
group of Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31). 
 
Reagents and Conditions: (a) TBTU, HOBt, DIPEA in DMF 
Scheme 7. Outline of Prodrug 1 (HZ32) synthesis 
 
The reaction was completed overnight at RT. The crude product was purified by 
extraction and silica gel column chromatography. The reaction solution was 
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 extracted with water and dichloromethane. Multiple extractions were required to 
wash away impurities. For the first extraction, citric acid was added to the water 
layer to get rid of excess propranolol free base. Secondly, the excess 
Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31) was removed from the organic phase 
by shaking the organic extract with aqueous sodium bicarbonate. The weak acid 
HZ31 can react with sodium bicarbonate to form the sodium salt, carbon dioxide 
and water. 
Because the starting material, reagents and crude product were colourless on 
TLC plate, a mini de-Fmoc colour test was performed to confirm the presence of 
the product (Prodrug 1). The product will have a free amine group which is able 
to be detected after the Fmoc deprotecting reaction. Piperidine 20% in DMF was 
added to the crude product sample solution. After 20 minutes, the solution was 
extracted with water and dichloromethane. The extract in organic layer was 
checked by TLC using the running solvent, dichloromethane and methanol 9:1. A 
few drops of 5% ninhydrin in ethanol were added on the TLC plate at the product 
lane. After 5min, there was a purple spot emerged which indicated the Fmoc free 
prodrug 1. 
The eluting solvent system, dichloromethane-ethyl acetate-ethanol (9: 2: 1) was 
used during the column chromatography. The difficulty of this purification 
process was that the crude product solution was colourless. In this case, many 
fractions were collected and every fraction was about 2-3 ml in volume. All 
fractions were confirmed by TLC under UV light. The appropriate fractions were 
combined, filtered and evaporated to dryness. Diethyl ether was used to 
precipitate the pure white product. Due to the small amount of solid precipitate in 
ether, the final product was collected in centrifuge tubes. 
Prodrug 1 compound (Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol) HZ32 was 
characterized by its electrospray mass spectrum which gave a signal at m/z 962 
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 for (M+H)+ corresponding to a molecular mass of 961 (Figure 12). 
 
 
 
Figure 12. The ESI (+) Mass spectrum of Prodrug 1 (HZ32) 
 
1.4.4 Synthesis of Prodrug 2: 
AQ-Spacer-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ34) 
Prodrug 2 had the same MMP-9 cleavable hexapeptide chain in the middle and 
active drug propranolol on one side as prodrug 1. The only difference is that 
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 Prodrug 2 has the capping group which is an anthraquinone derivative instead of 
Fmoc (Scheme 8).  
The N-Fmoc protected hexapeptide (Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH) HZ31 
was repeatedly synthesised by SPPS method for prodrug 2. However, this time 
instead of cleaving HZ31 off the resin, HZ31 was remained on the resin for the 
next step. The Fmoc group of HZ31 was removed by 20% piperidine in DMF to 
give an N-terminal free hexapeptide HZ32. 
The free amino group of the resin bound hexapeptide was then capped with a 
cytotoxic aminoanthraquinone via a carbamate bond, by reaction with the 
activated anthraquinone derivative (HB8) using DIPEA in DMF. 
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Reagents and Conditions: (a) 20% piperidine in DMF (b) DIPEA, in DMF (c) 87% TFA in 
dichloromethane (c) TBTU, HOBt, DIPEA in DMF 
Scheme 8. Outline of Prodrug 2 (HZ34) synthesis 
 
The compound HB8 used here had been previously synthesised from the 
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 reaction of 1-[3-hydroxypropyl)amino]-anthraquinone with 4-nitrophenyl 
chloroformate (NPC) in dichloromethane and pyridine; activated NPC derivatives 
of alcohols readily react with amines to give carbamates, with the 4-nitrophenol 
by-product being easily washed out with DMF during the SPPS process after 2 
hours of reaction. The anthraquinone-spacer-Pro-Ala-Gly-Leu-Ala-Ala-OH 
(HZ33) was cleaved off the resin by TFA in dichloromethane. The TLC test was 
performed and showed a major red product had formed. The product solution 
was evaporated to a small volume and added with diethyl ether to precipitate the 
pure red solid (HZ33).  
The collected HZ33 was then reacted via its free carboxylic acid group with the 
free amino group of propranolol•HCl salt, followed by the addition of TBTU, 
HOBt, and DIPEA as the standard coupling reagents. The reaction mixture was 
suspended in DMF. The reaction was completed in 4 hours by checking the TLC. 
After solvent extraction and column chromatography using 
dichloromethane-methanol (9:1), the pure prodrug 2 (HZ34) was precipitated in 
diethyl ether to give a red solid product. 
The prodrug 2 AQ-Space-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ34) was 
characterized by mass spectroscopy. A signal at m/z 1069 for the mono-cation 
(M+Na)+ confirmed the molecular mass of 1046 Daltons (Figure 13). 
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Figure 13. MALDI Mass spectrum of Prodrug 2 (HZ34) 
 
1.4.5 Synthesis of Prodrug 3: 
FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ43) 
 
The middle part of the chemical structure of prodrug 3 (HZ43) contains a MMP-9 
cleavable pentapeptide (Pro-Ala-Gly-Leu-Pro) and GABA. Fluorescein 
isothiocyanate isomer I (FITC) was attached to one side of the middle chain. The 
other side of the prodrug 3 was capped by the anthraquinone derivative 
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 (Scheme 9). 
Prodrug 3 (HZ43) was designed to release GABA and fluorescein in tumour cells 
which have over-expressed MMP-9. The prodrug can be a diagnostic probe of 
MMP-9 activity, and also the released GABA into tumour cells will be able to 
evaluate the expression level of GABA receptors.  
 
 
*This synthesis scheme is continued on the next page 
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Reagents and Conditions: (a) TBTU, HOBt, DIPEA in DMF (b) 20% piperidine in DMF (c) 
DIPEA, in DMF 
Scheme 9. Outline of Prodrug 3 (HZ43) synthesis 
 
The synthesis of Prodrug 3 
(FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ) started with the reaction 
of NU: UB 197 and Fmoc-γ-aminobutyric acid (GABA). NU:UB 197 is an 
aminopropylamino anthraquinone derivative that has been used extensively in 
previous and current research within this laboratory.  Where NU:UB can be 
described as an ‘anthraquinone-spacer’, coupling of NU:UB 197 to amino acids, 
to give spacer-linked anthraquinone-amino acid conjugates, afforded a series of 
compounds that were shown to be DNA binding, topoisomerase inhibitors 
(Pettersson, 2004; Turnbull, 2003; Young, 2006).  These compounds had 
broad-spectrum activity in vitro at low micromolar concentrations in panels of 
human and animal tumour cell lines, including those of the NCI 60 cell line 
anticancer drug screen (https://dtp.cancer.gov/default.htm). Additionally, leading 
members of the ‘NU:UB’ series were active in vivo in experimental colon cancer 
(Mincher et al., 1999) and have been used at various times throughout this 
research programme, for example, in chapter 2, the propyl- spaced proline, 
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 conjugate was incorporated into a cyclic baclofen prodrug. Here, GABA was 
coupled to NU:UB 197 to afford a novel spacer-linked anthraquinone-amino acid 
conjugate. Fmoc-γ-aminobutyric acid (GABA) was reacted with the free amino 
group of NU:UB 197 in DMF, using standard coupling reagents TBTU, HOBt, 
and DIPEA. The reaction was completed in 1 hour. The reaction solution was 
poured into water which contained a small amount of HCl. The red solid 
precipitate in the water was collected by filtration. The crude product was then 
purified by silica gel column chromatography, using the eluting solvent 
dichloromethane-methanol (9:1). The pure product (HZ35) was dried in an 
evaporating basin. Fmoc-GABA-[Propyl-spacer]-AQ (HZ35) was Fmoc 
deprotected for the further coupling reaction with amino acids, using 20% 
piperidine in DMF. After solvent extraction and evaporation, diethyl ether was 
added to precipitate the pure red solid product H-GABA-[Propyl-spacer]-AQ 
(HZ36).  
The MMP-9 specific peptide linker, Pro-Ala-Gly-Leu-Pro was added to HZ36 by 
solution phase peptide synthesis which allowed large-scale and high yield 
production of peptide. The solution phase peptide synthesis involved coupling of 
N-Boc protected amino acids and Boc group removal reaction. The Coupling 
reagents are as the same as solid phase peptide synthesis, which are TBTU, 
HOBt, and DIPEA. Solvent extraction and column chromatography were 
required. TFA was used to remove the Boc protecting group.   
Fluorescein isothiocyanate isomer I was coupled to 
Pro-Ala-Gly-Leu-Pro-GABA-spacer-Anthraquinone TFA salt (HZ42) in DMF by 
the addition of DIPEA to form the final product Prodrug 3. The reaction was 
completed overnight at RT. The reaction solution was poured into water to get 
orange solid precipitate. The crude product was purified by silica gel column 
chromatography using eluting solvent dichloromethane- methanol (6:1).  
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 The nanoelectrospray negative ion mass spectrum (M-H)- of prodrug 3 
(FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ) HZ43 had a strong 
signal at m/z 1188 confirmed the molecular mass of 1189 (Figure 14). 
 
 
 
Figure 14.  Mass spectrum of Prodrug 3 (HZ43) 
 
1.4.6 Synthesis of Prodrug 4: 
AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-ethylpiperidine-3-carboxylate 
(HZ45) 
The GABA receptor antagonist, (R)-ethylpiperidine-3-carboxylate (Zhang et al. 
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 2007) was used as the active drug in Prodrug 4 synthesis. The 
anthraquinone-spacer-Pro-Ala-Gly-Leu-Ala-Ala-OH conjugate (HZ44) was 
linked to it to form Prodrug 4. 
AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-OPFP (HZ44) was prepared from the 
overnight reaction of AQ-Spacer--Pro-Ala-Gly-Leu-Ala-Ala-OH HZ33 (from 
prodrug 2 synthesis) and pentafluorophenol in dichloromethane using DCC and 
DMAP as coupling reagents (Scheme 10). 
 
 
*This synthesis scheme is continued on the next page 
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Reagents and Conditions: (a) DCC & DMAP in Dichloromethane (b) DIPEA, in 
Dichloromethane 
Scheme 10. Outline of Prodrug 4 (HZ45) synthesis 
 
The carboxylic group of AQ-Spacer--Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ33) was 
converted into a pentafluorophenolate active ester which will be more reactive 
for adding the active drug (R)-ethylpiperidine-3-carboxylate. The precipitated 
dicyclohexylurea (DCU) was filtered off. The crude product was kept in the 
dichloromethane for the next reaction without further purification. 
(R)-Ethylpiperidine-3-carboxylate and DIPEA was put into the solution. Solvent 
extraction and column chromatography were performed to give a pure red 
product, Prodrug 4 
(AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-ethylpiperidine-3-carboxylate). 
 
The final HZ45 compound, 
anthraquinone-spacer-Pro-Ala-Gly-Leu-Ala-Ala-ethylpiperidine-3-carboxylate 
(Prodrug 4) was characterized by its mass spectrum (M+Na)+ and (M+K)+ which 
showed signals at m/z 967 and 983, corresponding to a relative molecular mass 
of 944 Da (Figure 15).  
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Figure 15. MALDI Mass spectrum of Prodrug 4 (HZ45) 
 
1.4.7 Synthesis of Prodrug 5: 
Podophyllotoxin-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ 47) 
The designed tumour activated Prodrug 5 (HZ47) consists of the cytotoxic drug 
podophyllotoxin (Canel et al. 2000), a MMP-9 cleavable pentapeptide 
(Pro-Ala-Gly-Leu-Pro), GABA, and a capping group (anthraquinone derivative). 
For the synthesis of prodrug 5 
Podophyllotoxin-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ47), 
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 H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ42 (from Prodrug 
3 synthesis) was reacted with succinic anhydride by the addition of DIPEA in 
DMF (Scheme 11). 
 
 
 
Reagents and Conditions: (a) DIPEA, in DMF (b) TEA & TBTU in DMF & Acetonitrile 
Scheme 11. Outline of Prodrug 5 (HZ47) synthesis 
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 The reaction was completed in 4 hours. The crude product was firstly isolated by 
partitioning between dichloromethane and water. During the process, the water 
phase was coloured purple. This is because 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ42) has relatively 
high solubility in water. The yield of HZ42 was low due to the loss during 
extraction. Further purification by column chromatography was performed using 
dichloromethane-methanol (4:1) eluting solvent. The pure HZ42 was collected in 
diethyl ether. 
Podophyllotoxin was coupled to the 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ42) by using the 
reagents TEA and TBTU (Balalaie, Mahdidoust and Eshaghi-najafabadi, 2008) in 
a mixture solvent of DMF and acetonitrile. The reaction was completed in 3 
hours by checking the TLC. Acetonitrile was evaporated off. The crude product 
in DMF was extracted with dichloromethane and water. Column chromatography 
was applied for further purification using the dichloromethane-methanol (9:1) 
eluting solvent. The final product 
Podophyllotoxin-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ47) was 
collected in an evaporating basin at RT. 
 
In the mass spectrum (Figure 16) of prodrug 5 (HZ47), a signal at 1321 m/z was 
assigned to the ion (M+Na)+ confirming the molecular mass of 1296 Da. 
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Figure 16. Mass spectrum of Prodrug 5 (HZ47) 
 
1.4.8 Synthesis of Prodrug 6: AQ-Spacer-Pro-Ala-Gly-Nva-Pro-Baclofen 
(HZ54) 
Prodrug 6 was designed to use active drug baclofen which is a GABAB agonist. 
The capping group anthraquinone derivative was attached to the MMP-9 specific 
pentapeptide (Pro-Ala-Gly-Nva-Pro). Baclofen was linked to the other side of the 
peptide chain. During the anticipated prodrug 6 metabolism, baclofen is 
expected to be released in the tumour cells which have over-expressed MMP-9 
53 
 and targets the GABAB receptor. 
 
 
*This synthesis scheme is continued on the next page 
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Reagents and Conditions: (a) 20% piperidine in DMF (b) TBTU, HOBt, DIPEA, in DMF 
(c) 5% TFA in dichloromethane (d) DCC & DMAP, in dichloromethane (e) DIPEA, in 
dichloromethane 
Scheme 12. Outline of Prodrug 6 (HZ54) solid-phase synthesis 
 
H-Pro-2ClTrt resin was used for building up the MMP 9 cleavable peptide linker 
Fmoc-Pro-Ala-Gly-Nva-Pro-Resin (HZ51) for Prodrug 6 (HZ54) based on the 
SPPS method (Scheme 12). After completed synthesis of the pentapeptide 
Fmoc-Pro-Ala-Gly-Nva-Pro on resin, the Fmoc group was removed by 20% 
piperidine in DMF. The anthraquinone capping group (TL12) was coupled to the 
pentapeptide chain by TBTU, HOBt and DIPEA in DMF. The 
Anthraquinone-spacer-Pro-Ala-Gly-Nva-Pro-OH conjugate (HZ52) was cleaved 
off the resin using 5% TFA in dichloromethane. The red solid 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH (HZ52) was precipitated in diethyl ether 
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 and collected for the reaction with PFP. DCC and DMAP were used as standard 
reagents for the addition of PFP to AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH (HZ52). 
The reaction mixture was suspended in dichloromethane. The reaction was very 
slow at RT. In order to push the reaction, the round bottomed flask was put on 
40°C water bath. Due to the TLC test, there was still unreacted starting material 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH (HZ52) after 2 days. DCU was filtered off. 
Solvent extraction was done between chloroform and aqueous sodium 
bicarbonate (to remove unreacted HZ52). 
 
The purity of pentapeptide Fmoc-Pro-Ala-Gly-Nva-Pro-OH (HZ51) was 
analysied by HPLC (Figure 17). A reverse phase column (Agilent Zorbax Extend 
C18, 5 µm, 4.6 mm x 50 mm) was used with gradients developed over a 15 min 
period as shown in Table 1.  
 
 
Figure 17. HPLC chromatogram of HZ51 
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Table 1. HPLC gradient mobile phase composition 
 
The HPLC result (Figure 17) above confirms that pentapeptide 
Fmoc-Pro-Ala-Gly-Nva-Pro-OH (HZ51) has high purity through the solid phase 
peptide synthesis. 
 
The prodrug 6: AQ-Spacer-Pro-Ala-Gly-Nva-Pro-Baclofen (HZ54) was prepared 
by the reaction of AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OPFP (HZ53) and baclofen 
using DIPEA in dichloromethane. Because the solubility of baclofen in 
dichloromethane is very low, the reaction mixture was stirred over 30 hours. 
DCU and unreacted baclofen were filtered off and the crude compound was 
purified by thick TLC plate using the running solvent dichloromethane-methanol 
(6:1).  
 
Furthermore, the mass spectrum showed a signal at m/z 950 (M-H)- 
corresponding to the molecular mass of 951 for prodrug 6: 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-Baclofen (HZ54) as shown in Figure 18. 
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Figure 18.  ESI (+) Mass spectrum of Prodrug 6 (HZ54) 
 
1.4.9 Synthesis of Prodrug 7: 
5(6)-Carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ57) 
Prodrug 7 (HZ57) has the same chemical structure as prodrug 3 
(FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ), except for using the 
different fluorescent group, 5(6)-carboxyfluorescein. 
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Reagents and Conditions: (a) ByBOP & DIPEA, in DMF 
Scheme 13. Outline of Prodrug 7 (HZ57) synthesis 
 
For the synthesis of prodrug 7 
5(6)-Carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ57), 
the fluorescein agent 5(6)-carboxyfluorescein was coupled to the compound of 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ42), using 
PyBOP and DIPEA in DMF for overnight reaction (Scheme 13). The crude 
product was purified by extraction and silica gel column chromatography 
(dichloromethane-methanol 5:1). The appropriate fractions were combined, 
filtered to an evaporating basin and evaporated to dryness at RT. 
The final product Prodrug 7:  
5(6)-carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ57) 
was characterized by its mass spectrum (M+H)+ which has a strong signal at m/z 
1159 corresponding to a molecular mass of 1158 (Figure 19). 
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Figure 19. ESI (+) Mass spectrum of Prodrug 7 (HZ57) 
 
1.4.10 Synthesis of Prodrug 8: 
Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ16) 
1.4.10.1 Synthesis of Boc-Ala-Ala-Piperazinyl-AQ (HZ7) 
The synthesis of prodrug 8 started with the synthesis of a 2-piperazinyl 
anthraquinone spacer compound, NU: UB 341, where NU:UB 341  was 
synthesised following a previously described method (Mincher, Turnbull and Kay, 
2003), by nucleophilic displacement of chlorine from 2-chloroanthraquinone with 
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 a large excess of piperazine hexahydrate in DMSO. Crude NU:UB 341 was 
isolated by precipitation and purified by column chromatography before reaction 
with a commercially available Boc protected dipeptide (Boc-Ala-Ala-OH) in DMF, 
using standard peptide coupling conditions, TBTU, HOBt and DIPEA. The 
reaction mixture was kept at RT overnight (Scheme 14). 
 
Reagents and conditions: TBTU, HOBt, DIPEA, dissolved in DMF, RT, overnight 
Scheme 14. Synthesis of Boc-Ala-Ala-Piperazinyl-AQ (HZ7) 
 
Once the reaction was completed by checking TLC (dichloromethane-methanol 
9:1), the mixture solution was extracted using dichloromethane and water to 
remove DMF. The organic layer was dried (by the addition of anhydrous 
sulphate), filtered, evaporated to a small volume and the purified by column 
chromatography using the same solvent system as TLC test. The eluted solution 
was filtered to get rid of silica gel and then evaporated to dryness by using the 
rotational evaporating machine. The product remained in the round bottomed 
flask for the Boc-deprotection reaction. This procedure allowed two amino acids 
to be simultaneously incorporated by the use of a pre-formed dipeptide, ala-ala. 
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 Single amino acid conjugates of the 2-piperazinyl anthraquinone spacer 
compound, NU:UB 341, have previously shown anticancer activity in vitro. For 
example, a isoleucine conjugate, NU:UB 234, had broad-spectrum activity in 
vitro at low micromolar concentrations in the NCI 60 cell line anticancer drug 
screen and was a dual topoisomerase I and II inhibitor (Mincher, Turnbull and 
Kay, 2001; Young, 2006). From previous studies on this class of compound, 
where amino acids are coupled to piperazinyl spacers through a tertiary amide 
bond, it would be expected that after metabolism of prodrug 8 (HZ 16) at the key 
gly~leu bond by endoprotease cleavage by MMP-9, further protease 
degradation should result in release of a potentially cytotoxic 
anthraquinone-piperazinyl-alanine conjugate, with no further metabolism to the 
spacer compound (NU: UB 341), as tertiary amides are generally considered to 
be resistant to enzymatic cleavage. Hence, prodrug 8 has been designed as a 
dual acting ‘twin’ prodrug containing both cytotoxic anthraquinone derived and 
tubulin binding, vascular disrupting podophyllotoxin active agents. 
 
1.4.10.2 Synthesis of H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8) 
The Boc group of Boc-Ala-Ala-Piperazinyl-AQ (HZ7) was removed by TFA 
treatment for the next amino acids coupling reaction. TFA was added to the 
round bottomed flask until the solid had completely dissolved (Scheme 15). 
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Reagents and conditions: (a) TFA, RT, 1.15 hours 
Scheme 15. Synthesis of H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8) 
 
After 1.15 hours, the reaction had completed by checking TLC 
(chloroform-methanol 9:1). The solution was evaporated to dryness by using the 
rotary evaporator. Diethyl ether was added and the mixture was cooled at 5 °C 
for 1 hour. The precipitated compound was then filtered, dried and collected. The 
structure of H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8) was confirmed by is 1H 
NMR spectrum. The signals between 1.27 and 1.35 were assigned to the 
methylene groups of the Ala-Ala dipeptide. The anthraquinone protons were fully 
assigned; H-3 at 7.35 ppm, H-1 and H-4 gave a 2-proton multiplet at 7.5 ppm, 
H-6 and H-7 was a multiplet at 7.9 ppm, H-5 and H-8 a multiplet between 8.08 
and 8.2 ppm. The signals at 3.2-3.75 ppm reflected the protons of the piperazine 
spacer group.  
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 1.4.10.3 Synthesis of Boc-Leu-Ala-Ala-Piperazinyl-AQ (HZ9) 
The next step of the synthesis involved coupling leucine to the dipeptide chain of 
H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8). The synthesis of 
Boc-Leu-Ala-Ala-piperazinyl-AQ (HZ9) was carried out by initially dissolving HZ8 
and Boc-Leu-OSu in DMF, followed by addition of DIPEA at RT for 3 hours 
(Scheme 16). 
 
 
Reagents and conditions: (a) DIPEA, dissolved in DMF, RT, 3 hours 
Scheme 16. Synthesis of Boc-Leu-Ala-Ala-Piperazinyl-AQ (HZ9) 
 
After the completion of the reaction indicated by TLC test using 
dichloromethane-methanol 9:1 solvent system, the solution was evaporated to 
dryness. 
 
1.4.10.4 Synthesis of H-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ10) 
The Boc-Leu-Ala-Ala- piperazinyl-anthraquinone compound was de-protected 
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 by the addition of the strong acid, TFA at RT for 1.5 hours (Scheme 17). 
 
Reagents and conditions: (a) TFA, RT, 1.5 hours 
Scheme 17. Synthesis of H-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ10) 
 
The reaction was closely monitored by TLC (chloroform-methanol). Once the 
reaction was completed, the solution was evaporated to dryness and triturated in 
diethyl ether at 5°C for 1 hour. The mixture was then filtered, dried and collected.   
 
1.4.10.5 Synthesis of Boc-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ11) 
The previous tripeptide conjugate was extended by the use of another 
preformed dipeptide fragment, alanylglycine. After the reaction, the compound 
had the intended MMP-9 cleavage site which is gly and leu occupied the P1 and 
P1’ positions respectively. The Boc-protected pentapeptide anthraquinone 
conjugate was synthesised by dissolving the HZ10 and Boc-Ala-Gly-OSu in DMF, 
and the reaction mixture was added by DIPEA and reacted at RT overnight 
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 (Scheme 18). 
 
Reagents and conditions: (a) DIPEA, dissolved in DMF, RT, 25 hours 
Scheme 18. Synthesis of Boc-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ11) 
 
The TLC (chloroform-methanol 10:1) result showed that the reaction was not 
complete after 20 hours. Another 0.5 equivalent of Boc-Ala-Gly-OSu and DIPEA 
were added to the solution and left at RT for a further 3 hours. The TLC 
(chloroform-methanol 9:1) showed that still have starting material on the product 
lane. Continued addition of a further 0.5 equivalent of Boc-Ala-Gly-OSu to the 
solution was made and reacted at RT for 2 hours. There was only one clean red 
spot on the TLC plate, which indicated that the reaction had fully completed. 
Extraction was performed by using chloroform and water, anhydrous sodium 
sulphate was then added to the organic solution to absorb water. The solution 
was filtered and evaporated to dryness. The dried product was continued for the 
next step of synthesis without purification by column chromatography to 
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 maximize the yield. 
 
1.4.10.6 Synthesis of H-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt 
(HZ12) 
The Boc-protected pentapeptide anthraquinone compound was dissolved by the 
addition of TFA for the de-Boc reaction at RT for 2 hours (Scheme 19). 
 
Reagents and conditions: (a) TFA, RT, 2 hours 
Scheme 19. Synthesis of H-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ12) 
 
The TLC result (dichloromethane-methanol 9:1) showed that the reaction has 
completed. The solution was evaporated using a rotary evaporator. A few drops 
of methanol were added to the solution to help evaporation. The dried product 
was added with diethyl ether at 5°C for 1 hour and the mixture was filtered and 
collected. 
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 1.4.10.7 Synthesis of Boc-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ13) 
Finally, proline was added to form the target hexapeptide adduct which would 
place proline in the P3 position with respect to the cleavage site. The 
Boc-protected hexapeptide piperazinyl-anthraquinone compound was 
synthesised by using Boc-Pro-OH to react with 
D-Ala-Gly-Leu-Ala-Ala-anthraquinone in DMF at RT for 1 hour, followed by the 
addition of reagents TBTU, HOBt, and DIPEA to the solution (Scheme 20). 
 
 
Reagents and conditions: (a) TBTU, HOBt, DIPEA, dissolved in DMF, RT, 1 hour 
Scheme 20. Synthesis of Boc-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ13) 
 
Once the TLC test (dichloromethane-methanol 9:1) showed the appearance of 
the new red spot and the disappearance of starting material, HZ12 on the 
product lane, the reaction solution was evaporate to a small volume. Purification 
of the product was performed using column chromatography in the same solvent 
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 system as TLC analysis. The eluted solution was filtered and evaporated to 
dryness in vacuum.  
 
1.4.10.8 Synthesis of H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt 
(HZ14) 
Removal of the Boc group from Boc-protected hexapeptide 
piperazinyl-anthraquinone conjugate was carried out by dissolving the 
compound in TFA at RT for 2.5 hours (Scheme 21). 
 
Reagents and conditions: (a) TFA, RT, 2.5 hours 
Scheme 21. Synthesis of H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt 
(HZ14) 
 
Once the reaction was complete indicated by TLC using 
dichloromethane-methanol 9:1 solvent system, the solution was evaporated to 
dryness using a rotary evaporator. Addition of diethyl ether precipitated the 
product H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ14). The solid 
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 compound was dried in a desiccator and collected. 
 
1.4.10.9 Synthesis of Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ 
(HZ15) 
The starting material H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ14) 
was reacted with succinic anhydride in DMF with adding the base DIPEA at RT 
(Scheme 22). 
 
Reagents and conditions: (a) succinic anhydride, DIPEA, dissolved in DMF, RT, 2 days 
Scheme 22. Synthesis of Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ 
(HZ15) 
 
The TLC (dichloromethane-methanol 6:1) showed that there was no starting 
material present at the product lane. Column Chromatography was performed to 
purify the product using dichloromethane-methanol 7:1 solvent system. The 
solution was evaporated to dryness, and the solid compound 
Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ15) was precipitated by 
diethyl ether and collected. 
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 1.4.10.10 Synthesis of Prodrug 8:  
Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ16) 
Podophyllotoxin was used as the active drug of prodrug 8. Podophyllotoxin is a 
well-known naturally occuring lignan isolated from Podophyllin, a resin extract of 
Podophyllum species. Podophyllotoxin was commonly used in many Eastern 
countries, such as China and Japanese, as a folk antiviral remedy for gout, 
tuberculosis, syphilis and psoriasis (Gordaliza et al., 2004). The application of 
Podophyllotoxin inhibits the replication cycle of these viruses at early stage. 
Today, it is still an effective drug in the treatment of venereal warts (condyloma 
acuminate) caused by human papilloma virus (HPV) (Liu and Hou, 1997).  
Another important property of Podophyllotoxin is its antitumor activity that was 
first described by Kaplan in 1942. Podophyllotoxin and its derivatives were found 
to be effective in the treatment of genital tumours, lymphomas, lung cancer, 
multiple myeloma and some other malignant conditions (Castro et al., 2003). 
Podophyllotoxin acts as microtubule damaging agent like colchicine or 
vincristine on DNA. There are evidences that showed podophyllotoxin inhibits 
the polymerization of tubulin. However, the application of podophyllotoxin is 
often limited by severer toxicity. The podophyllotoxin derivative, etoposide is 
widely used as antineoplastic drugs with a different mode of action and less toxic 
(Bohlin and Rosen, 1996). Etoposide is a DNA topoisomerase II inhibitor which 
forms a DNA-drug-enzyme complex that induces DNA strands break and 
eventually lead to cell death (Greco and Hainsworth, 1996; Canel et al., 2000). 
 
Podophyllotoxin was attached to the succinyl end of the compound 
Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ15) to synthesise the 
podophyllotoxin-based prodrug 8. The reaction was carried out in DMF and 
acetonitrile (1:1) solution with adding the coupling agents, TEA and TBTU. 
71 
 During the reaction, there was solid formed in the solution. The reaction mixture 
was kept at RT overnight (Scheme 23). 
 
 
Reagents and conditions: (a) TEA, TBTU, dissolved in DMF & acetonitrile, RT, 48 hours 
Scheme 23. Synthesis of Prodrug 8:  
Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ16) 
 
The reaction solution was checked by TLC (dichloromethane-methanol 8:1) 
which indicated the reaction has completed. Furthermore, a small amount of the 
solid in the solution was dissolved in chloroform and checked by TLC which 
showed that it was the same product as in solution. The mixture was extracted 
with chloroform and water and then the organic layers were evaporated to 
dryness. The dried solid was checked by TLC again which showed two main 
spots, one was the product HZ16 and the other one was the starting material 
HZ15. The solid was dissolved in acetonitrile followed by the addition of TEA, 
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 TBTU and podophyllotoxin. The reaction was completed after 20 hours by 
checking the TLC. The solution was evaporated to dryness and dissolved by 
chloroform in a small volume. A thick TLC plate was used for product purification 
with a solvent system of dichloromethane-methanol 8:1. The product layer on 
the TLC plate was collected and dissolved in ethanol. After the filtration, the 
solution which contained the final product was evaporated, triturated by the 
addition of diethyl ether and collected. The molecular mass of the synthesised 
podophyllotoxin peptide prodrug 8 (HZ16) was expected to be 1268 Daltons 
according to its structure. The electrospray (+) mass spectrum revealed a strong 
and clear peak at m/z 1286 for the ion (MNH4)+ which confirmed the mass of 
1268 Daltons (Figure 20). Considering the mass spectrum results, the synthesis 
of podophyllotoxin-based MMP-9 activated prodrug 8 was successful and can be 
considered as a good candidate for cancer chemotherapy research. 
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Figure 20. Mass Spectrum of Prodrug 8 (HZ16) 
 
According to the chemical structure of the synthesised prodrug 8 
(Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ) in this study, 
the functional group of podopyllotoxin is hydroxyl which forms an ester bond with 
the carboxyl acid of succinate hexapeptide anthraquinone conjugate. An ester is 
the most common linkage of tumour activated prodrugs. The ester bond is 
relatively easy to synthesise, additionally, the functional groups, hydroxyl and 
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 carboxyl acid are widely common in active drugs or chemical linkers. Moreover, 
esterases that are able to hydrolyse the ester bond are everywhere distributed in 
the human body (Han & Amidon, 2000). There are four common types of ester 
bond which are listed shown in Figure 21. The half-life of an eater bond may 
vary from minutes to hours, depends on the structure of TAPs and the esterases 
activities. The carbamate ester found to be more stable than the other three 
ester bonds (Liederer & Borchardt, 2006). On the other hand, two TAPs with the 
same ester bond may also have different half-lives (Mahato et al., 2011). 
 
Figure 21. Four different types of ester bond 
(Adapted from Liederer & Borchardt 2006) 
 
The synthesised prodrug 8 (HZ16) has a carboxyl ester bond and a MMP-9 
sensitive peptide substrate. The hexapeptide (Pro-Ala-Gly-Leu-Ala-Ala) is 
expected to be cleaved by the tumour specific enzyme, MMP-9. The carboxyl 
ester bond will be hydrolysed by esterase to release the active drug, 
podophyllotoxin. 
The anticipated activation process of synthesised prodrug 8 in cancer cells has 
been illustrated in Figure 22. However, further in vitro and in vivo evaluations are 
needed, including HPLC studies of the in vitro breakdown in tumour versus 
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 healthy tissues. 
 
Figure 22. The expected activation of synthesized prodrug 8 in vivo 
 
1.4.11 HT1080 Cell Culture 
The human fibrosarcoma cell line (HT1080) provides a suitable tumour model for 
the study of MMPs activated prodrugs (Albright et al., 2005). HT1080 cells are 
identified to have overexpressed MMPs, particularly MMP-2 and MMP-9 
(Hofmann et al., 2003, Kline et al., 2004). 
 
1.4.11.1 Materials for HT1080 cell culture 
RPMI 1640 (without L-glutamine), penicillin/streptomycin, L-glutamine, foetal 
bovine serum (FBS), Sodium chloride solution, 1× Trypsin/EDTA (prepared in 
1:10 dilution with NaCl solution), all purchased from Sigma. HT1080 cells 
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 (obtained from the European Tissue Culture Collection) 
 
1.4.11.2 Method for HT1080 cell culture 
The HT1080 cells were epithelial adherent cell lines and grown in RPMI 1640 
medium with 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine. The cells 
were regularly examined under an inverted light microscope and passaged by 
using trypsin solution. The cell culture flaks were kept in a humidified incubator 
at 37⁰C with 5% CO2 and 95% air.  
 
1.4.12 Fluorescence Studies of Prodrug 3 (HZ43) and Prodrug 7 (HZ57) 
The fluorescent labelled Prodrug 7  
Carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ57) and 
Prodrug 3 FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ43) allowed 
the rapid detection of MMP-9 prodrug activation by fluorescence release. The 
fluorescence of the FITC/Carboxyfluorescein group was internally quenched by 
the anthraquinone chromophore by fluorescence resonance energy transfer 
(FRET). The FRET principle is discussed in chapter 3. The cleavage of the 
MMP-9 specific peptide will result in an increase level of fluorescence.  
 
PBS (Control) and HT1080 homogenate were added to the wells of a 96-well 
plate in the presence of 10 μM fluorescent labelled Prodrug 3 (HZ43) or Prodrug 
7 (HZ57). For comparison, HT1080 homogenate was pre-incubated with CTT 
(1.3 mM) which is a cyclic peptide gelatinase Inhibitor for MMP-2 and MMP-9 
(Ndinguri et al., 2012), for 1 hour before the addition of prodrugs. The 
fluorescence intensity was measured by a FLUOstar OPTIMA plate reader. 
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Figure 23. Fluorescence released by Prodrug 7 (HZ57) during metabolism. HZ57 (10 
μM) was added to HT1080 tumour homogenate (■), PBS buffer (◆), and HT1080 
homogenate with pre-incubation of MMP inhibitor CTT (1.3 mM, ▲) 
 
The background levels of fluorescence were shown by the addition of Prodrug 7 
(HZ57) into the PBS solution (tissue-free control). It was found that incubation of 
HZ57 with HT1080 tumour homogenate results in an increased fluorescence 
due to the cleavage of HZ57. Further evaluation of HZ57 was performed by 
pre-incubation of HT1080 tumour homogenate with MMP-2/MMP-9 specific 
inhibitor CTT. From Figure 23, the fluorescence of HZ57 was decreased by the 
CTT treatment.  
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Figure 24. Fluorescence released by Prodrug 3 (HZ43) during metabolism. HZ43 (10 
μM) was added to HT1080 tumour homogenate (■), PBS buffer (◆), and HT1080 
homogenate with pre-incubation of MMP inhibitor CTT (1.3 mM, ▲) 
 
Similarly, the FITC labelled prodrug 3 (HZ43) has an increased fluorescence with 
incubation of HT1080 tumour homogenate (Figure 24). However, the 
fluorescence intensity was lower than Prodrug 7 (HZ57) at the same drug 
concentration of 10 μM. The fluorescence level of HZ43 with CTT treatment 
showed no significant different with comparison of the tissue-free control. 
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 1.5  Conclusion 
The over expressed MMP-9 in tumour was used as a promising target for tumour 
activated prodrugs, and aimed to increase the drug selectivity and decrease the 
toxicity to other normal cells. 
A series of tumour activated prodrugs were synthesised in this study. All 
prodrugs (1-8) have the MMP-9 cleavable peptide chain in the middle part of the 
structure. The summarized structures of Prodrugs (1-8) with HZ codes are 
illustrated in Table 2. The red line indicates the MMP-9 cleavage ‘hot spot’. 
 
Table 2. Summary of selected synthesised MMP-9 activated prodrugs 
 
Prodrugs 1 and 2 have the same active drug propranolol attached to the 
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 hexapeptide substrate (Pro-Ala-Gly-Leu-Ala-Ala). The other side of the peptide 
was capped by Fmoc (Prodrug 1) or anthraquinone derivative (Prodrug 2). The 
difference between Prodrug 3 and 7 is the fluorescein compound which attached 
to the H-Pro-Ala-Gly-Leu-Pro-GABA-spacer-Anthraquinone conjugate. Prodrug 
3 used the FITC while Prodrug 7 used 5(6)-Carboxyfluorescein. In Prodrug 4, 
the GABA antagonist (R)-ethyl piperidine-3-carboxylate was linked to the 
Anthraquinone-spacer- Pro-Ala-Gly-Leu-Ala-Ala-OH conjugate. Prodrug 5 has a 
capping group (anthraquinone derivative) and cytotoxic agent (podophyllotoxin) 
at two sides of peptide chain (Pro-Ala-Gly-Leu-Pro-GABA). The GABA agonist 
baclofen was attached to Anthraquinone-spacer-Pro-Ala-Gly-Nva-Pro-OH 
conjugate to form Prodrug 6.  
 
Furthermore, fluorimetric assays evaluated and compared the MMP-9 cleavable 
substrates of different prodrugs in the HT1080 cancer cell line. The fluorescein 
labelled Prodrug 3 and 7 were selected for the assay. The results showed that 
the 5(6)-carboxyfluorescein labelled Prodrug 7 performed much better than the 
FITC labelled Prodrug 3 during the incubation with the same concentration of 
HT1080 tumour homogenate. 
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 1.6 Structure Library 
 
 
Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) 
 
 
H-Ala-Spacer-AQ TFA salt (HZ27) 
 
 
H-Ala-[Boc-Spacer]-AQ (HZ28) 
 
 
Fmoc-Ala-Propranolol (HZ29) 
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Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31) 
 
 
Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ32) 
 
 
AQ-Spacer--Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ33) 
 
 
AQ-Space-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ34) 
 
 
Fmoc-GABA-[Propyl-spacer]-AQ (HZ35) 
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H-GABA-[Propyl-spacer]-AQ (HZ36) 
 
 
Boc-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ37) 
 
 
H-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ38) 
 
 
Boc-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ39) 
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H-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ40) 
 
 
Boc-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ41) 
 
 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ42) 
 
 
FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ43) 
 
 
AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-OPFP (HZ44) 
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AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-ethylpiperidine-3-carboxylate 
(HZ45) 
 
 
Succinyl-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ46) 
 
 
Podophyllotoxin-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ47) 
 
 
Fmoc-Pro-Ala-Gly-Nva-Pro-OH (HZ51) 
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AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH (HZ52) 
 
 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OPFP (HZ53) 
 
 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-Baclofen (HZ54) 
 
 
5(6)-Carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ57) 
 
 
Boc-Ala-Ala-Piperazinyl-AQ (HZ7) 
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H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8) 
 
 
Boc-Leu-Ala-Ala-Piperazinyl-AQ (HZ9) 
 
 
H-Leu-Ala-Ala-Piperazinyl-AQ TFA (HZ10) 
 
 
Boc-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ11) 
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H-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ12) 
 
 
Boc-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ13) 
 
 
H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ14) 
 
 
Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ15) 
 
 
Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ16) 
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 1.7 Experimental 
1.7.1 General methods 
1.7.1.1 Thin layer chromatography (TLC) 
Kieselgel 60 F254 pre-loaded aluminium sheets were used for the TLC test. The 
compounds with colour were self-evident. For colourless compounds, the TLC 
sheets needed to be placed under the UV light for spots visualization.   
 
1.7.1.2 Thick TLC plate 
100g of Silica gel 60 PF254 and 300 ml of water were mixed well to make smooth 
slurry. The slurry was then spread onto 20×20 cm glass plates. The thickness of 
the absorbent silica gel was 1 mm. The plates were then put into the oven and 
heated at 60 °C for overnight. The plates were stored in a dry, cool and dark 
place. 
Once the Thick TLC plate was used for the purification of compounds, the 
compounds were first dissolved in a very small volume of organic solution (such 
as chloroform and dichloromethane). The solution was applied onto the plate by 
using a Pipette. After the solution has completely dried, the plate was put into the 
container with the suitable running solvent (about 90 ml) and a cover glass was 
placed on the top of the container. When the solvent moved no higher than the 
top of the TLC plate, the plate was removed and dried. The product layer was 
collected. 
 
1.7.1.3 Column chromatography 
Silica gel 60 [Merck] mesh 43 – 60 was used for all column chromatography.  
 
1.7.1.4 Mass spectrometry 
The samples of synthesised pure prodrugs were analysed by the EPSRC 
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 National Mass Spectrometry Service Centre at Swansea and the data was 
interpreted and compounds were characterized by the author. 
 
1.7.1.5 Proton Nuclear Magnetic Resonance (1H NMR) 
The samples were dissolved in either deuterated DMSO or deuterated 
chloroform and transferred to standard NMR testing tubes with a solution height 
range between 5 and 5.5cm. All experiments were performed by the author 
using a Bruker AC200 NMR Spectrometer (300 MHz) in Heriot-Watt University, 
Edinburgh. 
 
1.7.2 Chemical synthesis of MMP-9 activated prodrugs 
1.7.2.1 Synthesis of Boc-Ala-Ala-Piperazinyl-AQ (HZ7) 
The compound NU: UB 341 (1 g, 3.4 mmol) and Boc-Ala-Ala-OH (980.54 mg, 
3.7 mmol) were dissolved in DMF (10 ml), followed by the addition of TBTU 
(1209 mg, 3.7 mmol), HOBt (576 mg, 3.7 mmol), and DIPEA (1964.8 µl, 11.2 
mmol, 0.742 g/ml). The mixture was left at RT overnight. Mini extraction 
(dichloromethane and water) was performed for the TLC (Rf 0.714, 
dichloromethane-methanol 9:1) test. The product solution was extracted. The 
organic layer was added with anhydrous sodium sulphate and filtered. The 
filtrate was evaporated using rotary evaporator to a small volume and then 
performed the column chromatography (4.3 cm × 14.5 cm) with the 
dichloromethane-methanol 9:1 solvent system. The eluted product was filtered, 
evaporated to dryness and collected. The dried product was remained in the 
round bottomed flask for the next de-Boc reaction. 
 
1.7.2.2 Synthesis of H-Ala-Ala-Piperazinyl-AQ TFA salt (HZ8) 
TFA was added to the Boc-Ala-Ala-Piperazinyl-AQ (HZ7) until the solid was fully 
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 dissolved. The solution was left at RT for 1.15 h. The product (Rf 0.18, 
chloroform-methanol 9:1) solution was evaporated to dryness and triturated by 
10 ml diethyl ether at 5 °C for 1 h. The mixture was filtered, dried and collected. 
Crude product yield: 1.83 g, 97% 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.27 (3H, d, CH3-ala); 1.35 (3H, d, 
CH3-ala); 3.2-3.75 [11H, m, unresolved, 4×CH2 (piperazine) and NH3]; 3.88 (1H, 
q, NH3-α-CH); 4.85 (1H, quint, CONH-α-CH); 7.35 (1H, d, H-3 AQ); 7.5 (1H, s, 
H-1); 7.9 (2H, m, H-6 and H-7 AQ); 8.08 (1H, d, H-4); 8.18 (2H, m, H-5 and H-8 
AQ); 8.7 (1H, d, NHCO) 
 
1.7.2.3 Synthesis of Boc-Leu-Ala-Ala-Piperazinyl-AQ (HZ9) 
The crude H-Ala-Ala-Piperazinyl-AQ TFA salt HZ8 (1.8 g, 3.3 mmol) and 
Boc-Leu-OSu (1.2 g, 3.4 mmol) were dissolved in DMF (10 ml). DIPEA (1.2 ml, 
6.6 mmol, 0.742 g/ml) were added to the solution and left at RT for 3 h. The 
product (Rf 0.52, chloroform-methanol 9:1) solution was extracted (chloroform 
and water). The organic layer was filtered, evaporated to dryness and kept in the 
250ml round bottomed flask for the next de-Boc reaction. 
 
1.7.2.4 Synthesis of H-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ10) 
The 250ml round bottomed flask containing Boc-Leu-Ala-Ala-Piperazinyl-AQ 
(HZ9) was added by TFA until the solid had completely dissolved and reacted at 
RT for 1.5 h. The product (Rf 0.12, chloroform-methonal 10:1) solution was 
evaporated to dryness by rotational evaporator. About diethyl ether (10 ml) to 
precipitate the product at 5 °C for 1 h and the mixture was then filtered, dried and 
collected. Yield: 1.5 g, 70%. 
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 1.7.2.5 Synthesis of Boc-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ11) 
H-Leu-Ala-Ala-Piperazinyl-AQ TFA salt HZ10 (1.5 g, 2.3 mmol) and 
Boc-Ala-Gly-OSu (0.9 g, 2.5 mmol) were dissolved in DMF (10 ml), followed by 
the addition of DIPEA (800 µl, 4.6 mmol, 0.742 g/ml) and reacted at RT overnight. 
The reaction was not completed, and Boc-Ala-Gly-OSu (0.79 g, 2.3 mmol) and 
DIPEA (0.742 g/ml, 400 µl, 2.3 mmol) were added and left at RT for 5 h. The 
product (Rf 0.44, dichloromethane-methanol 9:1) mixture was extracted 
(chloroform and water), the organic layer was combined, dried (anhydrous 
sodium sulphate), filtered, evaporated to dryness for the next reaction. 
 
1.7.2.6 Synthesis of H-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt (HZ12) 
TFA was added to the Boc-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ11) in the 
round bottomed flask until solid was fully dissolved and reacted at RT for 1.5 h. 
The product (Rf 0.18, dichloromethane-methonal 9:1) solution was evaporated 
(a few drops of methanol was added to help evaporation) and triturated by 
diethyl ether (10 ml) at 5 °C for 1 h. The mixture was filtered, evaporated to 
dryness and collected. Yield: 1.5 g, 83%. 
 
1.7.2.7 Synthesis of Boc-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ13) 
The Boc-deprotected dipeptide anthraquinone spacer compound (1.5 g, 1.9 
mmol) was dissolved in DMF (10 ml), Boc-Pro-OH (0.5 g, 2.1 mmol), TBTU (0.7 
g, 2.1 mmol), HOBt (0.3 g, 2.1 mmol), and DIPEA (1.1 ml, 2.1 mmol, 0.742 g/ml) 
were added to the solution and left at RT for 1 h. The product (Rf 0.4, 
dichloromethane-methanol 9:1) solution was extracted (dichloromethane and 
water). The organic layer was collected, dried (anhydrous sodium sulphate), 
filtered and evaporated to a small volume for the column chromatography 
purification (4.3 × 17.5 cm) using dichloromethane-methanol 10:1 solvent 
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 system. The eluted solution was filtered to remove silica gel and then 
evaporated to dryness and kept in the 250 ml round bottomed flask for the 
de-Boc reaction. 
 
1.7.2.8 Synthesis of H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt 
(HZ14) 
TFA was added to the round bottomed flask which contained 
Boc-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ13) until the solid was 
completely dissolved and the mixture was left at RT for 1 h. The product (Rf 0.1, 
dichloromethane-methanol 9:1) solution was evaporated to dryness and added 
with 10 ml diethyl ether. The mixture was cooled at 5 °C for 1.5 h and then 
filtered, dried and collected. Yield: 1.5 g, 89%. 
 
1.7.2.9 Synthesis of Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ 
(HZ15) 
H-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ TFA salt HZ14 (300 mg, 0.34 mmol) 
and succinic acid (50.8 mg, 0.5 mmol) were dissolved in DMF (5 ml), followed by 
the addition of DIPEA (147.2 µl, 0.85 mmol, 0.742 g/ml) to the solution and 
reacted at RT over weekend. The product (Rf 0.4, dichloromethane-methanol 6:1; 
Rf 0.64, butanol-acetate acid-water 4:5:1) solution was extracted, evaporated to 
a low volume and purified by column chromatography (2.3 cm × 15.6 cm) using 
dichloromethane-methanol 6:1 solvent system. The product fraction was 
combined, filtered and evaporated to dryness by rotary evaporator. The product 
paste was re-dissolved by addition of small volume of ethanol and diethyl ether 
(10 ml) in a 25 ml round bottomed flask to precipitate the solid product. The 
solution mixture was cooled at 5 °C for 2 h, filtered, dried in the desiccator, and 
collected. Yield: 98.7 mg, 33%. 
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ESMS (+): 871 m/z (100%) (M-H)- 
 
1.7.2.10 Synthesis of 
Podophyllotoxin-Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ (HZ16) 
Succinyl-Pro-Ala-Gly-Leu-Ala-Ala-Piperazinyl-AQ HZ15 (90 mg, 0.1 mmol) was 
dissolved in DMF (2.5 ml) and acetonitrile (2.5 ml), podophylotoxin (43 mg, 0.1 
mmol), TBTU (33.13 mg, 0.1 mmol) and TEA (28.7 µl, 0.2 mmol, 0.727 g/ml) 
were added to the solution and reacted at RT overnight. The TLC showed the 
reaction was not complete. Additional podophylotoxin (21.37mg, 0.05 mmol), 
TBTU (16.57 mg, 0.05 mmol) and TEA (14.35 µl, 0.05 mmol, 0.727 g/ml) were 
added to the solution and left at RT for 5 h. There was solid present in the 
solution, so the solution was filtered. The solid was orange coloured and was 
dissolved by chloroform. The filtrate was combined with the dissolved solid and 
transferred to an evaporating basin and left to dryness overnight. The product 
was collected and checked by TLC for purity. However, some product had gone 
back to the starting material. The solid was dissolved in chloroform and added 
with anhydrous sodium sulphate. The solution was filtered and evaporated to 
dryness. Acetonitrile (3 ml) was added to dissolve the solid. The reagents, 
(21.37mg, 0.05 mmol), TBTU (16.57 mg, 0.05 mmol) and TEA (14.35 µl, 0.1 
mmol, 0.727 g/ml) were added to the solution and reacted at RT overnight. The 
product (Rf 0.74, dichloromethane-methanol 8:1) solution was evaporated to 
dryness, dissolved by chloroform in a very low volume and applied to a thick TLC 
(90 ml of dichloromethane-methanol (8:1) solvent) plate for purification. The 
product layer was collected, dissolved in ethanol, filtered and evaporated to 
dryness in vacuo. 10 ml of diethyl ether was added and the mixture was cooled 
in 5°C for 1 h. The product was precipitated in ether and the mixture was filtered, 
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 dried in a desiccator and collected. Yield: 57.5 mg, 45% 
 
ESMS (+): 1286 m/z (100%) (M+NH4)+ 
 
1.7.2.11 Synthesis of Fmoc-Ala-[Boc-Spacer]-AQ (HZ26) 
The AQ-spacer-Boc NU: UB 491 (500 mg, 1.26 mmol) was reacted with 
Fmoc-Ala-OH (432 mg, 1.4 mmol) in dichloromethane (30 ml). DCC (313 mg, 
1.5 mmol) and DMAP (15.4 mg, 0.13 mmol) were added and the reaction 
mixture was stirred for 1 h. The precipitated dicyclohexylurea (DCU) was filtered 
off and the filtrate was washed with water. The dichloromethane extract was 
combined, dried by sodium sulfate, and evaporated to dryness. The crude solid 
was purified by column chromatography using the eluting solvent, 
dichloromethane: ethyl acetate 7:1. The appropriate fractions were combined, 
filtered and evaporated to dryness. Diethyl ether was added to precipitate the 
solid product. The mixture was cooled at 5°C for 1 h. Yield: 392 mg, 45%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.48 [(9H, s, CH3 (Boc)]; 1.7 (1H, s); 2.7 
(2H, t, AQ-NH-CH2-CH-OCO-CH2); 3.4-3.7 (6H, m, AQ-NH-CH2-CH-CH2 and 
AQ-NH-CH2-CH-OCO-CH2-CH2); 4.15 [(1H, t, α-CH (Fmoc)]; 4.35 [(2H, d, CH2 
(Fmoc)]; 5.0 (1H, s, AQ-NH-CH2-CH); 5.3 (1H, t, NHCO-Boc); 5.79 (1H, s, 
NHCO-Fmoc); 7.15 (1H, d, H-2); 7.4 (2H, t, H-3 and H-4); 7.5-7.63 (2H, t, H-6 
and H-7); 7.63-7.78 [8H, m, CH (Fmoc)]; 8.12 (1H, d, H-5); 8.18 (1H, d, H-8); 9.9 
(1H, t, AQ-NH). 
 
1.7.2.12 Synthesis of H-Ala-Spacer-AQ trifluoroacetate salt (HZ27) 
Fmoc-Ala-[Boc-Spacer]-AQ HZ26 (60 mg, 0.15 mmol) was transferred into a 
round bottomed flask. TFA was added until all solid dissolved. The reaction was 
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 completed after 10 min. The solution was evaporated to dryness. Diethyl ether 
was added to precipitate the product. Yield: 50 mg, 98%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 2.4-2.65 (2H, t, 
AQ-NH-CH2-CH-OCO-CH2); 3.05-3.3 (4H, m, AQ-NH-CH2-CH-CH2); 3.3-3.6 (2H, 
m, CH2-NH-Fmoc); 3.6-3.8 [(1H, t, H-9 (Fmoc)]; 4.1-4.4 [(2H, m, CH2 (Fmoc)]; 
5.2 (1H, s, AQ-NH-CH2-CH); 7.2-7.5 [(7H, m, unresolved, H-2(AQ), H-1, H-2, 
H-4, H-5, H-7 and H-8 (Fmoc)]; 7.5-7.72 (2H, m, H-3 and H-4); 7.73-7.95 [(4H, m, 
H-3 and H-4 (AQ), H-3 and H-6 (Fmoc)]; 7.95-8.08 (2H, m, H-6 and H-7); 
8.08-8.26 (2H, m, H-5 and H-8); 9.75 (1H, t, AQ-NH). 
 
1.7.2.13 Synthesis of H-Ala-[Boc-Spacer]-AQ (HZ28) 
Fmoc-Ala-AQ HZ26 (150 mg 0.38 mmol) was dissolved in 4 ml of 2% piperidine 
in DMF. The reaction was completed in 30 min at RT by checking the TLC (Rf 
0.17, dichloromethane-methanol 9:1). The reaction solution was purified by 
extraction (dichloromethane and water) and column chromatography 
(chloroform-methanol 8:1). The product was collected in an evaporating basin. 
Yield: 70 mg, 69%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.4 [(9H, s, CH3 (Boc)]; 2.38-2.52 (2H, 
m, CH-OCO-CH2); 3.05-3.8 (6H, m, AQ-NH-CH2-CH-CH2 and CH2-NH2); 5.05 
(1H, m, AQ-NH-CH2-CH); 7.15-7.25 (1H, t, NHCO); 7.35 (1H, d, H-2); 7.4-7.5 
(1H, d, H-4); 7.6-7.7 (1H, t, H-3); 7.8-7.95 (2H, m, H-6 and H-7); 8.12 (1H, d, H-8); 
8.2 (1H, d, H-5); 9.78 (1H, t, AQ-NH). 
 
1.7.2.14 Synthesis of Fmoc-Ala-Propranolol (HZ29) 
Propranolol hydrochloride (1 g, 3.4 mmol) and Fmoc-β-Ala-OH (1.26 g, 4.1 mmol) 
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 were dissolved in 20ml DMF, followed by the addition of TBTU (1.3 g, 4.1 mmol), 
HOBt (621 mg, 4.1 mmol), and DIPEA (2.7 ml, 16 mmol). The reaction was 
completed overnight. The crude product (Rf 0.48, dichloromethane- ethyl acetate 
1:1) was extracted by dichloromethane and water, dichloromethane/aqueous 
citric acid and dichloromethane/aqueous sodium bicarbonate. Further 
purification was done by column chromatography (dichloromethane- ethyl 
acetate 1:1). The product was dried under vacuum. Yield: 271mg, 14%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.2-1.45 (6H, dd, CH3); 2.6-2.8 (2H, 
m, NCO-CH2); 3.5-3.87 [(3H, m, NCO-CH2-CH2 and H-9 (Fmoc)]; 4.05-4.2 (1H, 
m, CH-CH3); 4.2-4.35 [(4H, m, O-CH2-CH-CH2 (propranolol)]; 4.35-4.45 [(2H, m, 
CH2 (Fmoc)]; 5.63 [(1H, m, O-CH2-CH (propranolol)]; 6.9 [1H, d, H-2 
(propranolol)]; 7.28-7.58 [8H, m, unresolved, H-1, H-2, H-3, H-4, H-5, H-6, H-7 
and H-8 (Fmoc)]; 7.6-7.7 [2H, m, H-3 and H-4 (propranolol)]; 7.7-7.9 [4H, m, H-5, 
H-6, H-7 and H-8 (propranolol)]; 8.25 (1H, d, OH) 
 
1.7.2.15 Synthesis of Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31) 
Fmoc-Ala-Wang resin (1 g, 0.72 mmol/g) was used for the SPPS. The resin (1 g) 
was transferred into a SPPS reaction vessel, added with dichloromethane (10 ml) 
for swelling the beads and shaken at RT, 650 rpm for 1.5 h. The 
dichloromethane was drained off and the resin was washed with DMF three 
times (2 min, 5 ml for each time). Fmoc was removed by the addition of 5 ml of 
20% piperidine in DMF to the vessel and shaken for 15 min at RT. This step was 
repeated for 3 times. The resin was washed with DMF 3 times.  
A solution of Fmoc-Ala-OH (448.3 mg, 1.44 mmol), TBTU (439.2 mg, 1.4 mmol), 
HOBt (209.3 mg, 1.4 mmol) and DIPEA (500.7 µl, and 2.9 mmol, 0.742 g/ml) 
were dissolved in DMF (20 ml). The solution (10 ml) was transferred into the 
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 vessel and shaken for 30 min. After 30 min, the solution was drained off. Another 
10ml stock solution was added and shaken for 30 min. The resin was then Fmoc 
deprotected for the coupling reaction with next amino acid. The rest of the Fmoc 
protected amino acids were coupled by the same procedure as above in the 
order of: Fmoc-Leu-OH (509 mg, 1.44 mmol), Fmoc-Gly-OH (428 mg, 1.44 
mmol), Fmoc-Ala-OH (560 mg, 1.8 mmol), and Fmoc-Pro-OH (607.5 mg, 1.8 
mmol). Colour test was performed for Fmoc deprotection and amino acid 
coupling reaction. 
TFA (20 ml, 95%) in dichloromethane was prepared. 2-3 ml of the solution was 
added to the vessel and shaken at RT for 3 min. The solution was drained off 
and the procedure was repeated for 9 times. The resin was then washed with 
dichloromethane (×2), methanol (×2), and dichloromethane (×1). All the filtrates 
and cleavage fractions were combined, transferred into a round bottomed flask 
and evaporated to a small volume using a rotary evaporator. About 30 ml of 
diethyl ether was added to precipitate the white solid HZ31 at 5 °C for 1 h. The 
mixture was filtered and the product was dried in a desiccator. Yield: 176 mg, 
34%.  
 
1.7.2.16 Synthesis of Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol (HZ32) 
Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH HZ31 (106 mg, 0.15 mmol) was dissolved in 
DMF (20 ml), propranolol hydrochloride (48 mg, 0.17 mmol), TBTU (52 mg, 0.17 
mmol), HOBt (25 mg, 0.17 mmol), and DIPEA (0.742 g/ml, 110 µl, 0.65 mmol) 
were added to the solution and reacted at RT overnight. The product (Rf 0.43, 
dichloromethane-ethyl acetate-ethanol 7:2:1) solution was extracted 
(dichloromethane/ water, dichloromethane/aqueous citric acid, and 
dichloromethane/aqueous sodium bicarbonate). The organic layer was collected, 
dried by anhydrous sodium sulphate, filtered and evaporated to a small volume 
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 for the column chromatography purification using dichloromethane-ethyl 
acetate-ethanol 9:2:1 solvent system. The pure fractions were combined, filtered, 
evaporated, and precipitated in diethyl ether (10 ml). The white solid product was 
collected by centrifuging. Yield: 13 mg, 9%.  
 
ESMS (+): 962 m/z (100%) (M+H)+ 
 
1.7.2.17 Synthesis of AQ-Spacer--Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ33) 
The anthraquinone derivative HB8 (64.3 mg, 0.14 mmol) was dissolved in 4ml 
DMF. The solution was transferred into the SPPS reaction vessel which 
contained approximate 0.14 mmol of de-Fmoc hexapeptide on resin (HZ31). 
DIPEA (25 µl, 0.14 mmol) was also added. The mixture was shaken for 1 hour. 
The resin was washed with DMF 2 time and added with another portion of 
64.3mg HB8 and 25µl DIPEA, continued shaking for 1 h. The resin was washed 
with DMF (×5) and dichloromethane (×3). 15ml of 87% TFA in dichloromethane 
was measured in a 25ml cylinder. About 2ml solution was added to the resin and 
shaken for 3-4min. The solution was drained off into a small beaker. This step 
was repeated 5 times and all fractions were checked by TLC The resin was 
washed with dichloromethane (×2), methanol (×1), and dichloromethane (×2). All 
filtrates and fractions were combined and transferred to a round bottomed flask. 
The solution was evaporated to a small volume and added with diethyl ether (50 
ml). The flask was put into fridge at 5°C for cooling overnight. The product was 
collected by filtration and dried in a desiccator. Yield: 256.8 mg, 98% 
 
1.7.2.18 Synthesis of AQ-Space-Pro-Ala-Gly-Leu-Ala-Ala-Propranolol 
(HZ34) 
AQ-Space-Pro-Ala-Gly-Leu-Ala-Ala-OH HZ33 (150 mg, 0.19 mmol) was 
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 dissolved in 60 ml DMF, propranolol hydrochloride (61 mg, 0.21 mmol), TBTU 
(65.8 mg, 0.21 mmol), HOBt (31.3 mg, 0.21 mmol), and DIPEA (0.742 g/ml, 107 
µl, 0.21 mmol) were added to the solution and left to react at RT for 4 hour. The 
crude product (Rf 0.6, dichloromethane-methanol 9:1) was extracted with 
dichloromethane/water, dichloromethane/aqueous citric acid, and 
dichloromethane/aqueous sodium bicarbonate.  The organic layers were 
combined, dried by anhydrous sodium sulphate, evaporated to a low volume and 
purified by column chromatography (2.1 cm × 11 cm) using dichloromethane 
ethanol 10:1 eluting solvent. The pure product fractions were combined, filtered 
and evaporated to dryness by rotational evaporator. The red solid product was 
precipitated in diethyl ether and the mixture was filtered, dried in a desiccator 
and collected. Yield: 24 mg, 12%. 
 
ESMS (+): 1069 m/z 100% (M+Na)+ 
 
1.7.2.19 Synthesis of Fmoc-GABA-[Propyl-spacer]-AQ (HZ35) 
The AQ-propyl spacer NU: UB 197 (1500 mg, 5.36 mmol) was dissolved in 50 ml 
DMF, Fmoc-γaminobutyric acid (2100 mg, 6.4 mmol), TBTU (2100 mg, 6.4 
mmol), HOBt (984 mg, 6.4 mmol) and DIPEA (0.742 g/ml, 3.4 ml, 10.7 mmol) 
were added to the solution and reacted at RT for 1 hour. The crude product (Rf 
0.64, dichloromethane-methanol 9:1) solution was poured into water to get red 
solid precipitate. Further purification was done by column chromatography 
(dichloromethane-methanol 10:1). The pure fractions were combined, filtered 
and poured into an evaporating basin. Yield: 2880 mg. 91%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.7-1.85 (2H, m, AQ-NH-CH2-CH2); 
2.05-2.15 (2H, m, NHCO-CH2-CH2); 2.9-3.05 (2H, m, NHCO-CH2); 3.1-3.45 (7H, 
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 m, NH-Fmoc, AQ-NH-CH2-CH2-CH2 and NHCO-CH2-CH2-CH2); 4.17-4.25 [1H, t, 
H-9 (Fmoc)]; 4.25-4.33 [2H, d, CH2 (Fmoc)]; 7.2-7.48 [(6H, m, unresolved, H-3 
(AQ), NHCO, H-1, H-2, H-7 and H-8 (Fmoc)]; 7.6-7.72 [(3H, m, H-4 (AQ), H-4 
and H-5 (Fmoc)]; 7.8-7.98 [(4H, m, H-6 and H-7 (AQ), H-3 and H-6 (Fmoc)]; 
8.1-8.17 (1H, m, H-8 AQ); 8.17-8.25 (1H, m, H-5 AQ); 9.73 (1H, t, AQ-NH) 
 
1.7.2.20 Synthesis of H-GABA-[Propyl-spacer]-AQ (HZ36) 
Fmoc-GABA-[Propyl-spacer]-AQ HZ35 (1100 mg, 1.9 mmol) was suspended in 
20ml of 20% piperidine in DMF at RT for 1.5 hours. The crude product (Rf 0.14, 
butanol-acetic acid-water 15:4:1) was extracted with dichloromethane and water. 
The organic layers were combined, dried by sodium sulfate, evaporated to a 
small volume and added with diethyl ether. The red precipitate was collected in 
vacuum. Yield: 400 mg, 59%. 
 
1.7.2.21 Synthesis of Boc-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ37) 
H-GABA-[Propyl-spacer]-AQ HZ36 (400 mg, 1.1 mmol) was reacted with 
Boc-Leu-Pro-OH (396 mg, 1.2 mmol) in DMF by addition of the reagents TBTU 
(387 mg, 1.2 mmol), HOBt (184 mg, 1.2 mmol), and DIPEA (0.742 g/ml, 629 µl, 
3.3 mmol). The reaction had completed in 1 hour 20 min by checking the TLC (Rf 
0.6, dichloromethane methanol 5:1). The reaction solution was extracted by 
dichloromethane and water. The crude product was then purified by column 
chromatography (3.2 cm × 15.5 cm). The eluting solvent system 
dichloromethane to methanol 12:1 was used. The appropriate fractions were 
combined and dried in the round bottomed flask for the next de-Boc reaction. 
 
1.7.2.22 Synthesis of H-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt (HZ38) 
TFA was added to the flask containing Boc-Leu-Pro-GABA-[Propyl-spacer]-AQ 
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 (HZ37) until all solid dissolved. After 40 min, the reaction completed (Rf 0.2, 
dichloromethane methanol 9:1). TFA was then evaporated off by using the rotary 
evaporator. Solid product was precipitated in diethyl ether. Yield: 637 mg, 92%. 
 
1.7.2.23 Synthesis of Boc-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ39) 
H-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ38 (600 mg, 0.87 mmol) and 
Boc-Ala-Gly-OSu (329 mg, 0.96 mmol) were dissolved in DMF with adding 
DIPEA (0.742 g/ml, 303 µl, 1.74 mmol). After 5 hours, the TLC (Rf 0.56, 
dichloromethane methanol 9:1) showed the reaction had completed. The 
solution was extracted by dichloromethane and water. Further purification was 
performed by column chromatography (3.2 cm × 13.3 cm) using 
dichloromethane-methanol 12:1 solvent system. The appropriate fractions were 
combined, dried (using anhydrous sodium sulphate), filtered, and evaporated to 
dryness for the next reaction. 
 
1.7.2.24 Synthesis of H-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA 
salt (HZ40) 
TFA was added to the flask of Boc-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ39) until all solids were dissolved. The reaction completed in 45 min by 
checking the TLC (Rf 0.4, dichloromethane methanol 9:1). TFA was evaporated 
off and about 6 drops of ethanol was added to the sticky solution by pipetting. 
50ml of diethyl ether was then transferred to the flask. The flask was cooled in 
the fridge overnight. The solid precipitate in diethyl ether was collected. Yield: 
512 mg, 72%.  
ESMS (+): 704 m/z 100% (M-CO2CF3)+ 
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 1.7.2.25 Synthesis of Boc-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ41) 
H-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ40 (500 mg, 0.61 
mmol) was reacted with Boc-Pro-OH (145 mg, 0.67 mmol) in DMF followed by 
the addition of TBTU (216 mg, 0.67 mmol), HOBt (103 mg, 0.67 mmol), and 
DIPEA (0.742 g/ml, 351 µl, 2 mmol). The reaction completed in 1 hour by 
checking the TLC (Rf 0.6, dichloromethane methanol 9:1). After extraction by 
dichloromethane and water, column chromatography (3.2 cm × 12 cm) was 
performed for product purification. The appropriate fractions were combined, 
filtered and evaporated to dryness and ready for the de-Boc reaction. 
 
1.7.2.26 Synthesis of H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
TFA salt (HZ42) 
TFA was added to dissolve 
Boc-Pro-Ala-Gly-Leu-Pro-GABA-spacer-anthraquinone (HZ41) in a round 
bottomed flask. The reaction was complete in 45 min monitored by the TLC (Rf 
0.3, dichloromethane-methanol 9:1). The solution was then evaporated to 
dryness by using the rotary evaporator. A few drops of ethanol and diethyl ether 
(70 ml) were added to the flask. The red solid precipitate was collected by 
filtration and dried in a vacuum desiccator. Yield: 489 mg, 88%. 
ESMS (+): 801 m/z 100% (M-CO2CF3)+ 
 
1.7.2.27 Synthesis of FITC-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ43) 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ42 (100mg, 0.11 
mmol) and FITC (38.3 mg, 0.1 mmol) were dissolved in 5ml DMF, followed by 
the addition of DIPEA (0.742 g/ml, 38µl, 0.22 mmol). The reaction was left to 
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 react at RT overnight. The solution was poured into water to get orange 
precipitate. The crude product (Rf 0.46, dichloromethane-methanol 6:1) was 
purified by column chromatography using the eluting solvent 
dichloromethane-methanol 9:1. The pure fractions were combined, filtered and 
evaporated to dryness. The solid product was scratched off the flask and 
collected. Yield: 12.5 mg, 9%. 
ESMS (-): 1188 m/z 100% (M-H)- 
 
1.7.2.28 Synthesis of AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-OPFP 
(HZ44) 
AQ-Spacer--Pro-Ala-Gly-Leu-Ala-Ala-OH HZ33 (100 mg, 0,12 mmol) was 
reacted with PFP (50.3mg, 0.3 mmol), followed by the addition of DCC (61.4 mg, 
0.3 mmol) and DMAP (30 mg, 0.24 mmol) in 20ml DMF. The reaction mixture 
was stirred at RT for 7 hours. The precipitate DCU was filtered off. The crude 
product (Rf 0.64, dichloromethane-methanol 9:1) was kept in dichloromethane 
for the next reaction without further purification. 
 
1.7.2.29 Synthesis of AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-ethyl 
piperidine-3-carboxylate (HZ45) 
(R)-Ethyl piperidine-3-carboxylate (29.5 mg, 0.19 mmol) and DIPEA (0.742 g/ml, 
32.6 µl, and 0.19 mmol) were added to the 
AQ-[Propyl-spacer]-Pro-Ala-Gly-Leu-Ala-OPFP HZ44 (100 mg, 0.124 mmol) in 
dichloromethane. The reaction was completed in 2.5 hours by checking the TLC 
(Rf 0.27, dichloromethane-ethyl acetate-ethanol 7:2:1). The solution was washed 
with water and aqueous sodium bicarbonate. The dichloromethane layers were 
combined, dried by sodium sulfate, and evaporated to a small volume for column 
chromatography (dichloromethane-ethyl acetate-ethanol 7:2:1). The pure 
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 fractions were combined, filtered and transferred into an evaporating basin. Yield: 
34.8 mg, 30%. 
ESMS (+): 967 m/z 100% (M+Na)+, 983 m/z 100% (M+K)+ 
 
1.7.2.30 Synthesis of 
Succinyl-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ46) 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ42 (200mg, 0.22 
mmol) and succinic anhydride (24 mg, 0.24 mmol) were dissolved in DMF (3 ml), 
followed by the addition of DIPEA (0.742 g/ml, 80 µl, 0.46 mmol). After 4 h, the 
reaction was completed. The crude product (Rf 0.48, dichloromethane-methanol 
4:1) was extracted with dichloromethane and water. Column chromatography 
(dichloromethane-methanol 4:1) was performed for further purification. The 
product fractions were combined, filtered and evaporated to dryness by the 
rotary evaporator. The red solid was added with 50 ml diethyl in the round 
bottomed flask to precipitate the product. The mixture was cooled at 5 °C 
overnight, filtered, dried in the desiccator, and collected. Yield: 107 mg, 55%. 
 
1.7.2.31 Synthesis of 
Podophyllotoxin-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ (HZ47) 
Succinyl-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ HZ46 (80 mg, 0.09 
mmol) was dissolved in DMF (1 ml) and acetonitrile (2 ml), followed by the 
addition of podophyllotoxin (40.5 mg, 0.1 mmol), TEA (26 µl, 0.19 mmol) and 
TBTU (31.4 mg, 0.19 mmol), and reacted at RT for 3 hours. Acetonitrile was 
evaporated off first. The crude product (Rf 0.65, dichloromethane-methanol 6:1) 
in DMF was extracted with dichloromethane and water. The organic layers were 
combined, dried by anhydrous sodium sulphate, evaporated to a small volume 
for column chromatography. The eluting solvent dichloromethane-ethyl 
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 acetate-methanol 7:2:1 was used. The product fractions were combined, filtered 
and evaporated to dryness in an evaporating basin. Yield: 16.3 mg, 14%.  
ESMS (+): 1321 m/z 45% (M+Na)+, 
 
1.7.2.32 Synthesis of Fmoc-Pro-Ala-Gly-Nva-Pro-Resin (HZ51) 
H-Pro-2Cl-Trt resin (1 g, 0.84 mmol/g) was used for the SPPS. The pentapeptide 
(Fmoc-Pro-Ala-Gly-Nva-Pro-OH) was synthesised using the same method as 
Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31). About 23% of the resin (HZ51) was 
transferred into another resin for the synthesis of HZ52. The rest of 77% resin 
was treated with 5% TFA in dichloromethane. The cleavage process was done 
as same as HZ31 synthesis. The white product was precipitated in diethyl ether, 
filtered, dried in a desiccator and collected. Yield: 233 mg, 42%.     
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.2-1.4 [6H, m, CH3-CH2-CH2 (Nva) 
and CH3-CH (Ala)]; 1.4-1.68 [4H, m, 2×CH3-CH2-CH2 (Nva)]; 1.7-2.03 [4H, m, 
2×β-CH2 (Pro)]; 2.03-2.3 [4H, m, 2×γ-CH2 (Pro)]; 3.32-3.57 [2H, m, δ-CH2 (Pro)]; 
3.6-3.8 [4H, m, 2×CH2 (Gly)]; 3.9-4.32 [5H, m, CH2-(Fmoc), CH (Nva) and α-CH 
(Pro)]; 4.32-4.55 [2H, m, CH (Ala) and α-CH (Fmoc)]; 7.28-7.48 [4H, m, H-1, H-2, 
H-7 and H-8 (Fmoc)]; 7.6-7.7 [2H, m, H-4 and H-5 (Fmoc)]; 7.85-7.93 [2H, t, H-3 
and H-6 (Fmoc)]; 8.07 [1H, t, CONH (Gly)]; 8.18 [(1H, d, CONH (Ala)]; 8.34 [(1H, 
d, CONH (Nva)]; 
 
1.7.2.33 Synthesis of AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH (HZ52) 
Piperidine (15 ml, 20%) in DMF was added to Fmoc-Pro-Ala-Gly-Nva-Pro-Resin 
HZ51 (23%, 0.19 mmol) on resin. The vessel was shaken for 20 min (3 times, 5 
ml each time). The resin was washed 3 times with DMF for the next coupling 
reaction with TL12. TL12 (65 mg, 1 equivalent), TBTU (59 mg, 0.19 mmol), HOBt 
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 (28.2mg, 0.19 mmol), and DIPEA (67.5 µl, 0.38 mmol, 0.742 g/ml) were 
dissolved in DMF (8 ml), the solution was added to the de-Fmoc HZ51 resin, and 
shaken for 1 h. The remaining solution in the vessel was drained off. Another 
same amount of reagents in DMF was added to the resin and shaken for 1 hour. 
The resin was washed with DMF (×3) and dichloromethane (×3).  
25 ml of 5% TFA in dichloromethane was prepared. Each time 3-4ml of the stock 
solution was added to the resin and shaken for 8-10 min. All fractions were kept 
in different beakers for TLC (Rf 0.36, dichloromethane-methanol 9:1) test. The 
resin was washed with dichloromethane (×3). All filtrates and fractions were 
combined, evaporated to dryness, precipitated in diethyl ether and collected. 
Yield: 143 mg, 98%. 
ESMS (-): 755 m/z (100%) (M-H)- 
 
1.7.2.34 Synthesis of AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OPFP (HZ53) 
AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OH HZ52 (130 mg, 0.17 mmol), PFP (34.8 mg, 
0.19 mmol), DCC (39 mg, 0.19 mmol), and DMAP (21 mg, 0.19 mmol) were 
dissolved in dichloromethane (10 ml) and refluxed on 40°C water bath for 30 h. 
The crude product (Rf 0.53, chloroform-methanol 6:1) was extracted with 
chloroform and water. The organic layers were combined, dried by anhydrous 
sodium sulphate, and evaporated to dryness. The solid product was kept in the 
round bottomed flask for the next reaction with baclofen. 
 
1.7.2.35 Synthesis of AQ-Spacer-Pro-Ala-Gly-Nva-Pro-Baclofen (HZ54) 
The flask which contained pure AQ-Spacer-Pro-Ala-Gly-Nva-Pro-OPFP HZ53 
solid (assumed 0.17 mmol) was added with baclofen (36.7 mg, 0.17 mmol), 
DIPEA (60 µl, 0.34 mmol, 0.742 g/ml) in dichloromethane (15 ml). The mixture 
was stirred at RT for 40 h. The DCU precipitate was filtered off. The crude 
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 product (Rf 0.46, dichloromethane-methanol 6:1) was purified by column 
chromatography using the eluting solvent dichloromethane-methanol 9:1. The 
product was still not pure and further purification was needed. Thick TLC plate 
(dichloromethane-methanol 6:1) was used. The product layer was scratched off 
the plate and collected by filtration and dried in an evaporating basin. Yield: 4 mg, 
2%. 
ESMS (-): 950 m/z 45% (M-H)- 
 
1.7.2.36 Synthesis of 
5(6)-Carboxyfluorescein-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ 
(HZ57) 
5(6)-Carboxyfluorescein (62 mg, 0.16 mmol) was reacted with 
H-Pro-Ala-Gly-Leu-Pro-GABA-[Propyl-spacer]-AQ TFA salt HZ42 (150 mg, 0.16 
mmol) in DMF (8 ml), followed by the addition of PyBOP (102.3 mg, 0.2 mmol) 
and DIPEA (91 µl, 0.51 mmol, 0.742 g/ml) to the solution, and reacted with stir at 
RT for 1 hour. The crude product (Rf 0.37, dichloromethane-methanol 5:1) was 
extracted with dichloromethane and water. The organic layers were combined, 
dried by sodium sulfate and evaporated to a small volume. Further purification 
was done by column chromatography using the eluting solvent 
dichloromethane-methanol 9:1. The pure product fractions were combined, 
filtered, and evaporated to dryness in an evaporating basin at RT. Yield: 56.6 mg, 
31%. 
ESMS (-): 1159 m/z 100% (M+H)+ 
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 Chapter 2. Baclofen Based Prodrugs 
2.1 Abstract 
Gamma aminobutyric acids (GABA) are found to play an inhibitory role in most 
cancers, but the activation of GABAB receptor has been reported to have 
contradictory effects on the tumour progression. Baclofen, a GABAB receptor 
agonist, is demonstrated to reduce the incidence of some cancers. In this 
chapter, a series of baclofen based prodrugs and cyclic baclofen prodrugs have 
been designed and synthesised with the potential to cross the BBB and 
eventually target brain tumours.  
 
2.2  Introduction 
2.2.1 GABA 
GABA is the main inhibitory neurotransmitter throughout the human central 
nervous system (CNS). It functions via activation of GABAA and GABAB 
receptors. Many studies suggest that GABA is a tumour signalling amino acid in 
the brain and periphery. In most cases, the levels of GABA content and GAD 
activity are increased in human tumours (for a review, see Young and Bordey, 
2009).  
Both GABAA and GABAB receptors were found to be overexpressed in different 
tumours which make them important therapeutic targets for cancer treatment. 
The GABAB receptors were considered first in this research (described briefly 
below).  
 
2.2.2 GABAB receptor and tumours 
The GABAB receptor is composed of two subunits GABABR1 and GABABR2. 
126 
 The extracellular domain (ECD) of GABAB1 is capable of binding GABA, agonist 
and antagonist (Jiang et al., 2012). Growing evidence showed that GABAB 
receptors are involved in tumour proliferation and migration of tumour cells.  
Both GABABR1 and GABABR2 were found to be commonly expressed in 
human hepatocellular carcinoma (HCC) by RT-PCR (Wang et al., 2008). The 
expression level of GABAB receptors were upregulated in human colon cancer 
cell lines (Thaker et al., 2005) and breast cancer (Jiang et al., 2012). Zhu et al., 
(2004) detected that in gastric cancer tissue, not only the level of GBABB 
receptors is higher than normal tissues but also there are majority of GBABB 
receptors distributed on the surface of cancer cells. 
Schuller et al., (2007) first reported that GABAB receptors are potent targets for 
human pancreatic cancer therapy. The Western blotting and cell migration 
assays in pancreatic ductal adenocarcinoma cell line PANC-1 and BXPC-3 
showed that the migration of cells was significantly blocked by GABA and 
baclofen. The base level DNA synthesis was reduced in two cell lines after 
incubation with GABA and baclofen by BrdU incorporation assays. GABA and 
baclofen also inhibited intracellular cAMP signalling by immunoassays. All the 
data suggested that stimulation of GABAB receptors may have significant 
inhibitory effects on the migration of pancreatic tumour cells. 
By immunohistochemistry in 70 human thyroid tumour samples, GABABR2 was 
detected to be differentially expressed between normal, benign, and malignant 
thyroid tissues. The normal tissues have undetectable expression. Interestingly, 
the malignant adenomas have the highest expression and benign tumours 
display an intermediate level. The development of thyroid cancer is thought to be 
a multi-step process and the high expression of GABABR2 in thyroid adenomas 
suggests that GABAB receptors are involved in early stages of thyroid 
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 carcinogenesis (Roberts et al., 2009) 
The National Cancer Institute (NCI) data base provides the mRNA level of 
GABAB receptors expression in about 60 different cancer cell lines. According to 
the data, some cell lines of non-small cell lung cancer (HOP-92 and NCI-H226), 
CNS cancer (SF-268), Melanoma and breast cancer (MDA-MB-231/ATCC) have 
the high mRNA level of GABAB receptors (Ross et al., 2000). The breast cancer 
cell line MCF-7 will be considered in this project for biological testing. 
However, there are fewer studies examining the function of GABAB receptors on 
tumour cell proliferation than GABAA receptors. 
 
2.2.3 Baclofen and tumours 
Baclofen is an agonist of GABAB receptors. It is a derivative of gamma-butyric 
acid (Figure 25). It is also a licensed drug for the treatment of spasticity (Nielsen 
et al., 2002). 
 
Figure 25. Chemical Structure of Baclofen 
 
Several studies revealed that activation of GABAB receptors by baclofen plays 
an inhibitory role in most human tumour cell types such as human pancreatic 
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 (Schuller et al., 2008), lung, liver, breast (Azuma et al., 2003), colon (Joseph et 
al., 2002), and gastric tumours (Tatsuta et al., 1990, 1992) which makes it a 
promising drug for tumour chemotherapy.  
Although the mechanism of baclofen inhibiting tumour cells remains to be 
determined, there is evidence implied that GABAB receptor activation may 
induce the down-regulation of intracellular cyclic adenosine monophosphate 
(cAMP) and Increase MMP production (Loderwyks et al., 2011). 
In contrast, baclofen showed no inhibitory effect on human prostate cancer cells 
and even promote the invasion (Abdul et al., 2008, Jiang et al., 2012). 
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 2.3 Results and discussion 
2.3.1 Baclofen prodrug design strategy  
To increase the drug selectivity, tumour activated prodrug strategies in cancer 
chemotherapy represent a promising approach (Rautio et al. 2008). The 
prodrugs should be less toxic before activation by tumours. 
 
Figure 26. General concept of baclofen prodrug design 
 
Figure 26 shows the general concept of baclofen prodrug design. The baclofen 
prodrug for brain tumour therapy is designed to have an anthraquinone capping 
group and a linker connected to baclofen. Because baclofen itself is a polar drug 
and can poorly absorb across the cell membrane, the designed prodrugs here 
will increase the lipophilicity and more likely to cross the BBB (Blood Brain 
Barrier) and target the brain tumour. The acidic environment in tumours will 
cause the amino peptide linker to be hydrolysed and release the active agent 
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 baclofen. 
The uncyclised baclofen prodrugs can be converted into the cyclic baclofen 
prodrugs using the dehydrating agent acetic anhydride (Abdel-Hafez and 
Abdel-Wahab, 2008). The cyclic analogues of baclofen should have greater 
lipophilic properties and the prodrug permeation through the BBB will be 
improved. 
 
2.3.2 Synthesis of AQ-Ahx-Baclofen (HZ68) 
1-Chloroanthraquinone was used as the starting material. It was reacted with the 
6-aminohexanoic acid using the strong base NaOH in DMSO to form the 
anthraquinone spacer conjugate (HZ66) as shown in Scheme 24. 
 
*This synthesis scheme is continued on the next page 
131 
  
Reagents and Conditions: (a) 6-aminohexanoic acid, NaOH, DMSO, 95°C (b) 
pentafluorophenol, DCC, DMAP, dichloromethane; (c) baclofen, NaOH(aq), DMF 
Scheme 24. Outline of Baclofen Prodrug (HZ68) Synthesis 
 
The acid end of AQ-Ahx-OH (HZ66) was converted into a pentafluorophenolate 
ester (OPFP) before adding the baclofen. The solubility of baclofen is very low in 
both DMF and DMSO. For the coupling of baclofen, firstly NaOH was dissolved 
by a drop of water in a round bottomed flask. Secondly, baclofen in DMF was 
added to the flask. The mixture was heated on the hot water bath (95ºC). 
Another flask with AQ-Ahx-OPFP (HZ67) in DMF was also put on same water 
bath. The baclofen mixture was slowly added to HZ67 drop wise. The reaction 
was completed in 5 days by checking the TLC The crude product was extracted 
and purified by column chromatography. The appropriate fractions were 
combined, filtered and collected in diethyl ether. 
The final product AQ-Ahx-Baclofen (HZ68) was characterized by NMR and its 
mass spectrum (M+H)+ which has a strong signal at m/z 533 corresponding to a 
molecular mass of 532 (Figure 27). The 1H NMR spectrum had the amino proton 
at C-1 of the anthraquinone group that gave a triplet signal at 9.65 ppm. The 
methylene protons of the hexanoic spacer were identifiable between 1.4 and 3.4 
ppm. The anthraquinone protons were fully assigned between 7.42 and 8.25 
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 ppm. Signals for H-2, H-3, H-5 and H-6 of the chlorobenzene group were found 
from 7.2 to 7.38 ppm. 
 
 
 
Figure 27. The ESI (+) Mass spectrum of prodrug AQ-Ahx-Baclofen (HZ68) 
 
2.3.3 Synthesis of AQ-Ahx-cyclic Baclofen (HZ69) 
The baclofen prodrug (HZ68) was converted to the cyclic baclofen prodrug 
AQ-Ahx-cyclic Baclofen (HZ69) using the dehydrating agent acetic anhydride 
(Scheme 25). The reaction was heated on the water bath and completed in 1 
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 hour by checking the TLC The reaction solution was cooled at RT and poured 
into distilled water. The precipitated compound was collected. The cyclic 
baclofen prodrug is expected to have stronger lipophilic properties and enhance 
the permeation through the BBB with improved therapeutic potency. 
 
Reagents and Conditions: (a) (Ac)2O reflux 
Scheme 25. Outline of Baclofen Prodrug (HZ69) Synthesis 
 
The structure of AQ-Ahx-cyclic Baclofen (HZ69) was confirmed by NMR and its 
ESI (+) Mass spectrum which gave a signal at m/z 515 for the molecular mass of 
514. (Figure 28) The lactone type structure of HZ69 compound exhibited a 
multiplet signal at 3.45-3.65 ppm assigned to the methine proton (H-5). The 
signals at 2.7-2.84 ppm and 3.7-3.8 ppm recognised to be H-6 (O-CO-CH2) and 
H-4 (C=N-CH2), respectively. The protons of chlorobenzene were also found 
between 7.15 and 7.4 ppm. 
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Figure 28. ESI (+) Mass spectrum of prodrug AQ-Ahx-cyclic Baclofen (HZ69) 
 
2.3.4 Synthesis of AQ-Ava-cyclic Baclofen (HZ75) 
The prodrug AQ-Ava-cyclic Baclofen (HZ75) used 5-aminopentanoic acid as the 
spacer which is shorter than the prodrug AQ-Ahx-cyclic Baclofen (HZ69). The 
synthesis process was the same as the prodrug HZ69 (Scheme 25). The 
prodrugs with different spacers were supposed to have varying solubility 
properties. 
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Reagents and Conditions: (a)6-aminohexanoic acid, NaOH, DMSO, 95°C (b)PFP, DCC, 
DMAP, dichloromethane (c)baclofen, NaOH(aq), DMF (d)(AC)2O reflux 
Scheme 26. Outline of Baclofen Prodrug (HZ75) Synthesis 
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 The prodrug AQ-Ava-cyclic Baclofen (HZ75) chemical structure was confirmed 
by its 1H NMR spectrum. The lactone type structure of HZ75 compound gave a 
multiplet signal at 3.5-3.67 ppm assigned to the methine proton (H-5). The 
signals at 2.72-3.15 ppm and 3.7-4.38 ppm recognised to be H-6 (O-CO-CH2) 
and H-4 (C=N-CH2), respectively. The p-substituted pattern of aromatic protons 
of the phenyl ring together with the anthraquinone protons showed signals from 
7.15-7.22 ppm and from 7.3 to 8.33 ppm. Furthermore, the mass spectrum 
(M+H)+ showed a signal at m/z 501 corresponding to the molecular mass of 500 
for prodrug HZ75 (Figure 29), together with m/z 501 for (M+Na)+. 
 
 
Figure 29. ESI (+) Mass spectrum of prodrug AQ-Ava-cyclic Baclofen (HZ75) 
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 2.3.5 Synthesis of AQ-GABA-cyclic Baclofen (HZ79) 
Gamma-Aminobutyric acid was used to build up the prodrug AQ-GABA-cyclic 
Baclofen (HZ79) Scheme 27. For the chemical structure of HZ79, it has a 
shorter spacer in the middle than AQ-Ava-cyclic Baclofen (HZ75) and 
AQ-Ahx-cyclic Baclofen (HZ69).    
 
 
 
*This synthesis scheme is continued on the next page 
138 
  
Reagents and Conditions: (a) Gamma-aminobutyric acid, NaOH, DMSO, 95°C (b) 
pentafluorophenol, DCC, DMAP, dichloromethane; (c) baclofen, NaOH(aq), DMF; (d) (AC)2O 
Scheme 27. Outline of Baclofen Prodrug (HZ79) Synthesis 
 
The final compound AQ-GABA-cyclic Baclofen (HZ79) was characterized by its 
mass spectrum (M+H)+ which showed a signal at m/z 487, corresponding to a 
relative molecular mass of 486 Da (Figure 30).  
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Figure 30. ESI (+) Mass spectrum of prodrug AQ-GABA-cyclic Baclofen (HZ79) 
 
2.3.6 Synthesis of AQ-[PEG Spacer]-Succinyl-Baclofen (HZ82) 
The starting material for the synthesis of prodrug AQ-[PEG 
Spacer]-Succinyl-Baclofen (HZ82) as shown in Scheme 28 was the 
anthraquinone derivative (NU:UB 432). This compound which consists of 
anthraquinone and polyethylene glycol (PEG) has been used extensively in 
previous research within this laboratory, particularly in the design of fluorogenic 
probes (Ding, 2014). The anthraquinone-PEG spacer (NU:UB 432) was reacted 
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 with succinic anhydride in DMF by the addition of DIPEA to the solution (Scheme 
5). The reaction was completed overnight. The crude product AQ-[PEG 
Spacer]-Succinyl (HZ80) was purified by solvent extraction and silica gel column 
chromatography. The pure HZ80 was collected in diethyl ether. DCC and DMAP 
were used as standard regents for the addition of PFP to the AQ-[PEG 
Spacer]-Succinyl (HZ80). The reaction mixture was suspended in 
dichloromethane. The byprodruct dicyclohexylurea (DCU) was filtered off.  
 
 
 
*This synthesis scheme is continued on the next page 
141 
  
Reagents and Conditions: (a) succinic anydride, DIPEA, DMF; (b) pentafluorophenol, DCC, 
DMAP, dichloromethane; (c) baclofen, NaOH(aq), DMF 
Scheme 28. Outline of Baclofen Prodrug (HZ82) Synthesis 
 
Baclofen was finally coupled to the AQ-[PEG Spacer]-Succinyl-OPFP (HZ81). 
Two round bottomed flask were used. One of them had baclofen, NaOH and 
water in DMF. Another flask had the AQ-[PEG Spacer]-Succinyl-OPFP (HZ81) in 
DMF. Both flasks were put on a hot water bath. The baclofen mixture in flask one 
was added to the HZ81 flask drop wise. The reaction was very slow. By the TLC 
test, the reaction had mostly completed in 1 week. The mixture was extracted 
and purified by column chromatography. 
Prodrug AQ-[PEG Spacer]-Succinyl-Baclofen (HZ82) was characterized by NMR 
and its electrospray mass spectrum which gave a signal at m/z 650 for (M+H)+ 
corresponding to a molecular mass of 649 (Figure 31). The 1H NMR spectrum 
showed signals between 2.15 and 3.8 ppm were assigned to the methylene 
groups of the PEG spacer. The anthraquinone protons were fully assigned; H-2 
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 at 7.2 ppm, H-4 at 7.45 ppm, H-3 at 7.6-7.7 ppm, H-6 and H-7 gave a multiplet at 
7.78-7.95 ppm, H-8 at 8.08-8.15 ppm, H-5 at 8.15-8.25 ppm. The signals at 
7.2-7.37 reflected the chlorobenzene protons of baclofen group.  
 
 
 
Figure 31. ESI (+) Mass spectrum of prodrug AQ-[PEG Spacer]-Succinyl-Baclofen 
(HZ82) 
 
2.3.7 Synthesis of AQ-[PEG Spacer]-Succinyl-cyclic Baclofen (HZ83) 
The baclofen prodrug AQ-[PEG Spacer]-Succinyl-Baclofen (HZ82) was further 
reacted with acetic anhydride to form the lipophilic analogue of baclofen 
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 AQ-[PEG Spacer]-Succinyl-cyclic Baclofen HZ83 (Scheme 29). 
 
 
Reagents and Conditions: (a) (Ac)2O 
Scheme 29. Outline of Baclofen Prodrug (HZ83) Synthesis 
 
The final compound AQ-[PEG Spacer]-Succinyl-cyclic Baclofen (HZ83) was 
characterised by NMR and mass spectrometry. The lactone type structure of 
HZ83 compound exhibited a multiplet signal at 3.5-3.7 ppm assigned to the 
methine proton (H-5). The signals at 2.9-3.25 ppm and 3.8-4.25 ppm recognised 
to be H-6 (O-CO-CH2) and H-4 (C=N-CH2), respectively. All of the aromatic 
protons of anthraquinone were successfully assigned; H-2 appeared at 
7.06-7.22 ppm, H-3 and H-4 were found between 7.53-7.68 ppm, H-6 and H-7 at 
7.68-7.85 ppm, H-5 and H-8 at 8.22-8.35 ppm. In the mass spectrum (Figure 32) 
of prodrug HZ83, a signal at 632 m/z was assigned to the ion (M+H)+ confirming 
the molecular mass of 631. 
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Figure 32. ESI (+) Mass spectrum of prodrug AQ-[PEG Spacer]-Succinyl-cyclic Baclofen 
(HZ83) 
 
2.3.8 Synthesis of AQ-[propyl spacer]-Pro-succinyl-Baclofen (HZ86) 
The starting material for the synthesis of prodrug AQ-[propyl 
spacer]-Pro-succinyl-Baclofen (HZ86) (Scheme 30) was the anthraquinone 
D-proline derivative, NU:UB 46. NU:UB 46 is the D-isomer of one of the leading 
members of the NU:UB series of spacer-linkedanthraquinone-amino acid 
conjugates, NU:UB 31. Both NU:UB 31 (L-pro conjugate) and NU:UB 49 (D-pro 
conjugate) were active in vitro against the MAC15A colon adenocarcinoma cell 
line, with IC50 values of 2.5 and 3.5µM, respectively, for the L and D isomers. 
Additionally, NU:UB 31 has broad-spectrum activity in vitro at low micromolar 
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 concentrations in panels of human and animal tumour cell lines, including those 
of the NCI 60 cell line anticancer drug screen; NU:UB 31 retains activity in cell 
lines that over-express P-glycoprotein.  It is a dual topoisomerase I and II 
inhibitor and is active in vivo in experimental colon cancer (Mincher et 
al., 2000; Turnbull, 2003). Previously, NU:UB 31 has successfully been 
incorporated into a MMP activated prodrug, EV1-FITC  (Van Valckenborgh et al., 
2005). Here, the D-isomer of NU:UB 31, NU:UB 46, has been conjugated with 
baclofen via a succinate linker to afford a prodrug with dual topoisomerase 
inhibiting cytotoxicity together with potential GABA modulating activity. The 
reactions condition was same as the synthesis of AQ-[PEG 
Spacer]-Succinyl-Baclofen (HZ82). 
 
 
*This synthesis scheme is continued on the next page 
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Reagents and Conditions: (a) succinic anhydride, DIPEA, DMF; (b) pentafluorophenol, DCC, 
DMAP, dichloromethane; (c) baclofen, NaOH(aq), DMF 
Scheme 30. Outline of Baclofen Prodrug (HZ86) Synthesis 
 
The 1H NMR spectrum of AQ-[propyl spacer]-Pro-succinyl-Baclofen (HZ86) 
showed signals between 1.7 and 4.25 were assigned to the methylene groups of 
the propyl and proline spacer. The anthraquinone protons were fully assigned; 
H-2 at 7.05-7.38 ppm, H-3, H-4, H-6 and H-7 gave a multiplet at 7.7-7.95 ppm, 
H-5 and H-8 gave a quartet between 8.1 and 8.3 ppm. The signals at 7.05-7.38 
reflected the chlorobenzene protons of baclofen group. 
 
The mass spectrum (M+H)+ showed a signal at m/z 673 corresponding to the 
molecular mass of 672 for prodrug HZ86 (Figure 33). 
147 
  
 
Figure 33. ESI (+) Mass spectrum of prodrug AQ-[propyl spacer]-Pro-succinyl-Baclofen 
(HZ86) 
 
2.3.9 Synthesis of AQ-[propyl spacer]-Pro-succinyl-cyclic Baclofen (HZ87) 
The prodrug AQ-[propyl spacer]-Pro-succinyl-Baclofen (HZ86) was converted to 
the cyclic baclofen prodrug AQ-[propyl spacer]-Pro-succinyl-cyclic Baclofen 
(HZ87) using the dehydrating agent acetic anhydride (Scheme 31). 
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Reagents and Conditions: (a) (Ac)2O 
Scheme 31. Outline of Baclofen Prodrug (HZ87) Synthesis 
 
Figure 34 below shows the tumour pH activation of AQ-[propyl 
spacer]-Pro-succinyl-cyclic Baclofen (HZ87). HZ87 has the cyclic baclofen 
indicated by the red colour. The acidic environment of the tumour cells will cause 
the hydrolysis reaction. The cyclic ring will be opened and further hydrolysis to 
break the prodrug and release anthraquinone-D-proline and baclofen. They are 
both anticancer agents. So the cyclic baclofen prodrug AQ-[propyl 
spacer]-Pro-succinyl-cyclic Baclofen (HZ87) is actually a twin drug. 
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Figure 34. Tumour pH (5-6) activation of HZ87 
 
The cyclic baclofen prodrug HZ87 was characterized by NMR and Mass 
spectroscopy. The structure of HZ87 was confirmed by its 1H NMR spectrum.   
Most of the aromatic protons of anthraquinone were successfully assigned; H-3 
and H-4 appeared at 7.5-7.67 ppm, H-6 and H-7 were found between 7.68-7.84 
ppm, H-5 and H-8 at 8.12-8.3 ppm. The protons of chlorobenzene were also 
found between 6.9 and 7.35 ppm. 
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 For mass spectrum, a signal at m/z 655 for the mono-cation (M+H)+ confirmed 
the molecular mass of 654 Daltons (Figure 35). 
 
 
Figure 35. ESI (+) Mass spectrum of prodrug 
AQ-[propyl-spacer]-Pro-succinyl-cyclic Baclofen (HZ87) 
 
2.3.10 Lipophilicity test: Determination of the Distribution Coefficient 
Because high lipophilic properties are crucial for the prodrugs to cross the BBB 
the lipophilicity assay was performed. The prodrugs were partitioned between 
octanol and PBS. The Eppendorf tubes were shaken for 24 hours. The Figure 
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 36 below is an example of the images of the Eppendorf tubes with prodrugs. The 
top phases are Octanol used to mimic the lipophilic environment. It can be seen 
from the colour difference; all the four compounds have more prodrugs in the 
octanol phase than in the PBS water phase. The concentrations of prodrugs 
present in each layer were determined from the calibration curves and the 
distribution coefficient was calculated using the equation given in [Graph 1~4]. 
Figure 37 is for calculation of distribution coefficient (Leo, Hansch and Elkins, 
1971). 
 
 
 HZ82         HZ83         HZ86         HZ87 
Figure 36. Eppendorf tubes of Lipophilicity test 
 
 
 
Figure 37. Equation of distribution coefficient 
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Graph 1. Calibration curve and distribution coefficient of HZ82 in both Octanol 
and PBS 
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Graph 2. Calibration curve and distribution coefficient of HZ83 in both Octanol 
and PBS 
 
154 
  
 
 
Graph 3. Calibration curve and distribution coefficient of HZ86 in both Octanol 
and PBS 
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Graph 4. Calibration curve and distribution coefficient of HZ87 in both Octanol 
and PBS 
 
2.3.11 DNA binding assay 
The DNA binding properties of the prodrugs were tested by using the ethidium 
bromide displacement DNA binding assay. Ethidium bromide is a dye that can 
intercalate into the DNA double helix. The double stranded DNA will be saturated 
by ethidium bromide binding. The fluorescence of the DNA-bound ethidium 
bromide can be measured and by competing with the drug, the intensity should 
decrease with drug concentration and time (Olmsted and Kearns, 1997).  
The binding affinity of each compound was determined by the QE50 and the 
binding constant values (Kapp). QE50 is the mean concentration of compound that 
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 causes 50% reduction of initial fluorescence intensity. The binding constant can 
be calculated using the equation: Kapp= (KEB[EB])/[Drug]. The KEB value (1.0 × 
107M-1) is the binding constant of ethidium bromide (Ghosh et al., 2010). 
The compound will has greater binding affinity if QE50 value is smaller and 
binding constant is bigger. The Graphs 5~9 below showed both QE50 value and 
binding constant of tested prodrugs. 
 
 
Kapp=(KEB[EB])/[Drug]=(1×107M-1×30)/49.4=0.61×107M-1 
Graph 5. Variation of relative fluorescence intensity with different concentration 
of HZ74 in Tris-HCl buffer 
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Kapp=0.72×107M-1 
Graph 6. Variation of relative fluorescence intensity with different concentration 
of HZ82 in Tris-HCl buffer  
 
 
Kapp=0.75×107M-1 
Graph 7. Variation of relative fluorescence intensity with different concentration 
of HZ83 in Tris-HCl buffer 
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Kapp=0.56×107M-1 
Graph 8. Variation of relative fluorescence intensity with different concentration 
of HZ86 in Tris-HCl buffer 
 
 
Kapp=0.54×107M-1 
Graph 9. Variation of relative fluorescence intensity with different concentration 
of HZ87 in Tris-HCl buffer 
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 Drug QE50(µM) Kapp(×107M-1) 
Mitoxantrone 1.7 17.34 
HZ74 49.4 0.61 
HZ82 41.4 0.72 
HZ83 39.8 0.75 
HZ86 53.2 0.56 
HZ87 55.1 0.54 
Table 3. Comparison of drug DNA binding affinity 
 
Mitoxantrone is widely used as a chemotherapeutic drug in the treatment of 
breast cancer, lymphoma and leukaemia. The nuclear DNA was indicated as the 
major target of Mitoxantrone based on numerous studies (Mazerski et al., 1998). 
Mitoxantrone has a planar anthraquinone ring which can intercalate between 
DNA base pairs and its side chains further bind to the phosphate groups of DNA. 
This will cause the DNA condensation and thus inhibits DNA replication. 
Mitoxantrone also shows strong binding affinity to histone proteins besides DNA 
(Hajihassan and Rabbani-Chadegani, 2009). 
The DNA-binding properties of synthesized baclofen based prodrugs were 
investigated. When comparing the results to the well-known anticancer drug 
mitoxantrone, as shown in Table 3 here, the binding constant value of prodrugs 
HZ74 to HZ87 is much smaller than mitoxantrone, which indicates they all have 
low DNA binding affinities.  
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 2.4 Conclusion 
Table 4 below shows the synthesised baclofen prodrugs (on the left) and cyclic 
baclofen prodrugs (on the right). The synthesis process was difficult because of 
the poor solubility of baclofen. The reaction of AQ-spacer-OPFP and baclofen 
was very slow (up to 10 days). The prodrug structures were characterised by 
their Mass spectrum, further analysis by NMR was performed. However due to 
the low yield of prodrugs, some them need to be resynthesised in greater 
quantities for full NMR analyses. 
 
 
Table 4. List of synthesised baclofen based prodrugs 
 
Because of the difficulty for prodrugs to pass through the blood brain barrier 
(BBB), the most effective way to make a drug move through a lipophilic barrier is 
to increase its lipophilicity. Lipophilicity assay was conducted to investigate the 
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 compound’s ability to transverse the blood–brain barrier. The lipophilicity assay 
proved that the prodrugs tested all have high lipophilic properties. This is crucial 
for the prodrugs to cross the BBB and eventually target the brain tumours. The 
DNA binding results of prodrugs showed relatively low DNA binding affinities 
when comparing them to the anticancer drug mitoxantrone.  
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 2.5 Structure Library 
 
6-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic acid  
 
AQ-Ahx-OH (HZ66) 
 
 
6-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic acid pentafluorophenyl ester  
 
AQ-Ahx-OPFP (HZ67) 
 
 
3-(4-Chloro-phenyl)-4-[6-(9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoylamino]-butyric acid  
 
AQ-Ahx-Baclofen (HZ68) 
 
 
1-{5-[5-(4-Chloro-phenyl)-7-oxo-4,5,6,7-tetrahydro-[1,3]oxazepin-2-yl]-pentylamino}-anthraquinone  
 
AQ-Ahx-cyclic Baclofen (HZ69) 
 
163 
  
5-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-pentanoic acid  
 
AQ-Ava-OH (HZ72) 
 
 
5-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-pentanoic acid pentafluorophenyl ester  
 
AQ-Ava-OPFP (HZ73) 
 
 
3-(4-Chloro-phenyl)-4-[5-(9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-pentanoylamino]-butyric acid  
 
AQ-Ava-Baclofen (HZ74) 
 
 
1-{4-[5-(4-Chloro-phenyl)-7-oxo-4,5,6,7-tetrahydro-[1,3]oxazepin-2-yl]-butylamino}-anthraquinone  
 
AQ-Ava-cyclic Baclofen (HZ75) 
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AQ-GABA-OH (HZ76) 
 
 
 
 
 
AQ-GABA-OPFP (HZ77) 
 
 
 
 
AQ-GABA-Baclofen (HZ78) 
 
1-{3-[5-(4-Chloro-phenyl)-7-oxo-4,5,6,7-tetrahydro-[1,3]oxazepin-2-yl]-propylamino}-anthraqui
none 
 
AQ-GABA-cyclic Baclofen (HZ79)  
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AQ-[PEG Spacer]-Succinyl (HZ80) 
 
 
N-(2-{2-[2-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-ethoxy]-ethoxy}-ethyl)-succinamic acid pe
ntafluorophenyl ester  
 
AQ-[PEG Spacer]-Succinyl-OPFP (HZ81)  
 
 
 
 
AQ-[PEG Spacer]-Succinyl-Baclofen (HZ82) 
 
 
3-[5-(4-Chloro-phenyl)-7-oxo-4,5,6,7-tetrahydro-[1,3]oxazepin-2-yl]-N-(2-{2-[2-(9,10-dioxo-9,10-dihy
dro-anthracen-1-ylamino)-ethoxy]-ethoxy}-ethyl)-propionamide 
 
AQ-[PEG Spacer]-Succinyl-cyclic Baclofen (HZ83)  
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AQ-[propyl spacer]-Pro-succinyl (HZ84) 
 
 
 
 
 
AQ-[propyl spacer]-Pro-succinyl-OPFP (HZ85) 
 
 
 
 
AQ-[propyl spacer]-Pro-succinyl-Baclofen (HZ86) 
 
 
 
 
AQ-[propyl spacer]-Pro-succinyl- cyclic Baclofen (HZ87)  
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 2.6 Experimental 
2.6.1 DNA binding assay 
Materials for DNA binding assay 
The Tris-HCI buffer (pH7.4) was prepared by dissolving NaCl (25 mM), CaCl2 (1 
mM) and Tris-HCI (10 mM) in distilled water (200 ml). The buffer was stored in 4 
ºC fridge. A stock solution of ethidium bromide 10 mg/ml in distilled water was 
also prepared and stored at 4 ºC for further use. About one centimetre portion of 
calf thymus DNA was dissolved in Tris-HCI buffer (4 ml) at 4 ºC for 24 h. The 
undissolved DNA was filtered off. The concentration of the DNA stock solution 
was measured at 260 nm by using the Beckman Coulter DU800 UV/Vis 
Spectrophotometer. The blank was Tris-HCI buffer (3 ml) in cuvette. The 
unquantified DNA stock solution (200~300 µl) was added to another cuvette and 
diluted with buffer to 3 ml. The ideal absorbance should be between 0.4 and 0.7. 
The absorbance was read three times and the mean value was used to calculate 
the DNA concentration using the Beer-Lambert Law. The test prodrug (1 mg) 
was dissolved in DMSO (1 ml) to make a 1 mg/ml stock solution. 
 
Method for DNA binding assay 
The Perkin Elmer Luminescence Spectrometer LS50B was used to measure the 
DNA-bound ethidium bromide fluorescence intensity.  The solutions were 
added into the 3 ml cuvette by order with different final concentrations: 1) 60 µM 
DNA; 2) 30 µM Ethidium bromide; 3) Tris-HCl buffer up to 3 ml.  
Certain volume of test compound to give the final concentration of 5 µM was 
added into the cuvette. The fluorescence intensity was recorded. After 5 min, 
another same portion of test compound was added to give the final 
concentration of 10 µM. The process was repeated until it reached 50% 
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 reduction of the relative fluorescence intensity. 
 
2.6.2 Lipophilicity test 
Materials for lipophilicity test 
One tablet of Phosphate Buffered Saline (PBS) was dissolved in distil water (200 
ml) to give a solution of 0.01 M phosphate, 0.0027 M KCl and 0.137 M NaCl. 
PBS buffer (100 ml) and octanol solutions (100 ml) were transferred into a 
separating funnel and shaken for 24 h. The two layers of octanol-saturated PBS 
and PBS-saturated octanol solutions were then separated.  
 
Method for lipophilicity test 
1mg/ml of each compound in DMSO (1 ml) was prepared for creating the 
calibration curve. A series of standard solutions with concentration of 20 µM, 30 
µM, 40 µM, 50 µM, 60 µM and 70 µM were prepared in cuvettes. The 
absorbance of the solutions was measured. The value should be from 0 to 0.7. 
Both octanol and PBS calibration curves were prepared. Calibration curves were 
used to determine the concentration of drugs in two phases.   
The test compound (0.5 mg) was put into a 2 ml eppendorf tube. 
Octanol-saturated PBS (900 µl) and PBS-saturated octanol (900 µl) were added. 
The tube was shaken for 24 h at RT. 
The tube was centrifuged for 2 min to separate the solutions. The upper octanol 
layer (100 µl or 200 µl) was carefully removed by pipetting and transferred into a 
3 ml cuvette and made up to 3 ml by PBS-saturated octanol or octanol-saturated 
PBS. By measuring the absorbance, the concentration of drug can be 
determined. The distribution coefficient was calculated.  
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 2.6.3 Synthesis of AQ-Ahx-OH (HZ66) 
1-Choloroanthraquinone (3 g, 12 mmol) was reacted with 6-aminohexanoic acid 
(3.24 g, 24 mmol) by the addition of NaOH (1.5 g, 36 mmol) in 70 ml of DMSO. 
The reaction was heated on a 100ºC water bath for 8 h. The solution was cooled 
to RT and poured into 250 ml of acidic water (HCI was added). The precipitate 
red compound was collected by filtration. The dried crude product (Rf 0.31, 
dichloromethane-methanol 9:1) was purified by column chromatography using 
the eluting solvent chloroform and methanol 10:1. The pure product fractions 
were combined, filtered and evaporated. The red solid compound was collected 
from diethyl ether (60 ml). Yield: 558 mg, 16.6%. 
 
2.6.4 Synthesis of AQ-Ahx-OPFP (HZ67) 
The starting compound AQ-Ahx-OH HZ66 (400 mg, 1.19 mmol) and PFP (327 
mg, 1.78 mmol) were dissolved in 50 ml of dichloromethane, followed by the 
addition of coupling reagents DCC (490 mg, 2.38 mmol) and DMAP (435 mg, 
3.57 mmol). The reaction completed in 4 h by checking the TLC (Rf 0.73, 
dichloromethane-ethyl acetate 5:1). DCU precipitate was filtered off. The product 
was purified by column chromatography using dichloromethane and ethyl 
acetate 6:1. The product fractions were combined, filtered and evaporated to 
dryness. Hexane (40 ml) was used to precipitate the solid compound. Yield: 245 
mg, 41%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.58-1.7 (2H, m, AQ-NH-CH2-CH2-CH2); 
1.8-1.98 (4H, m, AQ-NH-CH2-CH2-CH2-CH2); 2.75 (2H, t, 
AQ-NH-CH2-CH2-CH2-CH2-CH2); 3.4 (2H, q, AQ-NH-CH2); 7.1 (1H, d, H-2); 
7.52-7.63 (2H, m, H-3 and H-4); 7.7-7.8 (2H, m, H-6 and H-7); 8.28 (2H, m, H-5 
and H-8); 9.8 (1H, t, AQ-NH) 
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 2.6.5 Synthesis of AQ-Ahx-Baclofen (HZ68) 
Two round bottomed flasks were used. One of them had AQ-Ahx-OPFP HZ67 
(200 mg, 0.4 mmol) in 10 ml of DMF. The other one had NaOH (14 mg, 0.36 
mmol), H2O (about 20 µl) and baclofen (94 mg, 0.44 mmol) in DMF (10 ml). The 
two flasks were both refluxed on the hot water bath (90ºC). The baclofen solution 
was added to the flask of HZ67 by drop wise. The reaction was checked by TLC 
(Rf 0.22, dichloromethane-methanol 6:1) and had mostly completed in 5 days. 
The reaction solution was extracted between dichloromethane and water (1:4, 
300 ml). The organic phase was dried by anhydrous sodium sulphate, filtered, 
and evaporated to a small volume. The crude product was purified by column 
chromatography using the eluting solvent dichloromethane methanol 12:1. The 
pure fractions were combined, filtered, evaporated to dryness and collected. 
Yield: 53.6 mg, 25%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.4-1.68 (4H, m, 
AQ-NH-CH2-CH2-CH2-CH2); 2.0-2.1 (2H, m, AQ-NH-CH2-CH2); 2.4-2.55 (2H, m, 
CH2-COOH); 3.17-3.4 (5H, m, unresolved, AQ-NH-CH2, CONH-CH2 and 
CH-Benzene-Cl); 7.2-7.29 [(3H, q, H-2 (AQ), H-3 and H-5 (Benzene-Cl)]; 
7.29-7.38 [(2H, d, H-2 and H-6 (Benzene-Cl)]; 7.42 (1H, d, H-4); 7.6-7.7 (1H, t, 
H-3); 7.75-7.96 (3H, m, unresolved, CONH, H-6 and H-7); 8.05-8.25 (2H, m, H-5 
and H-8); 9.65 (1H, t, AQ-NH) 
ESMS (+): 533 m/z 100% (M+H)+ 
 
2.6.6 Synthesis of AQ-Ahx-cyclic Baclofen (HZ69) 
AQ-Ahx-Baclofen HZ68 (25 mg, 0.05 mmol) was dissolved in acetic anhydride (3 
ml) and refluxed on 95 ºC water bath for 1 hour. The solution was cooled to RT 
and poured into distilled water. The precipitated product (Rf 0.6, 
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 dichloromethane-methanol 6:1) was collected by centrifuge. Yield: 14 mg, 54%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.55-1.68 (2H, m, 
AQ-NH-CH2-CH2-CH2); 1.72-1.9 (4H, m, AQ-NH-CH2-CH2-CH2-CH2); 2.7-2.84 
(1H, m, O-CO-CH2); 2.93-3.08 (3H, m, O-CO-CH2 and 
AQ-NH-CH2-CH2-CH2-CH2-CH2); 3.38-3.45 (2H, q, AQ-NH-CH2); 3.45-3.65 (1H, 
m, CH-Benzene-Cl); 3.7-3.8 (1H, q, C=N-CH2); 4.25-4.35 (1H, q, C=N-CH2); 
7.05-7.15 (1H, d, H-2); 7.15-7.23 [(2H, q, H-3 and H-5 (Benzene-Cl)]; 7.3-7.4 
[(2H, q, H-2 and H-6 (Benzene-Cl)]; 7.52-7.65 (2H, m, H-3 and H-4); 7.7- 7.82 
(2H, m, H-6 and H-7); 8.3 (2H, m, H-5 and H-8); 9.8 (1H, t, AQ-NH) 
ESMS (+): 515 m/z 100% (M+H)+ 
 
2.6.7 Synthesis of AQ-Ava-OH (HZ72) 
1-Choloroanthraquinone (4 g, 17 mmol), 5-aminopentanoic acid (6 g, 51 mmol) 
and NaOH (2.7 g, 68 mmol) were suspended in 90 ml of DMSO. The reaction 
was heated on 100ºC water bath for 10 h. The mixture was poured into the 300 
ml of acidic water (HCI was added). The red precipitate was collected by filtration. 
The crude compound (Rf 0.42, dichloromethane-methanol 9:1) was purified by 
column chromatography using solvent system dichloromethane and methanol 
9:1. The appropriate fractions were combined, filtered and evaporated to 
dryness. The product was precipitated in diethyl ether (70 ml) and collected. 
Yield: 909 mg, 17%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.8-1.95 (4H, m, AQ-NH-CH2-CH2-CH2); 
2.5 (2H, t, AQ-NH-CH2-CH2-CH2-CH2); 3.32-3.45 (2H, q, AQ-NH-CH2); 7.0-7.1 
(1H, d, H-2); 7.5-7.65 (2H, m, H-3 and H-4); 7.68-7.8 (2H, m, H-6 and H-7); 
8.2-8.33 (2H, m, H-5 and H-8); 9.75 (1H, t, AQ-NH) 
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 2.6.8 Synthesis of AQ-Ava-OPFP (HZ73) 
AQ-Ava-OH HZ72 (800 mg, 2.5 mmol), PFP (684 mg, 3.75 mmol), DCC (1030 
mg, 5 mmol) and DMAP (915 mg, 7.5 mmol) were dissolved in dichloromethane 
(60 ml). The reaction had completed in 4 h by checking the TLC (Rf 0.67, 
dichloromethane- ethyl acetate 5:1). The DCU precipitate was filtered off. The 
product was purified by column chromatography using dichloromethane and 
ethyl acetate 5:1. The product fractions were combined, filtered and evaporated 
to dryness. Hexane (40 ml) was used to precipitate the solid compound. Yield: 
610 mg, 50%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.9-2.1 (4H, m, AQ-NH-CH2-CH2-CH2); 
2.78-2.85 (2H, t, AQ-NH-CH2-CH2-CH2-CH2); 3.4-3.5 (2H, q, AQ-NH-CH2); 7.1 
(1H, d, H-2); 7.55-7.68 (2H, m, H-3 and H-4); 7.7-7.83 (2H, m, H-6 and H-7); 
8.25-8.35 (2H, m, H-5 and H-8); 9.82 (1H, t, AQ-NH) 
 
2.6.9 Synthesis of AQ-Ava-Baclofen (HZ74) 
Two round bottomed flasks were used. One of them had AQ-Ava-OPFP HZ73 
(500 mg, 1 mmol) in DMF. The other one had NaOH (36 mg, 0.9 mmol), H2O 
(about 15 µl) and baclofen (235 mg, 1.1 mmol) in DMF. The two flasks were both 
refluxed on the hot water bath (90ºC). The baclofen solution was added to the 
flask of HZ73 by drop wise. The reaction was checked by TLC (Rf 0.75, 
dichloromethane methanol 9:1) and had mostly completed in 8 days. The 
reaction solution was extracted between dichloromethane and water (1:5, 200 
ml). The organic phase was dried by anhydrous sodium sulphate, filtered, and 
evaporated to a small volume. The crude product was purified by column 
chromatography using the eluting solvent dichloromethane and methanol 13:1. 
The pure fractions were combined, filtered, evaporated to dryness and collected. 
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 Yield: 110 mg, 21%. 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.5-1.6 (4H, m, 
AQ-NH-CH2-CH2-CH2); 2.1 (2H, t, AQ-NH-CH2-CH2-CH2-CH2); 2.4-2.5 (2H, m, 
CH2-COOH); 3.2-3.4 (5H, m, unresolved, AQ-NH-CH2, CONH-CH2, and 
CH-Benzene-Cl); 7.2-7.28 [(3H, m, H-2, H-3 and H-5 (Benzene-Cl)]; 7.28-7.34 
[(2H, m, H-2 and H-6 (Benzene-Cl)]; 7.4-7.48 (1H, d, H-4); 7.6-7.7 (1H, t, H-3); 
7.8-7.95 (3H, m, CONH, H-6 and H-7); 8.1-8.17 (1H, d, H-8); 8.17-8.25 (1H, d, 
H-5); 9.67 (1H, t, AQ-NH) 
ESMS (+): 517 m/z 100% (M-H)- 
 
2.6.10 Synthesis of AQ-Ava-cyclic Baclofen (HZ75) 
AQ-Ava-Baclofen HZ74 (60 mg, 0.12 mmol) was dissolved by acetic anhydride 
(3 ml) and refluxed on water bath (95ºC) for 1 h. The solution was cooled to RT 
and poured into distilled water. The precipitate product (Rf 0.55, 
dichloromethane-methanol 6:1) was collected by centrifuge. Yield: 48 mg, 80%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.6 (2H, m, AQ-NH-CH2-CH2-CH2); 
1.85-2.0 (4H, m, AQ-NH-CH2-CH2); 2.72-2.85 (1H, dd, O-CO-CH2); 2.95-3.15 
(3H, m, O-CO-CH2 and AQ-NH-CH2-CH2-CH2-CH2); 3.38-3.5 (2H, m, 
AQ-NH-CH2); 3.5-3.67 (1H, q, CH-Benzene-Cl); 3.7-3.8 (1H, dd, C=N-CH2); 
4.26-4.38 (1H, dd, C=N-CH2); 7.05-7.15 (1H, d, H-2); 7.15-7.22 [(2H, m, H-3 and 
H-5 (Benzene-Cl)]; 7.3-7.4 [(2H, q, H-2 and H-6 (Benzene-Cl)]; 7.54-7.68 (2H, m, 
H-3 and H-4); 7.7-7.83 (2H, m, H-6 and H-7); 8.25-8.33 (2H, m, H-5 and H-8); 
9.8 (1H, t, AQ-NH) 
ESMS (+): 501 m/z 100% (M+H)+ 
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 2.6.11 Synthesis of AQ-GABA-OH (HZ76) 
1-Choloroanthraquinone (3 g, 12 mmol), gamma-aminobutyric acid (3.8 g, 37 
mmol), NaOH (1.44 g, 36 mmol) and DMSO (80 ml) were transferred into a 
round bottomed flask. The flask was put on a 100ºC water bath and heated for 6 
h. The solution mixture was poured into the 300ml of acidic water (HCl was 
added). The red precipitate (Rf 0.27, dichloromethane-methanol 9:1) was filtered 
and purified by column chromatography using solvent system dichloromethane 
and methanol 11:1.  The pure product fractions were combined, filtered and 
evaporated to dryness by using the rotational evaporator. The red solid product 
was precipitated in diethyl ether (50 ml) and the mixture was filtered, dried in a 
desiccator and collected. Yield: 605 mg, 20%. 
 
2.6.12 Synthesis of AQ-GABA-OPFP (HZ77) 
AQ-GABA-OH HZ76 (500 mg, 1.6 mmol), PFP (442 mg, 2.4 mmol), DCC (659 
mg, 3.2 mmol) and DMAP (586 mg, 4.8 mmol) were dissolved in 
dichloromethane (50 ml). The reaction had completed in 7 h by checking the 
TLC (Rf 0.7, dichloromethane- ethyl acetate 4:1). The DCU precipitate was 
filtered off. The product was purified by column chromatography using 
dichloromethane and ethyl acetate 4:1. The product fractions were combined, 
filtered and evaporated to dryness. Hexane (40 ml) was used to precipitate the 
solid compound. Yield: 335 mg, 44%. 
 
2.6.13 Synthesis of AQ-GABA-Baclofen (HZ78) 
Two round bottomed flasks were used. One of them had AQ-GABA-OH HZ77 
(300 mg, 0.63 mmol) in DMF (15 ml). The other one had NaOH (23 mg, 0.57 
mmol), H2O (about 15 µl) and baclofen (148 mg, 0.69 mmol) in 10ml of DMF. The 
two flasks were both refluxed on the hot water bath (90ºC). The baclofen solution 
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 was added to the flask of HZ77 by drop wise. The reaction was checked by TLC 
(Rf 0.35, dichloromethane- methanol 6:1) and had mostly completed in 10 days. 
The reaction solution was extracted between dichloromethane and water (1:5, 
200 ml). The organic phase was dried by anhydrous sodium sulphate, filtered, 
and evaporated to a small volume. The crude product was purified by column 
chromatography using the eluting solvent dichloromethane and methanol 13:1. 
The pure fractions were combined, filtered, evaporated to dryness and collected. 
Yield: 43 mg, 14%. 
 
2.6.14 Synthesis of AQ-GABA-cyclic Baclofen (HZ79) 
AQ-GABA-Baclofen HZ78 (25 mg, 0.05 mmol) was dissolved by acetic 
anhydride (5 ml) and refluxed on water bath (95ºC) for 1 h. The solution was 
cooled to RT and poured into distilled water. The precipitate product (Rf 0.45, 
dichloromethane-methnol 6:1) was collected by centrifuge. Yield: 11.7 mg, 48%. 
ESMS (+): 487 m/z 100% (M+H)+ 
 
2.6.15 Synthesis of AQ-[PEG Spacer]-Succinyl (HZ80) 
Succinic anhydride (249 mg, 2.7 mmol) and anthraquinone derivative (800 mg, 
2.26 mmol) were dissolved in DMF (40 ml) followed by the addition of the DIPEA 
(864 µl, 5 mmol, 0.742 mg/ml) and reacted at RT overnight. The product (Rf 0.27, 
dichloromethane-methanol 9:1) solution was extracted by dichloromethane and 
water (1:5, 200 ml). The organic layer was collected, dried by anhydrous sodium 
sulphate, filtered and evaporated to a small volume for the column 
chromatography purification using dichloromethane-ethyl acetate-ethanol 6:2:1 
solvent system. The pure fractions were combined, filtered, evaporated, and 
precipitated in diethyl ether (50 ml). The solid product was collected. Yield: 520 
mg, 61%. 
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 2.6.16 Synthesis of AQ-[PEG Spacer]-Succinyl-OPFP (HZ81) 
AQ-[PEG Spacer]-Succinyl HZ80 (450 mg, 0.73 mmol), PFP (200 mg, 1.1 mmol), 
DCC (300 mg, 1.46 mmol) and DMAP (267 mg, 2.19 mmol) were dissolved in 
dichloromethane (60 ml). The reaction had completed in 6 h by checking the 
TLC (Rf 0.75, dichloromethane- ethyl acetate 4:1). The DCU precipitate was 
filtered off. The product was purified by column chromatography using 
dichloromethane and ethyl acetate 5:1. The product fractions were combined, 
filtered and evaporated to dryness. Hexane (50 ml) was used to precipitate the 
solid compound. Yield: 250 mg, 53%. 
 
2.6.17 Synthesis of AQ-[PEG Spacer]-Succinyl-Baclofen (HZ82) 
Two round bottomed flasks were used. One of them had AQ-[PEG 
Spacer]-Succinyl-OPFP HZ81 (200 mg, 0.32 mmol) in 15 ml of DMF. The other 
one had NaOH (11 mg, 0.29 mmol), H2O (about 15 µl) and baclofen (110 mg, 
0.35 mmol) in DMF (8 ml). The two flasks were both refluxed on the hot water 
bath (90ºC). The baclofen solution was added to the flask of HZ81 by drop wise. 
The reaction was checked by TLC (Rf 0.38, dichloromethane-methanol 6:1) and 
had mostly completed in 8 days. The reaction solution was extracted between 
dichloromethane and water (1:3, 200 ml). The organic phase was dried by 
anhydrous sodium sulphate, filtered, and evaporated to a small volume. The 
crude product was purified by column chromatography using the eluting solvent 
dichloromethane and methanol 10:1. The pure fractions were combined, filtered, 
evaporated to dryness and collected. Yield: 120 mg, 56%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 2.15-2.4 (4H, m, unresolved, 
AQ-NH-CH2-CH2 and CONH-CH2); 2.4-2.55 (2H, m, CH2-COOH); 3.1-3.3 (4H, m, 
NHCO-CH2-CH2); 3.32-3.48 (2H, m, AQ-NH-CH2); 3.5-3.7 (7H, m, 
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 CH-Benzene-Cl, AQ-NH-C2H4-O-C2H4-O-CH2 and AQ-NH-C2H4-O-C2H4); 
3.7-3.8 (2H, q, CH2-NHCO); 7.2-7.37 [(4H, m H-2, 3, 5, 6 (Benzene-Cl)]; 7.45 
(1H, d, H-4); 7.6-7.7 (1H, t, H-3); 7.78-7.95 (4H, m, unresolved, NHCO, CONH, 
H-6 and H-7); 8.08-8.15 (1H, d, H-8); 8.15-8.25 (1H, d, H-5); 9.79 (1H, t, AQ-NH) 
ESMS (+): 650 m/z 100% (M+H)+ 
 
2.6.18 Synthesis of AQ-[PEG Spacer]-Succinyl-cyclic Baclofen (HZ83) 
AQ-[PEG Spacer]-Succinyl-Baclofen HZ82 (60 mg, 0.09 mmol) was dissolved by 
acidic anhydride (5 ml) and refluxed on water bath (95ºC) for 1 h. The solution 
was cooled to RT and poured into distilled water. The precipitate product (Rf 0.55, 
dichloromethane-methanol 6:1) was collected by centrifuge. Yield: 37 mg, 65%. 
 
1H NMR spectrum (CDCl3, 300 MHz) δ: 2.45-2.52 (2H, t, AQ-NH-CH2-CH2); 
2.68-2.78 (2H, q, NHCO-CH2); 2.9-3.0 (1H, dd, O-CO-CH2); 3.15-3.25 (1H, dd, 
O-CO-CH2); 3.45-3.7 (7H, m, unresolved, AQ-NH-CH2, NHCO-CH2-CH2, and 
CH-Benzene-Cl); 3.7-3.8 (4H, m, AQ-NH-C2H4-O-C2H4); 3.8-3.9 (3H, m, 
C=N-CH2 and CH2-NHCO); 4.16-4.27 (1H, dd, C=N-CH2); 6.45 (1H, t, NHCO); 
7.06-7.22 [(3H, m, H-2 (AQ), H-3 and H-5 (Benzene-Cl)]; 7.25-7.4 [(2H, q, H-2 
and H-6 (Benzene-Cl)]; 7.53-7.68 (2H, m, H-3 and H-4); 7.68-7.85 (2H, m, H-6 
and H-7); 8.22-8.35 (2H, m, H-5 and H-8); 9.93 (1H, t, AQ-NH) 
ESMS (+): 632 m/z 100% (M+H)+ 
 
2.6.19 Synthesis of AQ-[propyl spacer]-Pro-succinyl (HZ84) 
Anthraquinone-spacer-D-Pro (400mg, 1.1 mmol) and succinic anhydride (127 
mg, 1.3 mmol) were dissolved in 30 ml of DMF followed by the addition of DIPEA 
(0.742 mg/ml, 420 µl, 2.2 mmol) and reacted at RT overnight. The product (Rf 
0.25, dichloromethane methanol 9:1) solution was extracted by dichloromethane 
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 and water (1:3, 300 ml). The organic layer was collected, dried by anhydrous 
sodium sulphate, filtered and evaporated to a small volume for the column 
chromatography purification using dichloromethane-ethanol 7:1 solvent system. 
The pure fractions were combined, filtered, evaporated, and precipitated in 40 ml 
of diethyl ether. The solid product was collected. Yield: 218 mg, 42%. 
 
2.6.20 Synthesis of AQ-[propyl spacer]-Pro-succinyl-OPFP (HZ85) 
AQ-[propyl spacer]-Pro-succinyl HZ84 (200 mg, 0.42 mmol), PFP (116 mg, 0.63 
mmol), DCC (173 mg, 0.84 mmol) and DMAP (154 mg, 1.26 mmol) were 
dissolved in dichloromethane (40 ml). The reaction had completed in 4 h by 
checking the TLC (Rf 0.8, dichloromethane- ethyl acetate 5:1). The DCU 
precipitate was filtered off. The product was purified by column chromatography 
using dichloromethane and ethyl acetate 5:1. The product fractions were 
combined, filtered and evaporated to dryness. Hexane (50 ml) was used to 
precipitate the solid compound. Yield: 120 mg, 44% 
 
2.6.21 Synthesis of AQ-[propyl spacer]-Pro-succinyl-Baclofen (HZ86) 
Two round bottomed flasks were used. One of them had AQ-[propyl 
spacer]-Pro-succinyl-OPFP HZ85 (100 mg, 0.16 mmol) in DMF (20 ml). The 
other one had NaOH (5.6 mg, 0.14 mmol), H2O (about 10 µl) and baclofen (38 
mg, 0.18 mmol) in DMF (8 ml). The two flasks were both refluxed on the hot 
water bath (90ºC). The baclofen solution was added to the flask of HZ85 by drop 
wise. The reaction was checked by TLC (Rf 0.43, dichloromethane-methanol 6:1) 
and had mostly completed in 6 days. The reaction solution was extracted 
between dichloromethane and water (1:5, 300 ml). The organic phase was dried 
by anhydrous sodium sulphate, filtered, and evaporated to a small volume. The 
crude product was purified by column chromatography using the eluting solvent 
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 dichloromethane and methanol 14:1. The pure fractions were combined, filtered, 
evaporated to dryness and collected. Yield: 96 mg, 89%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.7-2.0 (6H, m, unresolved, 
AQ-NH-CH2-CH2, β-CH2 and γ-CH2); 2.1-2.7 (6H, m, unresolved, NCO-CH2-CH2 
and CH2-COOH); 3.1-3.3 (4H, m, AQ-NH-CH2-CH2-CH2 and CONH-CH2); 
3.3-3.8 (5H, m, unresolved, CH-Benzene-Cl, AQ-NH-CH2 and δ-CH2); 4.25 (1H, 
m, α-CH pro); 7.05-7.38 [(5H, m H-2, 3, 5, 6 (Benzene-Cl) and H-2 (AQ)]; 7.4 
(1H, t, CONH); 7.65 (1H, t, NHCO); 7.7-7.95 (4H, m, H-3, H-4, H-6 and H-7); 
8.1-8.3 (2H, q, H-5 and H-8); 9.72 (1H, t, AQ-NH) 
ESMS (+): 673 m/z 100% (M+H)+ 
 
2.6.22 Synthesis of AQ-[propyl spacer]-Pro-succinyl- cyclic Baclofen 
(HZ87) 
AQ-[propyl spacer]-Pro-succinyl-Baclofen HZ86 (50 mg, 0.07 mmol) was 
dissolved by acetic anhydride (5 ml) and refluxed on water bath for 1 hour. The 
solution was cooled to RT and poured into distilled water. The precipitate product 
(Rf 0.71, dichloromethane-methanol 9:1) was collected by centrifuge. Yield: 37 
mg, 80%. 
1H NMR spectrum (CDCl3, 300 MHz) δ: 1.75-2.1(6H, m, unresolved, 
AQ-NH-CH2-CH2, β-CH2 and γ-CH2); 2.35-2.95 (6H, m, unresolved, 
NCO-CH2-CH2 and O-CO-CH2,); 3.15-3.9 (7H, m, unresolved, 
AQ-NH-CH2-CH2-CH2, CH-Benzene-Cl and C=N-CH2); 4.0-4.3 (1H, m, α-CH); 
4.68-4.75 (2H, m, δ-CH2); 6.9-7.35 [(5H, m H-2, 3, 5, 6 (Benzene-Cl) and H-2 
(AQ)]; 7.45 (1H, t, NHCO); 7.5-7.67 (2H, m, H-3 and H-4); 7.68-7.84 (2H, m, H-6 
and H-7); 8.12-8.3 (2H, m, H-5 and H-8); 9.75 (1H, t, AQ-NH) 
ESMS (+): 655 m/z 100% (M+H)+ 
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 Chapter 3 Legumain Activated GABA Prodrugs 
3.1 Abstract 
Legumain represents a recently identified lysosomal protease that is upregulated 
in most human cancers. Legumain activity is thought to promote tumour invasion 
and metastasis. Consequently, legumain is a promising target for probe design 
in cancer diagnosis.  
A quenched activity-based probe for legumain Rho-Pro-Ala-Asn-GABA-[Propyl 
spacer]-AQ (HZ101) was chemically synthesised. The probe comprises the 
fluorochrome Rhodamine B, a legumain specific peptide substrate and the dark 
quencher anthraquinone. This probe is highly selective for legumain due to the 
asparagine residue at the P1 position. Peptide cleavage by legumain relieves 
the self-quenching of the probe and generates fluorescence. The evaluation of 
probe activity by MTT, HPLC and lipophilicity assays demonstrated that HZ101 is 
an ideal biomarker for the imaging and diagnosis of human breast cancer and is 
a potential prodrug for the delivery of GABA to tumours to modulate the GABAB 
receptor response. 
 
3.2  Introduction 
3.2.1 Legumain 
Legumain, an asparaginyl endopeptidase, is a member of the C13 cysteine 
protease family and was first identified in plants (Ishii, 1993). Mammalian 
legumain has been discovered in the liver, spleen and kidney. Legumain has 
been proposed to play an important role in the degradation of the extracellular 
matrix (Morita et al., 2007). Each legumains is first produced as a pro-enzyme 
(50-60 kDa), which is converted into the active form by auto cleavage under 
acidic conditions (pH 4.0 to 5.8). The size of mature active legumain varies from 
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 30 kDa to 40 kDa. Legumain is irreversibly denatured at a pH of 7 or higher 
(Chen et al., 1997, Chen et al., 2001). In cells, mammalian legumain is mainly 
localized in the endo-lysosomal system. The acidic pH environment of 
lysosomes facilitates legumain activity (Dall and Brandstetter, 2015). 
 
3.2.2 Legumain Substrate Specificity 
The crystal structure of legumain provides insights into its substrate specificity. 
The S1 pocket of legumain has a dual charge character and is consequently an 
ideal binding site for the asparagine at the P1 substrate position (Dall and 
Brandstetter, 2013).  
 
Legumain has less selectivity at other substrate positions. A peptide library was 
constructed to determine the optimal substrate sequences for the P3-P2-P1 
positions. The tripeptide Thr-Ala-Asn was identified as the ideal substrate for 
Schistosoma legumain whereas human legumain prefers a proline (Pro) residue 
at P3. These observations suggest that legumain substrate specificity is species 
dependent (Mathieu et al., 2002). At the P1' position, amino acids with small side 
chains such as Gly and Ala, are tolerated, but proline is excluded (Schwarz et al., 
2002).  
 
The endogenous cystatin E/M is the most potent inhibitor of legumain and also 
serves as a tumour suppressor. The auto-activation of prolegumain is inhibited 
by cystatin E/M in both intra- and extracellular environments (Smith et al., 2012). 
The crystal structure of the legumain-cystatin complex revealed that cystatin 
acts as a substrate and the cleavage product remains bound to the legumain 
active site. The development of legumain inhibitors has been considered. 
Recently, a series of aza-peptidyl inhibitors with non-natural amino acids were 
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 synthesised. It was found that inhibitors with small alkyl groups in the P3 position 
had the improved inhibitory activity (Lee and Bogyo, 2012).  
 
3.2.3 Legumain expression in tumours 
Several studies have shown that legumain is highly expressed in tumours in vitro 
and in vivo, such as colorectal, prostate, gastric, ovarian, and breast cancers 
(Zhen et al., 2015). 
Immunohistochemical and western blotting methods have revealed that the 
expression of legumain is increased in primary colorectal cancer compared with 
normal mucosa. Patients with lower legumain expression and weak staining 
have a better survival rate. These findings suggest that legumain may play a 
greater role in the early development of colorectal cancers and that its 
prognostic importance should be considered (Murthy et al., 2005). 
The expression and activity of legumain in melanoma were first addressed in 
2010. The endogenous cystatin E/M was detected to inhibits the legumain 
activity and suppresses tumour growth and metastasis (Briggs et al., 2010). 
Legumain expression has also been confirmed in prostate cancer by RT-PCR 
and Western blot. An immunohistochemical study revealed that a vesicular 
staining pattern of legumain was associated with prostate tumour invasion and 
metastasis (Ohno et al., 2013). In gastric cancer, legumain is over-expressed 
and is significantly correlated with tumour cell invasion and malignant 
transformation. Legumain has been proposed as a biomarker to predict the 
prognosis for metastasis in gastric cancer (Guo et al., 2013). 
 
Gawend et al. (2007) investigated legumain expression in breast cancer. 
Non-neoplastic breast tissues exhibited a pattern of negative or low staining 
pattern for legumain, whereas a positive vesicular pattern was observed in 
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 invasive breast tumour cells by immunohistochemistry. Another study supported 
the hypothesis that targeting tumour associated macrophages and reducing their 
density in tumour tissues leads to a reduction of tumour mass. Macrophages are 
responsible for the secretion of many tumour invasive factors such as MMP-9, 
VEGF, and TNF-α. Legumain overexpressed by tumour-associated 
macrophages was used as the target molecule and a legumain based DNA 
vaccine was used to target tumour associated macrophages (Luo et al., 2006). 
In ovarian cancer, patients with high legumain expression had a worse prognosis 
and survival rate. Legumain was found to be upregulated in ovarian cancer 
tissues at both the mRNA and protein levels (Wang et al., 2012).  
 
3.2.4 Legumain Activated Prodrugs 
The protease activated prodrug approach for cancer therapy was first described 
in 1980 (Carl et al., 1980). The created prodrugs aim to be locally activated by 
tumour-associated protease and have less toxicity to normal cells. 
 
Legubicin (as shown in Figure 38) was designed as the legumain activated 
prodrug for cancer chemotherapy (Liu et al., 2003). The prodrug was 
synthesized by addition of a peptide extension (Boc-Ala-Ala-Asn-Leu) to the 
amino group of doxorubicin. The Boc protecting group at the NH2 terminus 
prevented the hydrolysis of peptide component. After cleavage by legumain, the 
prodrug will be converted into two molecules Boc-Ala-Ala-Asn-OH and 
Leu-doxorubicin.  
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Figure 38. Chemical structure of 
N-(-t-Butoxycarbonyl-L-alanyl-L-alanyl-L-asparaginyl-L-leucyl)doxorubicin 
(Legubicin) prodrug 
 
The cytotoxicity of legubicin was analysed in vitro. On tumour cells not 
expressing legumain, the cytotoxic effect of legubicin was less than 1% 
compared with doxorubicin. In contrast, on legumain positive cells, the effect of 
legubicin with conversion to Leu-doxorubicin was similar to doxorubicin. This 
result indicated that the peptide conjugation on legubicin prodrug had 
successfully eliminated the cytotoxic effect of doxorubicin (liu at al., 2003). 
 
The in vitro effects of legubicin were investigated on mice model with CT26 colon 
carcinoma. The injection of legubicin at 5 mg/kg three times in 2 days to mice 
arrested the tumour growth. The weight of mice was monitored during the 
therapy and there was no evidence of weight loss which indicated that legubicin 
was tolerated in mice and has little toxicity. Moreover, the organs that express 
legumain such as liver and kidney were not injured. At the same dose, 
doxorubicin was fatal to mice and failed to produce similar antitumour effect as 
legubicin. The TUNEL assays showed that the apoptotic index of legubicin was 
higher that doxorubicin. 
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Figure 39. legumain cleavable colchicine prodrug 
 
Figure 39 shows another example of a legumain-cleavable prodrug 
incorporating colchicine as the cytotoxic agent (Smith et al., 2014). The 
synthesised prodrug has the legumain peptide substrate Val-Asn-Ala-Ala. The 
amino acid valine was linked to deacetyl colchicine to increase the lipophilicity of 
the released active agent after legumain cleavage. The prodrug activity was 
investigated by MTT assay on the colorectal cell lines HCT116 and SW620. The 
legumain activity in HCT116 showed approximately 25% higher than SW620 cell 
line. At the same prodrug concentration (10 μM), the cell viability for HCT116 
was lower than in SW620 cells. Furthermore, the legumain inhibitor cystatin E/M 
was able to reduce the toxicity of the colchicine prodrug by approximately 33% in 
legumain over-expressing cell line M38L (Smith et al., 2014). 
 
3.2.5 Legumain Activated Probes 
In 2013, (Edgington et al., 2013) developed a legumain probe (LE28) that is 
fluorescently quenched. The chemical structure of LE28 was shown in Figure 
40.  
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Figure 40. Chemical structure of LE28 
 
 
Figure 41. Mechanism of LE28 binding to legumain 
 
The mechanism of LE28 has been illustrated in Figure 41. The catalytic thiol in 
the active site of legumain attacks the acyloxymethyl ketone of LE28 and results 
in loss of quenching group. The probe covalently binds to legumain and 
becomes fluorescent. LE28 was found to be highly quenched. The capacity of 
LE28 bind to legumain was tested by incubation of RAW cell extracts with 
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 increasing concentrations (0-5 μM) of LE28 at pH 4.5. The proteins were 
resolved by fluorescent SDS-PAGE and a legumain size at 36 kDa was 
observed.  
 
In vivo imaging with LE28 was first performed on healthy nude mice. The mice 
were injected with LE28 and the fluorescence was imaged on an IVIS machine. 
LE28 already started to produce low fluorescence at early time (5-25 min) of 
injection. After 1 hour, the fluorescent imaging intensity in the kidney became 
strong and continued to increase. The major organs were collected after 8 hours 
of injection and a biochemical analysis was performed. Kidney appeared to have 
the highest LE28 labelling. Liver had a lesser level of LE28 labelling than kidney.  
The imaging ability of LE28 on tumour cells was evaluated using the HCT-116 
(human colorectal carcinoma cells) and tumour bearing mice. The injected mice 
were monitored for 28 hours. After 30 min of injection, the fluorescence signal of 
LE28 became detectable. The fluorescent imaging intensity reached the 
maximal value at 7 hours and remained constant until 28 hours. The probe LE28 
effectively imaged the legumain activity in normal tissues and tumours. Future 
efforts on design of the fluorescently quenched probe target legumain for 
different tumour types have great importance (Edgington et al., 2013).  
 
Another recent study developed a new MRI contrast agent 
Gd-NBCB-TTDA-Leg(L) and a near-infrared fluorescent probe 
CyTE777-Leg(L)-CyTE807 for detection of legumain activity in tumours (Chen et 
al., 2014). Both of the two compounds have the same legumain specific 
substrate peptide Leg(L). The MTT assay evaluated the cytotoxicity of 
Gd-NBCB-TTDA-Leg(L) and CyTE777-Leg(L)-CyTE807 on colon carcinoma cell 
line. They all showed low cytotoxicity even at high concentrations. The in vitro 
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 and in vivo MR imaging were carried out for Gd-NBCB-TTDA-Leg(L), the results 
indicated that the new MRI contrast agent attained 55.3 fold higher imaging 
enhancement than control. In vivo optical imaging of the NIR fluorescent probe 
CyTE777-Leg(L)-CyTE807 showed efficiently fluorescent intensity.  
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 3.3 Results and Discussion 
3.3.1 Design of Legumain activated Probe HZ101 
Fluorescent probes have been developed as powerful tools for in vivo imaging of 
tumour microenvironment (Ueno and Nagano, 2011). The probe designed in this 
study for fluorescence imaging is based on the FRET principle (Figure 42). 
 
 
Figure 42. Schematic of the FRET process 
 
FRET (Fluorescence Resonance Energy Transfer) is one of the most commonly 
exploited mechanisms for the design of fluorescent probes. FRET is the process 
of energy transfer from an excited donor to an acceptor through dipole-dipole 
interactions. The transfer of energy reduces the fluorescence intensity of the 
donor (Demchenko, 2010). The emission spectrum of the donor should overlap 
with the acceptor absorption spectrum, whereas, the absorption spectra of the 
donor and acceptor should be well separated. The donor is a fluorophore with 
brightness comparable to that of the acceptor dye. The linker between the donor 
and acceptor is selected to prevent fluorescence quenching (Kobayashi et al., 
2010).  
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Figure 43. Designed structure of the legumain activated probe (HZ101) 
 
The legumain activated probe (HZ101) designed here Figure 43 contains a 
legumain specific substrate (Pro-Ala-Asn↓) in the middle. The arrow denotes the 
cleavage site adjacent to the carboxy terminus of asparagine. The C-terminal 
side of asparagine at the P1 site is cleaved by legumain in a number of 
substrates. One side of the substrate (N-terminus) was attached to rhodamine B 
as the fluorophore. The quenching group anthraquinone spacer was added to 
the other side (C-terminus) of the tripeptide substrate.  
 
The designed probe HZ101 (Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ) aims 
to exploit the proteolytic activity of overexpressed legumain in the breast cancer 
cell line MCF-7. The fluoro group of rhodamine B can be silenced by the dark 
quenching group of the anthraquinone spacer due to the principle of FRET. After 
peptide cleavage by legumain, which is indicated by fluorescence restoration, 
the anthraquinone spacer is further activated by aminopeptidases to release the 
ligand GABA.  
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Reagents and conditions: (1) Boc-GABA-OH, PyBOP , DIPEA, in DMF, RT(2) TFA, RT (3) 
Fmoc-Asn(Trt)-OH, TBTU, HOBt, DIPEA, DMF, RT, (4) 20% piperidine in DMF, RT (5) Fmoc- Ala-OH, TBTU, 
HOBt, DIPEA, DMF, RT (6) 20% piperidine in DMF, RT (7) Fmoc-Pro-OH, TBTU, HOBt, DIPEA, DMF, RT (8) 
20% piperidine in DMF, RT (9) Rhodamine B, TBTU, HOBt, DIPEA, DMF (10) TFA, RT 
Scheme 32. Overview of the synthesis of the legumain activated prodrug (HZ101) 
 
Scheme 32 presents the overall scheme of the whole synthesis of the legumain 
prodrug HZ101. The tetrapeptide (Pro-Ala-Asn(Trt)-GABA) was built on the 
anthraquinone spacer by solution phase peptide synthesis. The trityl protecting 
group of asparagine was removed at the last step after adding rhodamine B to 
the tetrapeptide anthraquinone conjugate H-Pro-Ala-Asn(Trt)-GABA-[Propyl 
spacer]-AQ.  
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 3.3.2 Synthesis of H-[Propyl spacer]-AQ (HZ103) 
The starting point in the synthesis of the legumain targeted theranostic prodrug 
(HZ101) as shown in Scheme 33 was the preparation of the 
aminoanthraquinone (HZ103), which serves as both the quencher of the 
rhodamine fluorophore in FRET for diagnostic applications and a DNA binding 
cytotoxic agent in anticancer therapeutics. 
In general, the introduction of hydroxy groups into the anthracenedione ring 
system enhances cytotoxic potency; hydroxylation of the nucleus, as in the case 
of mitoxantrone may be expected to increase cytotoxicity due to stronger binding 
to DNA and slower dissociation kinetics due to the presence of the hydroxyl 
groups (Smithet al., 1990). 
Here, the strategy adopted for the synthesis of the 4, 8-dihydroxylated 
aminoanthraquinone-spacer compound (HZ 103) was based on the controlled 
mono-amination of leuco-1,4,5-trihydroxyanthraquinone 
(leuco-5-hydroxyquinizarin). The methods were based on the reported 
regiospecific amination of this leuco-trihydroxyanthraquinone by Morris, Mullah 
and Sutherland (1986), who synthesised a series of 
aminohydroxyanthraquinones from leuco-5-hydroxyquinizarin. It was found that 
if the leuco-intermediates were oxidised and then hydrolysed using HCl or NaOH, 
they each gave 5-hydroxyquinizarin. However, if these intermediates were 
stirred with triethylamine in dichloromethane in the presence of air, the 
aminoanthraquinones were formed. These conditions were adopted for the 
synthesis of HZ103. 
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Reagents and Conditions: (a) CH2Cl2, water bath (1 hour), then Et3N (0.5 ml) and O2 for 
2 hours 
Scheme 33. Outline of HZ103 synthesis 
 
Leuco-1,4,5-trihydroxyanthraquinone was reacted with diaminopropane in 
dichloromethane. The reaction mixture was refluxed in 60ºC water bath for 1 
hour. Triethylamine was then added to the reaction. The mixture was oxidized by 
O2 for 2 hours. The brown insoluble solid was removed by filtration and the 
remaining solution was extracted with dichloromethane and water. The organic 
layers were combined and dried. The dark blue product H-[Propyl spacer]-AQ 
(HZ103) was collected for the next reaction. 
 
3.3.3 Synthesis of Boc-GABA-[Propyl spacer]-AQ (HZ104) 
The coupling reaction of H-[Propyl spacer]-AQ (HZ103) and Boc-GABA-OH was 
performed in DMF by the addition of reagents PyBOP and DIPEA (Scheme 34). 
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Reagents and Conditions: (a) PyBOP, DIPEA, in DMF 
Scheme 34. Outline of HZ104 synthesis 
 
The reaction was monitored by TLC and pure HZ104 was obtained by silica gel 
chromatography and collection of appropriate fractions. The product 
Boc-GABA-[Propyl spacer]-AQ (HZ104) was then used in the de-protection 
reaction. 
 
3.3.4 Synthesis of H-GABA-[Propyl spacer]-AQ TFA Salt (HZ105) 
The Boc protecting group of Boc-GABA-[Propyl spacer]-AQ (HZ104) was 
removed by using TFA (Scheme 35). After confirmation of Boc removal by TLC 
the excess TFA was removed by evaporation. 
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Reagents and Conditions: (a) TFA 
Scheme 35. Outline of HZ105 synthesis 
 
To obtain pure H-GABA-[Propyl spacer]-AQ TFA salt (HZ105) for HPLC analysis, 
further purification was performed using thick layer chromatography. The 
compound H-GABA-[Propyl spacer]-AQ TFA salt (HZ105) was characterised by 
NMR. The 1H NMR spectrum revealed signals between 1.7 and 3.4 were 
assigned to the methylene groups of the GABA and propyl spacer. The 
anthraquinone protons were fully assigned; H-2 and H-3 gave a 2-proton 
multiplet at 7.18 to 7.3 ppm, H-7 was a doublet at 7.3 to 7.4 ppm, and H-6 was a 
multiplet between 7.58 and 7.7 ppm.  
 
3.3.5 Synthesis of H-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ99) 
The amino acid coupling reaction with the anthraquinone spacer compound 
(HZ105) was performed by solution phase peptide synthesis as shown in 
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 Scheme 36. 
 
Scheme 36. Outline of HZ99 synthesis 
 
HZ105 was reacted with Fmoc-Asn-OH in DMF, followed by the addition of the 
coupling reagents TBTU, HOBt, and DIPEA. The product 
Fmoc-Asn-spacer-anthraquinone was treated with 20% piperidine in DMF to 
remove the Fmoc protecting group. The next amino acid was added using the 
same method. The solution phase peptide synthesis produced the substrate 
conjugate Pro-Ala-Asn-GABA-Spacer-anthroquinone (HZ99). 
 
3.3.6 Synthesis of Rho-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ100) 
The fluorescent agent rhodamine B was coupled with 
H-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ99) in DMF using the reagents 
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 PyBOP and DIPEA (Scheme 37). 
 
 
Reagents and Conditions: (a) PyBOP, DIPEA, in DMF 
Scheme 37. Outline of HZ100 synthesis 
 
The reaction was considered successful if monitoring of the TLC plate under the 
light of a UV lamp (360 nm) revealed an absence of fluorescent spots in the 
product lane. Rho-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ100) was 
further purified by silica gel chromatography. Chloroform to methanol (8:1) was 
used as the solvent system. The product was collected under vacuum.  
 
3.3.7 Synthesis of Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) 
The N-protecting group triphenylmethyl (trityl) on the asparagine of 
Rho-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ100) was removed by TFA 
treatment. The synthesis of HZ101 was illustrated in Scheme 38. 
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Reagents and Conditions: (a) TFA 
Scheme 38. Outline of legumain activated prodrug (HZ101) synthesis 
 
After confirmation of reaction completion by TLC, the reaction solution was 
evaporated to dryness. The solid compound was precipitated in diethyl ether. To 
obtain a high purity of Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) for 
HPLC analysis, further purification by thick layer chromatography was performed. 
Dichloromethane to methanol (6:1) was used as the solvent system for thick 
layer chromatography.  
 
Mass Spectral characterization of HZ101 
The Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) was successfully 
characterised by nanoelectrospray positive ionisation mass spectrometry 
(Figure 44). The signal at m/z 1104 in the nanoelectrospray positive ion mass 
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 spectrum for the species (M-CO2CF3)+ corresponds to a molecular mass of 1217 
Da. In addition, the observed data and theoretical isotope model were in good 
agreement. 
 
 
 
Figure 44. ESI (+) Mass spectrum of Probe:  
Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) 
 
3.3.8 Legumain PCR results 
The legumain expression in MCF-7 cells was determined by end-point PCR. 
Before the PCR experiment, RNA was extracted from the MCF-7 cells. The 
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 isolated RNA was then used for cDNA synthesis. As shown in Figure 45, beta 
actin was used as the positive control.  
 
 
Figure 45. PCR results for legumain  
The legumain primers were designed using the program Primer-BLAST to 
amplify only the legumain transcript.  
Forward primer: Sequence (5’3’): ATCCGGCAAAGTCCTGAAGAG 
Reverse primer: Sequence (5’3’): ATGAACCACCTGCCGGATAAC 
 
From Figure 45 above, it is obvious to see the brands of legumain which 
indicate the presence of legumain expression in the breast cancer (MCF-7) cell 
line. 
 
3.3.9 HZ101 Activity Study: Fluorophore Quenching Study 
In Figure 46, the graph showed that the highest relative fluorescence intensity of 
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 rhodamine B is 825 at the wavelength of at 577nm. 
 
Figure 46. Comparison of fluorescence intensities of rhodamine B (0.5 µM) and 
probe HZ101 (5 µM) in legumain assay buffer, pH 5.0. Excitation/Emission (nm): 
550/590. 
 
By contrast, the fluorogenic probe HZ101 had a maximum relative fluorescence 
intensity of 5, at a wavelength of 580 nm, demonstrating excellent quenching of 
rhodamine fluorescence by the aminodihydroxyanthraquinone chromophore. 
There was a 165 fold difference between the two compounds. In addition, the 
concentration of HZ101 (5 µM) was 10 times higher than that of rhodamine B 
(0.5 µM) in the fluorophore quenching study. This result determines the high 
efficiency of the anthraquinone spacer in quenching the fluorophore rhodamine 
B in the probe HZ101. 
 
3.3.10 HZ101 Fluorimetric Assay 
The legumain activated prodrug (HZ101) was incubated with recombinant 
human legumain (40 ng) at 37ºC in 96 well plates (Figure 47). The total volume 
of each well was 100 µl. The concentration of HZ101 was varied from 5 µM, 10 
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 µM, 25 µM, 50 µM to 100 µM. At concentrations of 5 µM and 10 µM, the 
fluorescence intensity of HZ101 increased significantly during the first 30 min 
and gradually reached a maximum value (550) with in the next 30 min. At the 
concentration of 25 µM, the maximum fluorescence intensity was only 350. 
When the concentration was increased to 50 µM and 100 µM, the fluorescence 
intensity of HZ101 remained unchanged at 250 and 200, respectively, between 3 
min and 120 min.  
 
Figure 47. Relative fluorescence intensity released by HZ101 during the 
incubation with legumain. pH 5.0. Excitation: 544, Emission: 590, Gain: 800.  
 
3.3.11 HZ101 Cytotoxicity Assays 
The MTT cell proliferation assay has been widely used to estimate the number of 
viable cells in 96-well plates during cell culture. MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)  is a yellow 
reagent that can be cleaved by living cells to produce a dark blue formazan 
product (Ciapetti et al., 1993). The quantity of formazan (directly proportional to 
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 the number of viable cells) is measured by recording the absorbance at 550 nm 
using a plate reading spectrophotometer.  
 
As shown in Figure 48, the wells in lane 1 contained fresh medium only as the 
blank control. The MCF-7 cell suspension was pipetted into each well of the 
96-well plate from lanes 2 to 12. The plate was incubated at 37 ºC and 5% CO2 
overnight before treatment with HZ101. Drug dilutions were added to the wells 
from lanes 3 to 7 to achieve final drug concentrations of 1 µM, 5 µM, 25 µM, 50 
µM and 100 µM. Lanes 8 to 12 were loaded with the same array of HZ101 
concentrations. For the lane 2, cell culture was added as a control.  
 
 
Figure 48. MCF-7 cells incubated with HZ101 on a 96-well plate 
 
The plate was incubated for 72 hours at 37 ºC and then centrifuged at 1000rpm 
for 5 min. The cells were washed with NaCl before MTT treatment. The MTT 
solution was pipetted into each well, including the control (Figure 49). The plate 
was returned to the incubator for 4 hours and then centrifuged for 5 min. The 
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 medium was removed by pipetting and DMSO was added to each well. The plate 
was shaken gently and placed in the incubator for 30min. The plate was read at 
550 nm in a plate reader.  
 
 
Figure 49. MCF-7 cells incubated with HZ101 on a 96-well plate after MTT 
treatment 
 
Baclofen and GABA were incubated with the MCF-7 breast cancer cell line. The 
MTT results in Graph 10 show that after 72 hours of incubation, the cell viability 
in both the baclofen and GABA groups did not differ significantly between 
concentrations of 1 μM to 100 μM. Even at the highest concentration of 100 μM, 
more than 90% of the cells remained alive, which indicates that baclofen and 
GABA had no cytotoxic effect on MCF-7 cells. However, to obtain statistically 
significant data, the chemosensitivity of the MTT assays had to be determined 
twice (n = 3 for the MTT assay). 
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Graph 10. MTT cell proliferation assay of Baclofen and GABA (measured at 
550nm, n=3) 
 
 
Graph 11. MTT cell proliferation assay of HZ101 (measured at 550nm, n=3) 
 
The cytotoxicity of the legumain activated probe HZ101 against MCF-7 breast 
cancer cells was evaluated by MTT assay. As shown in Graph 11 after 72 hours 
of incubation with HZ101 (at the concentration of 1 µM), more than 95% of cells 
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 remained alive. The percentage of living cells decreased slightly to 85% when 
the concentration of HZ101 was 5 µM. At concentrations of 25 µM and 50 µM, 
only 25% and 18% of living cells were detected, respectively. At the highest 
concentration 100 µM of HZ101, the percentage of living cells dropped to 6%. 
According to this MTT results, HZ101 has low cytotoxicity, which makes it a good 
biomarker probe for breast cancer diagnosis and treatment. 
 
3.3.11.1 Cytotoxicity Assays of HZ105 and HZ93 
More studies are required into the stability of the GABA conjugates. The GABA 
anthraquinone conjugates were designed as templates for delivering the ligand 
GABA upon protease-mediated cleavage of GABA from the template. However, 
it is possible that the intact GABA conjugates may exert a cytotoxic effect, given 
that many anthraquinone-amino acid conjugates are known to be cytotoxic 
(members of the NU:UB series). To date it is not possible to identify the 
structures responsible for conferring toxicity. HPLC analysis of the stability of the 
AQ-GABA conjugates is necessary to determine whether or not the GABA is 
removed upon exposure to cancer cells and if so, on what timescale. The GABA 
conjugates here were only moderately potent (above single figure micromolar 
concentrations) but perhaps exposure times of greater than the 48 hours 
employed are necessary to observe fuller cytotoxic effects. In other words, it 
may be necessary to allow time for the GABA to be released.  
The trend in cytotoxic potency observed in this study, however, correlates well 
with many reported studies of anthracenediones. Cheng and Zee-Cheng (1983) 
reported that the more OH side chains present in the anthraquinone ring the 
greater the cytotoxicity. Moreover, studies showed that removal of both OH 
groups in MTX to afford ametantrone reduced activity more than ten-fold 
(Cavalletti et al., 1996). Hydroxyl groups according to Cheng and Zee-Cheng 
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 (1978) do not necessarily improve intercalation itself but add to the overall DNA 
binding affinity where strong DNA binding is major driver for the intercalating 
agents to have long residence times between the base pairs to exert their 
cytotoxic effects.  
 
Compounds were tested for their cytotoxicity to compare the effects of there 
being two, one or no hydroxyl groups in the anthraquinone structure as show in 
Table 5. The IC50 value is the concentration of drug at which 50% of the cell 
population dies. From the data, the compound (HZ105) with two hydroxyl groups 
in the anthraquinone has the higher IC50 value than compound (AL4) with one 
hydroxyl group and the IC50 value of AL4 is higher than the compound (HZ93) 
with no hydroxyl groups. These results indicate that the presence of hydroxyl 
groups in the anthraquinone increased the drug toxicity. 
Tested Compound Structure Synthesis Code IC50 µM 
 
Mitoxantrone 0.005 
 
HZ93 68 
 
AL4 38 
 
HZ105 27 
Table 5. IC50 values of the tested compounds against MCF 7 cells (n = 3), 48 h. 
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 3.3.12 HPLC Analysis of HZ101 and Its Metabolites 
Further analysis of probe HZ101 activity was carried out by HPLC. Peptide 
cleavage of the probe HZ101 by legumain releases two potential compounds 
HZ105 and Rho-PAN-OH as illustrated in Figure 51. In order to determine a 
proper wavelength for the UV detecting HPLC assay, a UV spectrum of HZ101, 
HZ105 and Rho-PAN-OH was produced (Figure 52). The wavelength of 585 nm 
was selected, where the absorbance of HZ105 and Rho-PAN-OH were at 
identical value. The absorbance of HZ101 is higher than that of its metabolites. 
 
Figure 51. HZ101 and its metabolites after legumain activation 
 
213 
  
Figure 52. The UV spectra of HZ101, HZ105 and Rho-PAN-OH at same 
concentration (50 μM) 
 
During the HPLC analysis, stock solutions of compound were prepared in 100% 
DMSO. The drug solutions needed for HPLC were further diluted in 50% 
acetonitrile in dH2O. HPLC was performed using a Waters 2695 instrument 
(Napier University). The mobile phase A was acetonitrile with 0.01% TFA and 
mobile phase B was H2O. A reverse-phase column (C18 HiChrom HIRPB-250A; 
25 cm × 4.6 mm) was used with gradients developed over a 42 min period as 
shown in (Table 6). Samples were injected onto the column in volumes of 25 µl 
with a flow rate of 1 ml/min and a column temperature of 25ºC. The UV detector 
of the HPLC system recorded the absorbance at the wavelength of 585 nm.  
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Table 6. HPLC gradient mobile phase composition 
 
The retention times of the legumain activated probe HZ101 and its potential 
metabolites (HZ105 and Rho-PAN-OH) determined by HPLC analysis were 
essential for the identification of metabolites produced during the cleavage of 
probe HZ101 in legumain assay buffer. Because all compounds were dissolved 
in 50% acetonitrile in H2O, a solution of 50% acetonitrile in H2O was tested first 
as the blank control.  
The probe Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) was analysed 
by HPLC with different concentrations of 1 μM, 5 μM, 10 μM, 25 μM and 50 μM.  
As shown in Figure 53, the five chromatograms all have the same retention time 
of the peak which is 12.4 min. A calibration curve was created with the peak 
absorbance on the y-axis and the concentration of HZ101 on the x-axis. The R2 
value was 0.9996. These data indicate that the HPLC column was in good 
condition and the operation of the experiment was accurate.  
 
The calibration curve for the probe HZ101 is shown in Figure 54. The curve 
equation (y = 51255 x + 5149.5) provided the source to calculate the precise 
concentration of probe HZ101 when area was the only certain value.  
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Figure 53. HPLC chromatograms of 1 μM, 5 μM, 10 μM, 25 μM and 50 μM 
probe HZ101. RT: 12.4 min 
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Figure 54. HPLC calibration curve for probe HZ101 
 
The HPLC analysis of H-GABA-[Propyl spacer]-AQ (HZ105) is displayed in 
Figure 55. HZ105 is one of the metabolites from the legumain cleavage of probe 
HZ101. Five different concentrations (1 μM, 5 μM, 10 μM, 25 μM and 50 μM) of 
HZ105 were analysed and the retention time of the peak was 6.2 min. The 
calibration curve is shown in Figure 56.  
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Figure 55. HPLC chromatograms of 1 μM, 5 μM, 10 μM, 25 μM, 50 μM HZ105 
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Figure 56. HPLC calibration curve for HZ105 
 
The compound Rho-PAN-OH (Rhodamine B-Pro-Ala-Asn-OH) is the other 
metabolite from the legumain cleavage of probe HZ101 and was characterised 
by HPLC at the concentration of 50 μM. According to its HPLC chromatogram 
(Figure 57), the retention time of the peak was 7.26 min.  
 
 
Figure 57. HPLC chromatograms of Rho-Pan-OH 
 
219 
 A mixture of HZ101 and its metabolites HZ105 and Rho-Pan-OH was analysed 
by HPLC as shown in the chromatogram (Figure 58). At a wavelength of 585 nm, 
the peak absorbance of HZ105 and Rho-Pan-OH were nearly identical. The 
peak absorbance of probe HZ101 was nearly 4 times higher than those of the 
other two peaks. The three peaks were well separated using the designed HPLC 
mobile phase composition and the same conditions were considered in later 
drug-legumain assay.  
 
 
 
Figure 58. HPLC chromatograms of the mixture of HZ101, HZ105 and 
Rho-Pan-OH at concentration of 10 µM and 50 µM 
 
The probe HZ101 was incubated with legumain in the assay buffer for 3 hours. 
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 The mixture of legumain, MES and NaCl in assay buffer might be risky for the 
HPLC column because of its low pH and salt content and attempts were made to 
remove these components before the HPLC analysis. The buffer solution was 
poured into a clean evaporating basin. The evaporating basin was transferred to 
a fume cupboard and the solution was evaporated at room temperature. The 
dried solid in the evaporating basin was suspended in methanol and the mixture 
was transferred to Eppendorf tubes and centrifuged for 10 min at 1000 rpm. The 
supernatant was removed to a new evaporating basin and dried at room 
temperature. The solid was re-dissolved in 50% acetonitrile in H2O to a 
concentration of 30 µM (HZ101 before cleavage) and prepared for HPLC 
analysis. 
 
In Figure 59, the HPLC chromatogram of probe HZ101 after 3 hours of 
incubation with legumain is shown. The concentration of HZ101 during the 
incubation was 10 µM which is the optimal concentration for legumain activation 
according to the fluorimetric assay (see Figure 47). The appearance of the 
peaks for Rho-Pan-OH and HZ105 clearly indicated that probe HZ101 was 
cleaved by legumain and converted into the two anticipated metabolites.  
 
Figure 59. HPLC chromatogram of HZ101 (10µM) after 3 hours of incubation 
with rh-legumain 
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 After 24 hours’ of incubation of probe HZ101 with legumain, the probe was 
mostly cleaved into two compounds HZ105 and Rho-Pan-OH. As shown in 
Figure 60, the peak for probe HZ101 was very small and the absorbance value 
decreased to 0.001, whereas the absorbance values of the other two peaks 
were 0.012 and 0.04. Thus, HPLC analysis of HZ101 indicated that the probe 
was successfully activated by legumain and that the cleavage site was at the 
carboxyl end of asparagine. The HZ101 was converted into the anthraquinone 
quenching group HZ105 and the released fluoro group (Rho-Pan-OH).  
 
 
Figure 60. HPLC chromatogram of HZ101 (10µM) after 24 hours incubation with 
rh-legumain 
 
3.3.13 Lipophilicity Assay 
The partition coefficient of a chemical compound provides a measurement of its 
preference for the lipophilic or hydrophilic phases (Liu et al., 2011). A certain 
balance of lipophilicity and hydrophilicity is required for a drug to successfully 
pass through biological membranes. The most widely used model for lipophilicity 
is the partitioning of a compound between PBS buffer (pH 7.4) and octanol. The 
partition coefficient (LogP) refers to the unionised (neutral) form of the 
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 compound. In the case of ionisable compounds, the term ‘distribution coefficient 
(LogD)’ is often used. The distribution coefficient takes into account the solution 
pH, which is important for the analysis of drug lipophilicity in biological 
environments. LogD is the logarithm of the ratio of the concentrations of the 
ionised form of the compound in water and octanol media. 
 
In the experiment, the compounds were distributed between octanol and PBS in 
the Eppendorf tubes and shaken for 24 hours. The concentrations of the 
compounds in each layer were determined from the calibration curves by UV 
spectroscopic methods and the distribution coefficient was calculated. Figure 61 
to 63 shows the calibration curves for HZ101, HZ105 and Rho-PAN-OH in the 
two phases PBS and octanol. The distribution coefficient was 1.2 for probe 
HZ101 (Table 7) and 0.49 for HZ105 (Table 8). Rho-PAN-OH is hydrophilic and 
has a negative value of LogD which was -0.75 (Table 9). 
 
 
Figure 61. Calibration curves for HZ101 in octanol and PBS 
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Table 7. Distribution coefficient LogD of HZ101 
 
 
Figure 62. Calibration curves for HZ105 in octanol and PBS 
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Table 8. Distribution coefficient LogD of HZ105 
 
 
Figure 63. Calibration curves for Rho-PAN-OH in octanol and PBS 
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Table 9. Distribution coefficient LogD of Rho-PAN-OH 
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 3.4 Conclusion 
Legumain, an asparaginyl endopeptidase, is overexpressed in the majority of 
human tumours and is associated with tissue invasion and metastasis. An acidic 
environment is optimal for legumain proteolytic activity. Legumain has a unique 
enzyme substrate specificity towards the asparagine residue in the P1 position. 
Based on these properties, legumain is an attractive candidate for prodrug or 
probe design in the therapeutic or diagnostic applications. 
 
A legumain-activated probe, HZ101, was designed, synthesised and evaluated. 
The chemical structure of HZ101 (Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ) 
consists of a fluoro group (rhodamine B), a legumain-specific peptide substrate 
and a quenching aminodihydroxyanthraquinone spacer compound. The 
synthesis of HZ101 began with the reaction of 
leuco-1,4,5-trihydroxyhydroxyanthaquinone and diaminopropane to produce 
H-[Propyl spacer]-AQ (HZ103). The amino acid GABA was added to HZ103 as 
the anthraquinone-quenching group to form H-GABA-[Propyl spacer]-AQ TFA 
salt (HZ105). As the potential active agent and/or template for the release of 
GABA, the tripeptide Pro-Ala-Asn was attached to HZ105 by solution phase 
peptide synthesis. The product, H-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ 
(HZ99), was then reacted with rhodamine B. The N-protecting group 
triphenylmethyl (trityl) on the asparagine of HZ100 was removed by TFA 
treatment to yield the final compound probe HZ101, which was characterised by 
mass spectrometry. 
 
The biochemical properties of HZ101 were evaluated. The fluorimetric assay 
showed that incubation of HZ101 with legumain resulted in increased 
fluorescence intensity with time. The best result was obtained at a HZ101 
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 concentration of 10 μM. This concentration was later considered in the HPLC 
analysis. The MTT assay revealed that probe HZ101 had relatively poor 
cytotoxicity against breast cancer cell lines, supporting its potential as a good 
candidate prodrug and biomarker probe. HPLC analysis of HZ101 and its two 
metabolites (HZ105 and Rho-Pan-OH) confirmed the retention times of the three 
compounds. Furthermore, HZ101 was incubated with legumain for 3 hours and 
24 hours. The results demonstrated that HZ101 was successfully cleaved by 
legumain at the proposed site. The lipophilicity tests confirmed that the probe 
HZ101 has a good balance of lipophilic and hydrophilic properties, which is 
crucial to allow the probe to cross biological barriers and eventually target 
tumours. 
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 3.5 Structure Library 
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Fmoc-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ96)  
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H-GABA-[Propyl spacer]-AQ TFA salt (HZ105) 
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 3.6 Experimental 
3.6.1 Synthesis of Fmoc-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ94) 
H-GABA-[Propyl spacer]-AQ TFA salt HZ105 (400 mg, 0.78 mmol) was 
dissolved in DMF, followed by the addition of Fmoc-Asn-OH (513 mg, 0.86 
mmol), TBTU (276 mg, 0.86 mmol), HOBt (132 mg, 0.86 mmol), and DIPEA (449 
µl, 2.58 mmol). The reaction was allowed to proceed at RT for 4 h and was 
monitored by TLC in chloroform: methanol (9:1): Rf 0.5. The reaction solution 
was extracted with chloroform and water. The organic layers were combined and 
poured into an evaporating basin and left to dry in a fume cupboard overnight. 
The solid crude product was collected. Yield: 730 mg, 96%. 
 
3.6.2 Synthesis of H-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ95) 
Fmoc-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ94 (730 mg, 0.74 mmol) was 
suspended in 20% piperidine in DMF for 3 h. TLC was performed in chloroform: 
methanol (9:1): Rf 0.1. The solution was extracted with chloroform and water. 
The organic layers were combined and dried by rotary evaporator. The crude 
HZ95 was purified by silica gel chromatography (4.3 cm × 9.5 cm) and eluted 
with dichloromethane-methanol (6:1). The appropriate fractions were collected, 
filtered and evaporated to dryness. Yield: 503 mg, 90% 
ESMS (+): 754 m/z 100% (M-2H+H)+ 
 
3.6.3 Synthesis of Fmoc-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ96) 
H-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ95 (500mg, 0.66mmol), Fmoc-Ala-OH 
(227 mg, 0.73 mmol), TBTU (230 mg, 0.72 mmol), HOBt (109 mg, 0.72 mmol) 
and DIPEA (373 µl, 2.16 mmol) were dissolved in DMF and the reaction mixture 
was allowed to proceed at RT overnight. TLC was performed in 
chloroform-methanol (9:1): Rf 0.4. The solution was extracted with 
233 
 dichloromethane and water. The crude products in organic layers were collected. 
Yield: 595 mg, 86%. 
 
3.6.4 Synthesis of H-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ97) 
The crude Fmoc-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ96 (595 mg, 0.57 
mmol) was suspended in 20% piperidine in DMF for 2 h. The reaction solution 
was extracted with dichloromethane and water. The organic layers were 
combined, dried and evaporated to a small volume (～ 3 ml) for further 
purification by column chromatography (4.3 cm×151 cm). The solid product was 
collected. Yield: 356 mg, 76%. 
 
3.6.5 Synthesis of Fmoc-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ 
(HZ98) 
A quantity of 356mg, 0.43mmol of H-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ 
HZ97, Fmoc-Pro-OH (160 mg, 0.47 mmol), TBTU (153 mg, 0.48 mmol), HOBt 
(73 mg, 0.48 mmol) and DIPEA (248 µl, 1.44 mmol) were dissolved in DMF. The 
reaction was complete in 3 h confirmed by TLC in chloroform-methanol (6:1): Rf 
0.8. After extraction with chloroform and water, the organic layers were 
combined, and dried by rotary evaporation. The crude product was retained in 
the round-bottom flask for the next Fmoc de-protection reaction. 
 
3.6.6 Synthesis of H-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ99) 
H-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ98 was dissolved in 20% piperidine 
in DMF for 2.5 h. TLC was performed in chloroform-methanol (6:1): Rf 0.2. The 
solution was extracted with dichloromethane and water and the organic layers 
were combined and dried by rotary evaporation. The crude HZ99 was purified by 
silica gel chromatography (4.3 cm × 13.5 cm) and eluted with 
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 chloroform-methanol (10:1). The appropriate fractions were collected, filtered 
and evaporated to dryness. Yield: 336mg.  
ESMS (+): 922 m/z 100% (M-2H+H)+ 
 
3.6.7 Synthesis of Rho-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ (HZ100) 
Rhodamine B (150 mg, 0.31 mmol), PyBop (253 mg, 0.49 mmol) and DIPEA 
(120 µl, 0.7 mmol) were dissolved in DMF. A stir bar was placed in the 
round-bottom flask to aid dissolving. After 15 min of stirring, 
H-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ99 (320 mg, 0.35 mmol) was 
added to the reaction. The reaction was complete in 1 h as confirmed by TLC in 
chloroform-methanol (6:1): Rf 0.45. The solution was poured into an evaporating 
basin to dry overnight. HZ100 was further purified by silica gel chromatography 
(4.3 cm×13 cm) using chloroform-methanol (8:1) as the solvent system. The 
fractions containing pure HZ100 were combined, filtered and evaporated to 
dryness. Yield: 380 mg, 79%. 
 
3.6.8 Synthesis of Rho-Pro-Ala-Asn-GABA-[Propyl spacer]-AQ (HZ101) 
Rho-Pro-Ala-Asn(Trt)-GABA-[Propyl spacer]-AQ HZ100 (380 mg, 0.28 mmol) 
was treated with TFA at RT for 1 h. The reaction was monitored by TLC in 
chloroform-methanol (6:1): Rf 0.1. The solution was evaporated to dryness and a 
few drops of ethanol were added to the flask. Diethyl ether was then poured into 
the flask to dissolve the precipitated solid compound HZ101. The mixture was 
stored in the flask in a refrigerator overnight. The mixture was filtered and the 
product was dried in the desiccator and collected. Yield: 275 mg, 81% 
ESMS (+): 1104 m/z 100% (M-CO2CF3)+ 
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 3.6.9 Synthesis of H-[Propyl spacer]-AQ (HZ103) 
Leuco-hydroxyl anthraquinones (1 g, 3.7 mmol) and diaminopropane (1 ml) were 
suspended in dichloromethane (50 ml). The reaction solution was refluxed in a 
60ºC water bath. After 1 h, trimethylamine (0.5 ml) was added to the reaction. 
The round-bottom flask with the reaction mixture was removed from the water 
bath. After oxidation by pumping air into the flask, the colour of the compound 
became dark blue. The paste solid was filtered, extracted 
(dichloromethane-water), and dried. The crude product was collected. Yield: 200 
mg, 17%. 
 
3.6.10 Synthesis of Boc-GABA-[Propyl spacer]-AQ (HZ104) 
H-[Propyl spacer]-AQ HZ103 (200 mg, 0.64 mmol), Boc-GABA-OH (143 mg, 0.7 
mmol), PyBop (399 mg, 0.77 mmol) and DIPEA (256 µl, 1.5 mmol) were 
dissolved in DMF. The reaction was complete in 2 h as confirmed by TLC in 
chloroform-methanol (6:1): Rf 0.7. After extraction with chloroform and water, the 
crude HZ104 was purified by column chromatography with an elution system of 
dichloromethane and water (6:1). The appropriated fractions were combined, 
filtered and dried. The solid was collected. Yield: 150 mg, 47% 
 
3.6.11 Synthesis of H-GABA-[Propyl spacer]-AQ TFA salt (HZ105) 
HZ104 (150 mg, 0.3 mmol) was treated with TFA for 1 h. TLC was performed in 
chloroform-methanol (3:1): Rf 0.9. The solution was evaporated to dryness and 
further purification was performed by thick layer chromatography. The solvent 
system dichloromethane-methanol (9:1) was used. The product layer was 
scratched off the plate and the solid HZ105 was collected by filtration and 
evaporation. Yield: 70 mg, 45%. 
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 1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.7-1.85 (4H, m, AQ-NH-CH2-CH2 
and NH3-CH2-CH2); 2.15-2.3 (2H, t, NH3-CH2-CH2-CH2); 2.72-2.9 (2H, t, 
NH3-CH2); 3.12-3.25 [7H, m, unresolved, AQ-NH-CH2-CH2-CH2 and NH3 
(exchanged)]; 7.18-7.3 (2H, m, H-2 and H-3); 7.3-7.4 (1H, d, H-7); 7.58-7.7 (2H, 
m, H-6 and H-5); 8.1(1H, t, NHCO); 9.8 (1H, t, AQ-NH) 
ESMS (+): 398 m/z 100% (M-CO2CF3)+ 
 
3.6.12 Synthesis of Boc-GABA-Propyl-AQ (HZ92) 
The staring material H-Propyl-AQ NU:UB 197 (500 mg, 1.79 mmol) and 
Boc-GABA-OH (399 mg, 1.97 mmol) were dissolved in DMF (25 ml), followed by 
the addition of the coupling reagents TBTU (630 mg, 1.97 mmol), HOBt (300 mg, 
1.97 mmol) and DIPEA (1024 μl, 6.5 mmol). The reaction was complete in 4 h as 
determined by TLC (Rf 0.45). The reaction solution was extracted with 
dichloromethane and water. The organic layers were combined and poured into 
an evaporating basin to dry overnight. The crude product was purified by column 
chromatography (3.2 cm × 15 cm) using the solvent system 
dichloromethane-methanol (14:1). The appropriate fractions were combined, 
filtered and collected for the next de-protection reaction. 
 
3.6.13 Synthesis of H-GABA-Propyl-AQ TFA salt (HZ93) 
Boc-GABA-Propyl-AQ (HZ92) was dissolved in TFA for 40 min. After confirming 
the reaction b TLC, the solution was evaporated to a small volume 
(approximately 2 ml). Then diethyl ether (50 ml) was added to the flask to 
precipitate the product HZ93. The solid was collected by filtration. Yield: 450 mg, 
52%. 
 
1H NMR spectrum (DMSO-d6, 300 MHz) δ: 1.7-1.9 (4H, m, AQ-NH-CH2-CH2 and 
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 NH3-CH2-CH2); 2.18-2.38 (2H, m, NH3-CH2-CH2-CH2); 2.75-2.9 (2H, m, 
NH3-CH2); 3.15-3.28 (2H, q, AQ-NH-CH2-CH2-CH2); 3.28-3.5 (2H, q, 
AQ-NH-CH2); 7.26 (1H, d, H-2); 7.45 (1H, d, H-4); 7.6-7.7 (1H, t, H-3); 7.8-7.95 
(2H, m, H-6 and H-7); 8.05-8.16 (2H, m, H-5 and H-8); 8.16-8.27 (1H, t, CONH); 
9.7 (1H, t, AQ-NH) 
 
3.6.14 HZ101 Fluorimetric Assay 
Materials 
 Activation buffer: 50 mM sodium acetate, 100 mM NaCl, pH 4.0 
 Assay buffer: 50 mM MES hydrate, 250 mM NaCl, pH 5.0 
 Recombinant human legumain (R&D systems): The stock (10 µl) was 
diluted in activation buffer (100 µl) and stored at -80 ºC. The stock was 
incubated for 2 h at 37 ºC before assaying. The aliquots were then 
diluted to 1ng/µl in assay buffer. 
 Drug stock solutions:1mg/ml in DMSO 
 FluoStar Omega multi-mode microplate reader 
 
Method 
A 96-well plate was used for the assay. Wells A1～C1 contained assay buffer 
(100 µl), A2～C2 contained assay buffer (98.78 µl) and HZ101 (1.22 µl, 10 µM), 
and A3～C3 contained assay buffer (58.78 µl), HZ101 (1.22 µl, 10 µM) and 
rh-legumain (40 µl, 1 ng/µl).  
 
The plate was read in a FluoStar Omega multi-mode microplate reader and 
spectra were recorded every 5 min for 2 h. 
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 3.6.15 Cytotoxicity assays 
Method for MCF-7 cell culture 
MCF-7 mammary carcinoma cells were grown in 75 cm2 flask containing 30 ml 
of RPMI 1640 medium supplemented with 10% FBS, 1% penicillin/streptomycin 
and 1% L-glutamine at 37ºC in the incubator (5% CO2). The MCF-7 cells were 
adherent to the flask. Fresh medium was supplied every two to three days and 
the cells were passaged weekly. 
The cells were harvested when needed. The medium was poured out and the 
cells were washed with sodium chloride 3 times. After washing, 10% trypsin in 
NaCl was added to the flask and incubated for 8min at 37 ºC to suspend the 
cells. The mixture was poured into a 50 ml tube and centrifuged for 2 min at 
2000 rpm. The pelleted cells were then collected for MTT assays or passaged 
and resuspended in fresh medium. 
 
3.6.16 MTT Assay 
Materials for MTT assay 
The stock solution (1mM) of HZ101 in DMSO was sterilised by filtration. Further 
dilutions were prepared to obtain concentrations of 100, 50, 25, 5, and 1 µM in 
phenol red free RPMI medium. The cells were seeded, counted and diluted to 
achieve a cell suspension of 1.4×104 cells/ml.  
 
Methods for MTT assay 
The wells in lane 1 of a 96-well plate contained 200 µl of medium only as a blank 
control. In lanes 2 to 12, 150µl of cell suspension (1.4×104 cells/ml) was pipetted 
into each well. The plate was incubated at 37 ºC, 5% CO2 overnight before 
treatment with HZ101 compounds. The final drug concentrations in lanes 3 to 7 
were 1, 5, 25, 50, 100µM. If needed, 50 µl of the correct drug dilution was added 
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 to individual wells to achieve the above concentrations. Lanes 8 to 12 were 
loaded in the same manner as HZ101. In lane 2, 50 µl of cell culture was added 
as a control. 
 
After incubation for 72 hours at 37 ºC, the plate was centrifuged at 1000 rpm for 
5 min. The cells were washed with NaCl before MTT treatment. Then, 2 ml of 
MTT (5 mg/ml in 0.01 M PBS) was added to 5ml of RPMI medium. The solution 
(50 µl) was pipetted into each well, including the control. The plate was returned 
to the incubator for 4 hours and then centrifuged at 1000rpm for 5 min. The 
medium was removed by pipetting and DMSO (150 µl) was added to each well. 
The plate was shaken gently and placed in the incubator for 30min. The plate 
was read at 550 nm in a plate reader.  
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 Chapter 4 New colour reagents for Amino group 
detection and use in SPPS 
4.1 Abstract 
During the solid phase peptide synthesis (SPPS), it is essential to monitor the 
completion of the Fmoc cleavage and the coupling reaction. Some drawbacks 
with classical methods for amino group detection, notably unsatisfactory results 
with secondary amino acids and complex procedures have provided the 
motivation to develop a new colour test here as a simple, sensitive and efficient 
method for visual detection of the resin beads. Three compounds (HZ20, HZ22 
and HZ24) with different colours were synthesised and evaluated. The new 
compounds were each based on highly coloured aminoanthraquinones. The 
data presented here shows that these reagents are capable of detecting free 
amino groups on resin beads used for SPPS. In addition to reaction monitoring, 
for one of these reagents, it was shown that on-bead labelling can be performed, 
leading to recovery of a labelled peptide after cleavage, suitable for 
characterisation. HPLC methods were developed for separation of labelled 
structurally related compounds. 
 
4.2 Introduction 
Solid phase peptide synthesis (SPPS), pioneered by Merrifield, is largely used in 
construction of chemical libraries, particularly in medicinal chemistry (Merrifield, 
1963). SPPS has many advantages over traditional synthesis such as all 
reagents can be simply washed away each step, overall quicker time for 
synthesis, convenient work-up and the synthetic intermediates do not have to be 
isolated (ref). Fmoc-SPPS is the universally applied method of choice for SPPS, 
mainly due to the low cost of commercially available Fmoc amino acids and 
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 continuing improvements in Fmoc solid-phase technology (Behrendt, White, & 
Offer 2016). Fmoc-protected amino acids are increasingly used in automated 
technologies to synthesise medicinally useful peptides including chemically 
engineered peptides (Mäde, Els-Heindl S, & Beck-Sickinger AG, 2014). However, 
the efficiency of SPPS is often limited by the low level of completeness of amino 
acid coupling steps. Efficiency of coupling is especially important in the 
application of combinatorial methods to the synthesis of peptide based drug 
susbtances on solid-phase (Gordon et al., 1994). In this case, the development 
of a more reliable and sensitive visual colourimetric assay to detect free amines 
on solid support is essential.  
To date, several colourimetric assays are available for detection of the amino 
acid coupling in SPPS. The ninhydrin-based Kaiser test (Kaiser et al., 1970) and 
a later modification (Sarin et al., 1981), and use of TNBS (2,4,6 
trinitrobenzenesulphonic acid; (Hancock and Battersby, 1976) are two of the 
most common colourimetric tests. The ninhydrin based tests are not very 
sensitive to sensitive to aromatic amines, nor are they able to detect secondary 
amines such as proline. TNBS is not effective for sterically hindered amines. An 
alternative is 4-N,N’-dimethylaminoazobenzene-4’-isothiocyanate (DABITC) 
which is able to detect primary and secondary amines and has been used for 
detection HPLC detection of side-chain-labelled lysines in peptides (Nair et al., 
1994) and N-terminal sequencing of peptides (Chang, 1981). However, the 
visual colour of the treated resin is yellow to orange which cannot be desirable 
because the resin will become a similar colour during successive rounds of the 
SPPS process. The MGI (malachite green isothiocyanate) method is wasteful 
and time-consuming and needs 1 hour reaction time and 4 mg of resin. The 
so-called DMT (dimethoxytrityl) and NPIT (nitrophenylisothiocyanate-O-trityl) 
tests rely on UV-measurements. More recently, the use of a p-nitrophenylester of 
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 Disperse Red 1 (known as NF31) has been reported as a more sensitive method 
but requires a reacting condition of 70°C (Madder et al., 1999; Steven et al., 
2007). The latter, because it contains a diazo-group, cannot be used under 
reducing conditions. The shortcomings of all the above methods encouraged this 
work to develop a new colourimetric assay for SPPS. 
This chapter reports three new reagents with different colours (blue, red, and 
purple) for monitoring coupling step of SPPS were synthesized and evaluated. 
They are all rapid (within 2 min), sensitive and reactive at room temperature. 
Furthermore, these methods are applicable to both sterically hindered primary 
and secondary amines. These new colour reagents have very low toxicity and 
are safe to handle during SPPS; dry, they are stable stored in the solid state at 
4°C for more than 12 months.  
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 4.3 Results and discussion 
Three colour test reagents HZ20, HZ22 and HZ24 (blue, red and purple 
respectively) were developed for SPPS and their syntheses, properties and 
some applications are described in the following sections. The chromophores 
were aminoanthraquinones with varying numbers of additional hydroxy groups 
that enhance the colur of the compound (the visible absorption maxima being 
shifted to longer wavelength). The design of the new chemical tools for amine 
detection and peptide coupling reaction monitoring on-resin was based upon 
creating new O-pentafluorophenyl active esters of anthraquinone-spacer 
carboxylic acids (AQ-spacer-COOPfp). Reaction of on-resin amino groups with 
these reagents was expected to colour the beads unless all amino groups had 
been fully acylated during couplings. Removal of a sample of beads after a 
coupling step allowed treatment with the given 
anthraquinone-pentafluorophenolate and a positive colour on visual inspection 
indicated that the reaction had not gone to completion due to capping of residual 
amino groups in the beads.  
 
4.3.1 Synthesis of AQ-Gly-methyl (HZ18) 
Reaction of leucoquinizarin with amines is a well-known reaction to produce 
either 1-substituted or 1,4-disubstituted anthraquinones (Greenhalgh and 
Hughes, 1968), Zee-Cheng and Cheng,1978; Zee-Cheng et al., 1979; Murdock 
et al., 1979).  
Leucoquinizarin and glycine-methylester hydrochloride were mixed and 
dissolved in DMF, followed by the addition of K2CO3 as the base (Scheme 39). 
The reaction mixture was heated on a steam bath for 1 hour and then aerated for 
another 1 hour. The reaction solution was extracted with chloroform and water. 
The extraction process was very difficult as both aqueous and organic layers 
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 were darkly coloured. The organic layers were combined and dried with 
anhydrous sodium sulphate. After filtration and evaporation, the solid compound 
HZ18 was collected and purified by column chromatography using the solvent 
system chloroform to ethyl acetate 9:1. The appropriate fractions containing the 
major product were combined and collected. 
 
Reagents and Conditions: (a) K2CO3 in DMF 
Scheme 39. Outline of HZ18 synthesis 
 
The synthesis required conditions that allow the formation of the 
mono-amination product in order to prevent reaction at the 1-, and 4-positions of 
the leucoqunizarin ring. The TLC of the reaction mixture showed traces of the 
blue bis-aminated byproduct but the target compound was the major product 
unless reaction times were extended. The structure of HZ18 was confirmed by 
its 1H nmr spectrum (in CDCl3) which showed, for example, the expected pattern 
of signals for the AA’BB’ system at δ 8.41-8.39 (1H, d, H-8); 8.36-8.33 (1H, d, 
H-5) and 7.85-7.81 (1H, m, H-7); 7.80-7.75 (1H, m, H-6). The methyl ester 
protons were assigned to a three-proton singlet at 3.86 ppm and the 
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 anthraquinone NH proton was a clear one-proton triplet at 10.49 ppm. The 
4-hydroxy group proton was shifted to higher ppm as a result of chelation to the 
C-10 carbonyl group of the quinone. Remaining protons were all assigned. The 
product ester HZ18 formed the source of the required carboxylic acid (HZ19) by 
hydrolysis of the methyl ester. 
 
4.3.2 Synthesis of AQ-Gly-OH (HZ19) 
In order to introduce the required acid group into the new anthraquinone-glycine 
conjugate colour test reagent, the methyl ester had to be hydrolysed. 
AQ-Gly-methyl (HZ18) and lithium hydroxide (LiOH•H2O) were dissolved in 
aqueous methanol (Scheme 40). The mixture was stirred for 1.5 hours and then 
extracted by chloroform and water. All the organic layers were combined and 
evaporated to dryness. The dry crude product HZ19, clean on TLC was 
considered ready for the next reaction (conversion to the OPfp active ester) 
without further purification.   
 
Reagents and Conditions: (a) aqueous methanol  
Scheme 40. Outline of HZ19 synthesis 
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 4.3.3 Synthesis of AQ-Gly-OPFP (HZ20) 
The SPPS colour test reagent HZ20 was synthesised by mixing the glycine 
conjugate HZ19, DCC and pentafluorophenol (PFP) together in ethyl acetate 
(Scheme 41). The reaction was completed in 2 hours by checking the TLC. 
Silica gel chromatography was performed for the purification of HZ20 running 
with a solvent mixture of chloroform to ethyl acetate 7:1. The chromtographically 
homogeneous final product was collected by evaporation and drying under 
vacuum. 
 
Reagents and Conditions: (a) DCC, DMAP in ethyl acetate  
Scheme 41. Outline of HZ20 synthesis 
 
The structure of pentafluorophenolate HZ20 was confirmed by its 1H NMR 
spectrum (in CDCl3) that included two one-proton singlets at 13.46 and 10.52 
ppm for the 4-OH and NH protons, respectively. In addition to the assignment of 
all aromatic protons, the methylene group protons of the glycine residue were 
assigned to a distinct two-proton singlet at 4.61 ppm. In the proton decoupled 
and 13C decoupled, 19F nmr spectrum of HZ20 the three environments for the 
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 fluorine signals of the ortho, meta and para fluorine atoms were recorded at  
-152.4; -156.8 and -161.5, respectively. 
 
4.3.3.1 Colour test with HZ20 
H-Leu-2-ClTrt resin was first used for the colour test. A small amount of the 
commercially available resin (Novabiochem) was transferred into an SPPS 
reaction vessel. Dichloromethane was poured into the vessel to swell the resin 
beads for 1 hour. Dichloromethane was drained off by use of a vacuum pump 
and the resin was washed with DMF. A few beads were transferred into a small 
sample bottle. HZ20 in DMF (1 mmol, 200 μl) and about a drop of DIPEA were 
added to the bottle. After 2 minutes, the purple solution was pipetted out and the 
beads were washed with DMF. The beads became purple in colour and under 
the microscope the beads were captured in the image shown in Figure 64.  
 
 
Figure 64. Resin beads coloured by HZ20 
 
The resin beads clearly had become strongly coloured through reaction between 
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 the pentafluorophenolate active ester of HZ20 and the free amino groups on the 
surface of the native beads. The coloured reagent was clearly chemically 
attached to the beads since it the colour persisted when repeatedly washed with 
solvent.  
 
4.3.4 Synthesis of AQ-Ahx-OH (HZ21) 
For the synthesis of the second pentafluorophenolate colour test reagent HZ22, 
the starting material 1-chloroanthraquinone was reacted with 6-aminohexanoic 
acid in DMSO on the 100⁰C water bath (Scheme 42). The reaction was 
confirmed by TLC, showing the formation of a new major product spot of 
anthraquinone-acid HZ21, and the solution was cooled to room temperature. 
The purification of HZ21 used the silica gel chromatography with the solvent 
system of dichloromethane and methanol (9:1). The product fractions containing 
the new product were combined, dried and collected for further reaction and 
characterisation.  
 
Reagents and Conditions: (a) DMSO, 100⁰C water bath  
Scheme 42. Outline of HZ21 synthesis 
254 
 The structure of the anthraquinone aminohexanoic acid conjugate HZ21 was 
confirmed by its 1H NMR spectrum (in CDCl3), which showed, for example, a 
one-proton triplet (AqNH) at 9.77 ppm and a two proton multiplet at 3.40-3.36 
ppm for the adjacent methylene group protons. The Anthraquinone H-2 proton 
was a doublet at 7.09 ppm. The methylene group protons adjacent to the ester 
carbonyl group were assigned to a two-proton triplet at 2.46-2.43 ppm. All other 
protons could be assigned with the exception of the carboxylic acid proton which 
was deemed to have undergone proton exchange broadening. However, the 
presence of the carboxylic acid group was confirmed by identification of a third 
carbonyl quaternary carbon atom in the proton decoupled 13C NMR spectrum at 
178.4 ppm, in addition to the C-9 and C-10 quinone carbonyl carbons at 185.05 
and 183.85 ppm respectively. The anthraquinone acid HZ21 was then ready for 
esterification with pentafluorophenol to afford the target reagent HZ22. 
 
4.3.5 Synthesis of AQ-Ahx-OPFP (HZ22) 
The second SPPS colour test compound HZ22 was synthesised by the reaction 
of HZ21 and pentafluorophenol in dichloromethane, by using DCC and DMAP as 
the coupling reagents (Scheme 43). The final product was purified by column 
chromatography using the solvent system dichloromethane to ethyl acetate 9:1. 
The purified solid compound was collected by precipitation in hexane. 
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Reagents and Conditions: (a) DCC & DMAP in Dichloromethane  
Scheme 43. Outline of HZ22 synthesis 
 
The structure of the pentafluorophenolate HZ22 was confirmed by its 
nanoelectrospray ESI (+) spectrum that showed a strong signal at m/z 504 
corresponding to (M + H)+; M 503 Da.  
The structure was also confirmed by its 1H NMR spectrum, which showed 
signals for example at 9.79 ppm (one-proton triplet AqNH) and a two proton 
multiplet at 3.42-3.37 ppm for the adjacent methylene group protons. The 
anthraquinone H-2 proton was a doublet at 7.08 ppm. Adjacent to the ester 
carbonyl group, the methylene group protons were assigned to a two-proton 
triplet at 2.77-2.73. The remaining methylene group signals for the hexyl spacer 
in HZ22 were all assigned together with the AA’BB’ system for H5, H8 and H6, 
H7 and remaining aromatic protons. Furthermore, in the proton decoupled and 
13C decoupled, 19F NMR spectrum of HZ22 the three environments for the 
fluorine signals of the ortho, meta and para fluorine atoms were recorded at 
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 -152.8; -158.1 and -162.2, respectively. 
 
4.3.5.1 Colour test with HZ22 
A small amount of Fmoc-Ala-Wang resin was allowed to swell in 
dichloromethane. The resin beads were washed by DMF. A few beads were 
transferred to a small sample bottle which contained the solution of HZ22 
dissolved in DMF (1 mmol, 200 μl). One drop of DIPEA was added to the 
reaction. After 2 minutes, the red solution was pipetted out and the beads in the 
bottle were washed with DMF. The beads had no red colour by visual 
observation, indicative of there being no residual free amine groups on the Fmoc 
resin and confirming that there was no red colouration as a result of any possible 
staining or physical absorption of the reagent into the resin matrix. 
The Fmoc-Ala-Wang resin was N-terminal deprotected by using standard 
conditions of 20% piperidine in DMF. The resin beads were then washed by DMF 
3 times. The colour test by HZ22 showed that all beads turned red as shown in 
Figure 65. The beads were also observed under the microscope as shown in 
Figure 66. 
 
Figure 65. Resin beads coloured by HZ22 in the sample bottle 
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Figure 66. Resin beads coloured by HZ22 
 
4.3.6 Synthesis of AQ-[4-Hydroxyl]-Ahx-OH (HZ23) 
Preparation of a third candidate colour test pentafluorophenolate was carried out 
to create an analogue of HZ22 which had an additional hydroxyl group in the 
4-position of the anthraquinone chromophore. The procedure was analogous to 
that used for the synthesis of the 1-amino-4-hydroxy analogue, HZ20, to afford a 
mono aminated product. 
Leuoquinizarin was reacted with 6-aminohexanoic acid by the addition of K2CO3 
in DMF on the 100⁰C water bath (Scheme 44). The reaction solution was cooled 
to RT and aerated for 1 hour. The crude product AQ-[4-Hydroxyl]-Ahx-OH (HZ23) 
was purified by column chromatography using the solvent system 
dichloromethane to methanol 10:1. The resulting acid then required esterification 
with pentafluorophenol to afford the third candidate test reagent (HZ24). 
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Reagents and Conditions: (a) K2CO3 in DMF 
Scheme 44. Outline of HZ23 synthesis 
 
4.3.7 Synthesis of AQ-[4-Hydroxyl]-Ahx-OPFP (HZ24) 
The synthesis of the third SPPS colour test reagent HZ24 was completed by the 
coupling reaction of AQ-[4-Hydroxyl]-Ahx-OH (HZ23) and pentafluorophenol by 
the addition of DCC and DMAP. The reaction mixture was dissolved in 
dichloromethane (Scheme 45). Purification of the final target compound 
AQ-[4-Hydroxyl]-Ahx-OPFP (HZ24) was performed by silica gel chromatography. 
The column was eluted by a solvent mixture of dichloromethane and ethyl 
acetate. Hexane was then used to precipitate the purified solid product. 
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Reagents and Conditions: (a) DCC & DMAP in Dichloromethane  
Scheme 45. Outline of HZ24 synthesis 
 
The structure of HZ24 was confirmed by its 1H NMR spectrum (CDCl3), which 
showed signals for example, the singlet at 13.76 ppm for the strongly 
de-shielded 4-hydroxy group proton, chelated to the quinone carbonyl, and a 
one proton triplet at 10.37 ppm for the amino group proton. The anthraquinone 
H-2 and H-3 protons were assigned as one-proton multiplets at 7.25 and 7.23 
respectively. Methylene group signals adjacent to the anthraquinone and to the 
ester carbonyl appeared at 3.48-3.43 and 2.77-2.73 ppm respectively. 
Furthermore, in the proton decoupled and 13C decoupled, 19F NMR spectrum of 
HZ24, the three environments for the fluorine signals of the ortho, meta and para 
fluorine atoms were recorded at -152.7; -158.01 and -162.30, respectively. 
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 4.3.7.1 Colour test using HZ24 
Figure 67 shows the photograph of chlorotrityl resin beads with free amino 
groups and coloured by AQ-[4,Hydroxyl]-Ahx-OPFP (HZ24). The beads were all 
a dark purple colour. For comparison, samples of the resin beads coloured 
separately by the three new test reagents HZ20, HZ22 and HZ24 were mixed to 
obtain the photograph shown in Figure 68. 
 
 
Figure 67. Resin beads coloured by HZ24 
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Figure 68. Mixture of resin beads coloured by HZ20, HZ22 & HZ24 
 
4.3.8 HPLC analysis of HZ22 labelled peptides 
It was recognised that the newly synthesised colour reagents can have wider 
applications than just monitoring the coupling reaction of SPPS. It was 
envisaged the reagents could be used to label deprotected peptides on resin 
and then perhaps be cleaved from the resin to afford N-labelled peptides 
suitable for peptide characterisation. There are several methods reported for the 
characterisation of N-labelled peptides and the most common ones rely on 
analysis of their Fmoc derivatives since these are the ones that emerge from 
SPPS methods. Methods have relied on UV properties of the Fmoc group and 
have been combined with mass spectrometric characterisation for both free and 
resin-bound amino acid and peptides. Use of combined HPLC-tandem mass 
spectrometry after derivatisation with Fmoc chloride is a recent example (Ziegler 
and Abel 2014).  In this project, it was reasoned that, for example, the red 
reagent AQ-Ahx-OPFP (HZ22) is able to label peptides which will be further 
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 analysed by HPLC, provided an HPLC method could be developed. 
 
Figure 69 shows the chemical structure of an HZ22 labelled pentapeptide which 
was synthesised to investigate the potential for HZ22 labelling at the N-terminus 
followed by further characterisation by HPLC. The peptide sequence was 
chosen because it was relevant to the work described in Chapter one of this 
thesis. The sequence contained a gly-nva cleavage site for MMP-9. The 
pentapeptide was synthesied by standard SPPS methods. AQ-Ahx-OPFP (HZ22) 
was reacted with the free amine group of the pentapeptide on resin by using only 
the DIPEA catalyst in DMF. The resulting labelled product, 
AQ-Ahx-Pro-Ala-Gly-Nva-Pro-OH (HZ60) was cleaved from the resin by TFA 
treatment. Figure 70 illustrates the overall planned synthesis of HZ60. 
 
Figure 69. The chemical structure of HZ60 
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Figure 70. Synthesis route for N-labelled pentapeptide HZ60 
 
The N-labelled pentapeptide, AQ-Ahx-Pro-Ala-Gly-Nva-Pro-OH (HZ60) was 
successfully characterised by nanoelectrospray negative ionisation mass 
spectrometry (Figure 71). A signal at m/z 757 [M – 1]-, (100%) corresponded to a 
molecular mass of 758 Da.  
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Figure 71. The ESI (-) Mass spectrum of AQ-Ahx-Pro-Ala-Gly-Nva-Pro-OH 
(HZ60) 
 
The anthraquinone-pentapeptide conjugate HZ60 was shown to be accessible to 
characterisation by negative ion electrospray MS, affording a strong signal (100% 
R.A. and base peak), together with good agreement between the theoretical 
isotope pattern and the observed ions for M-1. 
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 4.3.8.1 Further examples of N-labelled members of the series 
Another two compounds AQ-Ahx-Pro-Ala-Gly-OH (HZ106) and AQ-Ahx-Pro-OH 
(HZ107) were synthesised by same SPPS method as 
AQ-Ahx-Pro-Ala-Gly-Nva-Pro-OH (HZ60) starting with the appropriate amino 
acid loaded resin. The chemical structures are shown in Figures 72 and 73. 
These compounds were prepared for an HPLC study to explore the feasibilty of 
deriving a simple, reliable method for separating closely structurally related 
series of labelled peptides.   
 
 
Figure 72. Chemical structure of HZ22 N-labelled prolylalanine HZ106 
 
 
Figure 73. Chemical structure of HZ22 N-labelled proline HZ107 
 
4.3.8.2 HPLC/UV analysis of HZ22 N-labelled amino acids and peptides 
HPLC was performed using a WATERS e2695 Alliance HPLC instrument and 
WATERS 2489 UV/VIS detector (Edinburgh Napier University). Mobile phase A 
consisted of 100% Acetonitrile, 0.1% TFA and mobile phase B of 100% HPLC 
water, 0.08% TFA, pH 2.00 (±0.05). A reverse phase column (Agilent Zorbax 
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 Extend C18, 5 µm, 4.6 mm x 50 mm) was used with gradients developed over a 
15 min period. Mobile phase A was changed from 40% to 42% over 5 minutes 
and isocratic hold at 42% A for 5 column volume time, then re-equilibration at 
initial conditions for 10 column volume time. Samples were injected onto the 
column in volumes of 10 μl with a flow rate of 1 ml/min and a column 
temperature of 40 ⁰C. The absorbance in the UV was recorded at wavelength 
505 nm. 
 
Stock solutions of compound (1 mg/ml) were prepared in 100% DMSO. The 
compound solutions were then diluted further in 50% acetonitrile in dH2O to the 
concentration of 100 μM.  
 
HPLC analysis of anthraquinone-pentapeptide conjugate 
AQ-(CH2)5-Pro-Ala-Gly-Nva-Pro-OH (HZ60) was conducted and the retention 
time was recorded. Figure 74 shows the HPLC chromatogram of the compound.   
 
 
Figure 74. HPLC chromatogram of 100 μM HZ60 (pentapeptide), Retention time: 
3.92 min 
 
The HPLC chromatogram of AQ-(CH2)5-Pro-Ala-Gly-OH (HZ106) was shown in 
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 Figure 75. There is a single peak in the chromatogam which indicated the high 
purity of the compound. The retention time is different from HZ60 above under 
the same column conditions. Figure 76 shows a chromatogam of the HPLC 
analysis of ‘red’-labelled proline: AQ-(CH2)5-Pro-OH (HZ107).  
 
 
Figure 75. HPLC chromatogram of 100 μM HZ106 (tripeptide), Retention time: 
2.62 min 
 
 
Figure 76. HPLC chromatogram of 100 μM HZ107 (proline conjugate), 
Retention time: 5.5 min 
 
A mixture of the three N-labelled compounds: pentapeptide 
AQ-(CH2)5-Pro-Ala-Gly-Nva-Pro-OH (HZ60), tripeptide 
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 AQ-(CH2)5-Pro-Ala-Gly-OH (HZ106) and single amino acid AQ-(CH2)5-Pro-OH 
(HZ107) was further analysed by HPLC as shown in Figure 77.  
 
 
Figure 77. HPLC chromatogram of the mixture of 100μM HZ60, 100μM HZ106 
and 100μM HZ107 
 
The data presented in Figure 77 shows that the HZ22 labelled proline amino 
acid conjugate (HZ107), the tripeptide (HZ106) and pentapeptide conjugates 
(HZ60) were separated with satisfactory base line resolution. 
This indicates that it is likely to be feasible to separate and identify components 
in a reaction mixture if, for example, a larger peptide such as the pentapeptide 
HZ60 is subjected to cleavage by action of a protease such as MMP-9.  
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 4.4 Conclusion 
The newly synthesised compounds HZ20, HZ22 and HZ24 were considered as 
useful colour test reagents to monitor coupling reactions involving free amines 
during SPPS. The red labelling agent HZ22 was used to demonstrate its 
versatility for labelling amines on resin and for isolation of N-labelled peptides to 
create derivatives that are helpful for characterising the peptide. A simple, 
time-efficient HPLC method using uv/visible detection was developed for 
separation of examples of closely related amino acids and peptides. The pattern 
of behaviour shown by HZ22 would be expected to occur in a similar manner for 
the other two reagents HZ20 and HZ24. In future work, it would be instructive to 
try to use e.g. HZ22 in reactions to label amino groups in natural peptides for 
biological process investigations. Furthermore, it is of interest to extend the 
characterisation to a combined HPLC-MS method, given the ease of ionisation 
of the carboxylic acid group of the pentapeptide HZ60 in negative ion 
electrospray ionisation mass spectrometry.  
  
270 
 4.5 Structure library 
 
(4-Hydroxy-9,10-dioxo-9,10-dihydro-anthracen-1-ylamin
o)-acetic acid methyl ester  
AQ-Gly-methyl (HZ18) 
 
 
(4-Hydroxy-9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-acetic acid  
AQ-Gly-OH (HZ19) 
 
(4-Hydroxy-9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-acetic acid 
pentafluorophenyl ester  
AQ-Gly-OPFP (HZ20) 
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6-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic 
acid  
AQ-Ahx-OH (HZ21) 
 
 
6-(9,10-Dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic acid pentafluorophenyl 
ester  
AQ-Ahx-OPFP (HZ22) 
 
 
6-(4-Hydroxy-9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic acid  
AQ-[4, Hydroxyl]-Ahx-OH (HZ23) 
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6-(4-Hydroxy-9,10-dioxo-9,10-dihydro-anthracen-1-ylamino)-hexanoic acid pentafluorophenyl 
ester  
AQ-[4, Hydroxyl]-Ahx-OPFP (HZ24) 
 
AQ-Ahx-Pro-Ala-Gly-Nva-Pro-OH (HZ60) 
 
AQ-Ahx-Pro-Ala-Gly-OH (HZ106) 
 
AQ-Ahx-Pro-OH (HZ107) 
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 4.6 Experimental 
4.6.1 Synthesis of AQ-Gly-methyl (HZ18) 
HZ18 was prepared from the reaction of Leucoquinizarin (1 g, 4.13 mmol) with 
glycine-methylester-hydrochloride (2.07 g, 16.5 mmol) and potassium carbonate 
(2.05 g, 14.9 mmol) in DMF (30 ml) on the boiling water bath for 1 h. TLC of the 
crude product (Rf 0.54) used the solvent system, toluene-ethyl acetate 4:1. The 
foregoing reaction mixture was aerated for 1 h and then extracted with 
chloroform-water. All the organic extracts were combined, dried with anhydrous 
sodium sulphate, filtered and evaporated to dryness. The compound was 
purified by column chromatography using the eluting system, chloroform-ethyl 
acetate 9:1. The product (purple) was dried under vacuum. Yield: 579 mg, 45%. 
 
1H NMR spectrum (CDCl3, 400 MHz) δ: 3.86 (3H, s, H-14); 4.21 (2H, s, H-12); 
7.08 (1H, d, H-2); 7.31 (1H, d, H-3); 7.80-7.75 (1H, m, H-6); 7.85-7.81 (1H, m, 
H-7); 8.36-8.33 (1H, d, H-5); 8.41-8.39 (1H, d, H-8); 10.49 (1H, s, NH); 13.52 (1H, 
s, OH). 
13C NMR spectrum (CDCl3, 100.6 MHz, 25°C) δ: 11.7 ; 52.6 ; 110.0 ; 114.1 ; 
123.3 ; 126.4 ; 127.0 ; 128.7 ; 132.7 ; 132.8 ; 134.3 ; 135.2 ; 146.1 ; 156.8 ; 
170.0 ; 183.0 ; 187.8 ppm. 
 
4.6.2 Synthesis of AQ-Gly-OH (HZ19) 
AQ-Gly-methyl HZ18 (100 mg, 0.32 mmol) and LiOH·H2O (44 mg, 0.32 mmol) 
were dissolved in 40ml of aqueous methanol (3:1) and reacted at RT for 1.5 h. 
TLC (Rf 0.15) was checked using the solvent system, chloroform-methanol 6:1. 
The reaction solution was extracted with chloroform, acetic acid and water. All 
the organic layers were combined, dried with anhydrous sodium sulphate, 
filtered and evaporated to dryness. The product (purple) was collected with a 
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 yield of 88.8 mg, 93%. The product was considered sufficiently pure for further 
use without further purification. 
 
4.6.3 Synthesis of AQ-Gly-OPFP (HZ20) 
AQ-Gly-OPFP HZ20 was prepared from the reaction of AQ-Gly-OH HZ19 (85 mg, 
0.29 mmol), DCC (65 mg, 0.32 mmol) and PFP (58 mg, 0.32 mmol) in ethyl 
acetate (30 ml) for 3 h. TLC of the crude product (Rf 0.93) used the solvent 
system, dichloromethane-ethyl acetate 5:1. Column chromatography was 
performed for the purification of HZ20 by using the solvent system, 
dichloromethane-ethyl acetate 7:1. The product (purple) solution was filtered and 
evaporated to dryness. Yield: 56 mg, 42%. 
 
1H NMR spectrum (CDCl3, 400 MHz) δ: 4.61 (2H, s, H-12); 7.14 (1H, d, H-2); 
7.38 (1H, d, H-3); 7.80-7.77 (1H, m, H-7); 7.86-7.81 (1H, m, H-7); 8.37-8.35 (1H, 
d, H-5); 8.40-8.38 (1H, d, H-8); 10.52 (1H, s, NH); 13.46 (1H, s, OH). 
13C NMR spectrum (CDCl3, 100.6 MHz, 25°C) δ: 25.0 ; 29.7 ; 34.0 ; 44.2 ; 114.3 ; 
122.6 ; 126.5 ; 127.1 ; 128.8 ; 133.2 ; 134.4 ; 135.0 ; 145.5 ; 157.0 ; 183.7 ; 187.9 
ppm. 
19F NMR spectrum (CDCl3) δ: -152.4; -156.8 and -161.5 
 
4.6.4 Synthesis of AQ-Ahx-OH (HZ21) 
1-Chloroanthaquinone (1 g, 4.12 mmol) and 6-aminohexanoic acid (2.16 g, 16.5 
mmol) were dissolved in 40 ml of DMSO and refluxed for 1 h. TLC of the crude 
product (Rf 0.57) used the solvent system, dichloromethane-methanol 9:1. The 
reaction solution was cooled to RT for extraction with chloroform. The crude 
product was purified by column chromatography using the same solvent system 
as TLC The product solution was evaporated to dryness. Diethyl ether (30 ml) 
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 was slowly added to the product and the mixture was refrigerated for 1 h after 
which gave the chromatographically pure dark red product precipitate. Yield: 352 
mg, 25%. 
 
1H NMR spectrum (CDCl3, 400 MHz) δ: 1.63-1.55 (2H, m, H-14); 1.79-1.74 (2H, 
m, H-15); 1.87-1.81 (2H, m, H-13); 2.46-2.43 (2H, t, H-16); 3.40-3.36 (2H, m, 
H-12); 7.09 (1H, d, H-4); 7.29 (1H, d, H-4); 7.63-7.57 (1H, m, H-3); 7.75-7.71 (1H, 
m, H-6); 7.81-7.77 (1H, m, H-7); 8.29-8.25 (1H, d, H-5); 8.32-8.30 (1H, d, H-8); 
9.77 (1H, s, NH). 
13C NMR spectrum (CDCl3, 100.6 MHz, 25°C) δ: 24.4 ; 26.6 ; 28.8 ; 33.7 ; 42.7 ; 
112.9 ; 115.7 ; 117.8 ; 126.7 ; 132.9 ; 133.1 ; 134.0 ; 134.7 ; 135.1 ; 135.3 ; 151.8 ; 
178.4 ; 183.9 ; 185.1 ppm. 
 
4.6.5 Synthesis of AQ-Ahx-OPFP (HZ22) 
AQ-Ahx-OPFP HZ22 was prepared from the reaction of AQ-Ahx-OH HZ21 (300 
mg, 0.89 mmol), DCC (202 mg, 0.98 mmol), DMAP (120 mg, 0.98 mmol), and 
PFP (180 mg, 0.98 mmol) in dichloromethane for 4 h. TLC of the crude product 
(Rf 0.94) used the solvent system, dichloromethane-ethyl acetate 9:1. Column 
chromatography was performed for the purification of crude HZ22 by using the 
eluting system, dichloromethane-ethyl acetate 8:1. The red product fractions 
were combined, filtered and evaporated to dryness. Yield (precipitation from 
hexane): 346 mg, 77.3%. 
 
1H NMR spectrum (CDCl3, 400 MHz) δ: 1.70-1.63 (2H, m, H-14); 1.87-1.83 (2H, 
m, H-15); 1.95-1.89 (2H, m, H-13); 2.77-2.73 (2H, t, H-16); 3.42-3.37 (2H, m, 
H-12); 7.08 (1H, d, H-2); 7.58-7.547(1H, m, H-4); 7.63-7.60 (1H, m, H-3); 
7.78-7.74 (1H, m, H-6); 7.80 (1H, m, H-7); 8.27-8.25 (1H, d, H-5); 8.30-8.28 (1H, 
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 d, H-8); 9.79; (1H, s, NH). 
13C NMR spectrum (CDCl3, 100.6 MHz, 25°C) δ: 24.5 ; 26.5 ; 28.7 ; 33.2 ; 42.6 ; 
113.0 ; 115.7 ; 117.7 ; 126.6 ; 126.7 ; 132.9 ; 133.0 ; 133.9 ; 134.7 ; 135.0 ; 135.3 ; 
139.1 ; 139.9 ; 140.7 ; 142.3 ; 151.7 ; 169.3 ; 183.8 ; 185.1 ppm. 
 
19F NMR spectrum (CDCl3) δ: -152.8; -158.1 and -162.2 
ESMS (+): 504 m/z 100% (M+H)+ 
 
4.6.6 Synthesis of AQ-[4-Hydroxyl]-Ahx-OH (HZ23) 
Leucoquinzarin (1 g, 4.1 mmol) was reacted with 6-aminohe`xanoic acid (2.2 g, 
16.7 mmol) by the addition of K2CO3 (2.05 g, 14.9 mmol) in DMF on the 100ºC 
water bath. The TLC was checked in the solvent system chloroform: methanol 
(9:1): Rf 0.65. After 1.5 hours the reaction had mostly completed. The round 
bottomed flask was cooled to RT and the reaction mixture was aerated for 1 h. 
The mixture was then filtered to get rid of solid impurity. The column 
chromatography was performed for the product purification. Solvent system 
dichloromethane to methanol 10:1 was used. The appropriate fractions were 
combined and collected. Yield: 900 mg, 62%. 
 
4.6.7 Synthesis of AQ-[4-Hydroxyl]-Ahx-OPFP (HZ24) 
AQ-[4-Hydroxyl]-Ahx-OH HZ23 (50 mg, 0.14 mmol) was dissolved in 
dichloromethane by the addition of the reagents PFP (28 mg, 0.15 mmol), DCC 
(32 mg, 0.15mmol) and DMAP (18.3 mg, 0.15 mmol). After 2 h, the TLC 
(chloroform to ethyl acetate 9:1, Rf 0.9) showed the reaction has completed. The 
crude product was purified by column chromatography using the solvent system 
dichloromethane to ethyl acetate 15:1. The appropriate fractions were combined, 
filtered and evaporated to dryness. The solid HZ24 compound was precipitated 
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 in Hexane. Yield: 38 mg, 52% 
 
1H NMR spectrum (CDCl3, 400 MHz) δ: 1.69-1.63 (2H, m, H-14); 1.88-1.83 (2H, 
m, H-15); 1.97-1.90 (2H, m, H-13); 2.77-2.73 (2H, t, H-16); 3.48-3.43 (2H, m, 
H-12); 7.23 (1H, m, H-3); 7.25 (1H, m, H-2); 7.74-7.73 (1H, m, H-7); 7.78-7.76 
(1H, m, H-6); 7.86-7.80 (2H, d, H-5 and H-8); 8.36-8.34 (1H, d, H-8); 10.37 (1H, 
s, NH); 13.76 (1H, s, OH). 
13C NMR spectrum (CDCl3, 100.6 MHz, 25°C) δ: 24.4 ; 26.4 ; 29.1 ; 33.2 ; 42.6 ; 
108.5 ; 113.7 ; 123.9 ; 126.4 ; 126.6 ; 129.0 ; 132.5 ; 132.7 ; 134.2 ; 147.6 ; 
156.8 ; 169.3 ; 182.2 ; 187.5 ppm. 
19F NMR spectrum (CDCl3) δ: -152.7; -158.01 and -162.30 
 
4.6.8 Synthesis of AQ-(CH2)5-Pro-Ala-Gly-Nva-Pro-OH (HZ60) 
The H-Pro-2-ClTrt resin (500 mg, 0.6 mmol/g) was used for the SPPS of 
AQ-(CH2)5-Pro-Ala-Gly-Nva-Pro-OH (HZ60). The pentapeptide 
(H-Pro-Ala-Gly-Nva-Pro-reisin) was synthesized on resin using the same 
method as Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH (HZ31). The red reagent HZ22 
(151 mg, 0.3 mmol) in DMF (8 ml) was added to the SPPS reaction vessel 
containing the bound, deprotected pentapeptide and shaken for 1.5 h. The red 
solution was drained off by the aid of a vacuum pump and another portion of 
HZ22 (151 mg, 0.3 mmol) in DMF (8 ml) was added to the vessel. The final 
target compound AQ-(CH2)5-Pro-Ala-Gly-Nva-Pro-OH (HZ60) was cleaved off 
the resin by 1% TFA in dichloromethane (30 ml in total). The solution was dried 
and the solid HZ60 was collected in diethyl ether (50 ml). The crude HZ60 was 
purified by thick layer silica gel chromatography using the solvent mixture of 
dichloromethane and methanol (9:1). The title compound was recovered from 
the silica in a chromatographically homogeneous form. Yield: 52 mg, 23 %.  
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 ESMS (-): 757 m/z (100%) (M-H)-  
HPLC Retention time: 3.92 min 
 
4.6.9 Synthesis of AQ-(CH2)5-Pro-Ala-Gly-OH (HZ106)  
The H-Gly-2-ClTrt resin (100 mg, 1.1 mmol/g) was used for the SPPS of 
AQ-(CH2)5-Pro-Ala-Gly-OH (HZ106). The tripeptide (H-Pro-Ala-Gly-reisin) was 
synthesized using the same method as Fmoc-Pro-Ala-Gly-Leu-Ala-Ala-OH 
(HZ31). The red reagent HZ22 (55 mg, 0.11 mmol) was dissolved in DMF (5 ml) 
first and then added to the SPPS reaction flask. After 1 h, the solution was 
drained off, and other portion of HZ22 (55 mg, 0.11 mmol) was dded to the 
reaction. The SPPS vessel was shaken for another 1 h. The final comound 
AQ-(CH2)5-Pro-Ala-Gly-OH (HZ106) was cleaved by 2% TFA in dichloromethane 
(20 ml in total). The solution was dried (Na2SO4, anhydrous) and the solid was 
collected in diethyl ether (30 ml). Yield: 20 mg, 32 % 
ESMS (-): 561 m/z (100%) (M-H)- 
HPLC Retention time: 2.62 min 
 
4.6.10 Synthesis of AQ-(CH2)5-Pro-OH (HZ107) 
The H-Pro-2-ClTrt resin (100 mg, 0.6 mmol/g) was used for the synthesis of 
AQ-(CH2)5-Pro-OH (HZ107). The resin was transferred into a SPPS reaction 
vessel, added with dichloromethane (10 ml) for swelling the beads and shaken 
at RT, 650 rpm for 1.5 h. Dichloromethane was drained off and the red reagent 
HZ22 (50 mg, 0.1 mmol) in DMF was added to the vessel. The vessel was 
shaken for 1.5 h. The product AQ-(CH2)5-Pro-OH (HZ107) was cleaved off the 
resin by 2% TFA in dichloromethane (15 ml in total). The solution was dried and 
the solid was collected under diethyl ether (20 ml). Yield: 11 mg, 42 %. 
ESMS (-): 433 m/z (100%) (M-H)-; HPLC Retention time: 5.5 min 
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